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Chapter 3, 4 and 5 in this thesis were prepared as manuscripts for submission to 
scientific journals. Chapter 3 has been published in Metallomics. Chapter 4 will 
be submitted to Brain Structure and Function. Chapter 5 will be submitted to 






Iron deposits in brain are a common hallmark of Alzheimer’s disease (AD) and 
Parkinson's disease (PD). This has led to the hypothesis that iron may play a 
functional role in the pathogenesis of AD/PD through free radical damage. Recent 
epidemiological findings point to a possible relationship between dietary iron and 
AD/PD. It remains, however, unclear how dietary iron affects brain iron. In this 
project, we have developed a novel methodological approach using stable iron 
isotopes to trace dietary iron and investigate the relationship between dietary iron 
and brain iron in an adult rat model in 3 studies.  
 
Previous short-term studies using radiotracers suggested that brain iron uptake is 
in minute quantity as compared to other tissues in adult rodents, leading to the 
assumption that brain iron uptake must be marginal in humans after brain 
development is complete. In Study I, a known amount of an enriched stable iron 
isotope (
57
Fe) was added to drinking water given to adult rats for a period of 4 
months to directly determine the fraction of iron that was transferred over time 
from diet to the brain. Uptake of tracer iron and final iron content in tissues were 
assessed by Isotope Dilution Mass Spectrometry (IDMS). In consistent with 
previous findings, we found that a minute amount of iron was taken up by the rat 
brain from diet (~0.000054%). But this amount is considerable when compared to 
the total amount of brain iron. About 9% of brain iron could be traced back to the 




To further investigate the brain iron dynamics, a dual-stable-isotope and a triple-
stable-isotope feeding approaches were adopted in Study II, to assess whether the 
process of brain iron deposition is uni-directional or bi-directional. Our result 
confirmed the hypothesis that iron deposition in brain is bi-directional. In 
addition, the half-life of dietary iron in the adult rat brain was estimated to be 
about 9 months, which could serve as an indicator for the turnover rate of dietary 
iron in the brain. The understanding of dietary iron trafficking in the brain will 
shed light on the possible role of dietary iron intake in iron-implicated 
neurodegenerative diseases. 
 
In Study III, the established dual-stable-isotope feeding technique was applied to 
investigate the changes in brain iron homeostasis in response to different levels of 
dietary iron intake in adult rats. IDMS was adopted to assess dietary iron recovery 
in brain as well as the relative iron efflux rate from brain. The most remarkable 
finding of this study was that uptake efficiency of dietary iron by the brain is 
determined by systemic iron influx. Accordingly, dietary iron recovery in brain 
was the lowest for the low dietary iron regimen. However, administration of high 
amounts of dietary iron resulted in down-regulation of intestinal iron absorption 
which, in response, resulted in a lower systemic iron influx as compared to the 
control group. Brain iron uptake and, thus, brain iron accumulation could 
therefore be lowered by giving either high and low amounts of iron to the rats. 
This finding points to brain iron uptake being determined by systemic iron influx 
and not by active regulation in response to body iron status in adult rats. 
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1 Chapter 1 Literature review 
1.1 Introduction 
As a result of successful socioeconomic development and, consequently, progress 
in scientific research, public health, nutrition and education, populations are 
ageing worldwide at an unprecedented scale. However, the concomitant morbidity 
with increasing longevity counteracts, to certain extent, the benefits of living 
longer. An ever-increasing number of people, especially in industrialized 
countries, are afflicted with age-related neurodegenerative diseases (NDD), 
including Alzheimer’s disease (AD), Parkinson’s disease (PD). The worldwide 
prevalence of AD is predicted to increase by 4 times (~100 million people) in the 
next four decades whereas that of PD is projected to double (9 million people) in 
the next 25 years (1, 2). In addition to the high public health costs, these diseases 
pose immense economic and emotional burden on patients and caregivers (3). The 
current situation necessitates a better understanding of the etiology of these 
diseases for the development of effective preventive and therapeutic interventions. 
 
The pathogenesis of AD/PD remains largely unknown,  but many lines of evident 
suggest that iron deposition in the brain with age might play a role in the 
development of these diseases with the associated oxidative stress as the 
underlying mechanism (4, 5). Iron is essential for life. Excess free iron, however, 
can participate in Fenton and Haber-Weiss chemistry, generating free radicals that 
can impose oxidative stress to cellular components which may ultimately lead to 
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cell death. Iron accumulation in the brain with age might result in over-exposure 
of brain to oxidative stress, enhancing the risks of AD/PD development. 
 
Surprisingly, the increasing trend of the prevalence of AD and PD still persists 
after age correction (6, 7), pointing to a possible role of diet on the development 
of these diseases. Worldwide affluence has led to increased consumption of high-
iron food products in the population, e.g. red meat, iron-fortified food and iron 
supplements (8). As the body has no active excretion mechanism for iron, high 
influx of dietary iron into the body may lead to high body iron, potentially 
increasing the brain iron uptake. Most epidemiological studies showed that high 
dietary intake was associated with higher risks of AD/PD whereas others found 
the opposite or no connection (9-15). This hypothesis was further evaluated by 
testing the efficacies of iron chelators/iron absorption inhibitors on 
neuroprotection in vitro and in vivo (16-23). Results of some of these studies are 
promising though others raise doubts on the effect of dietary iron supply on brain 
iron accumulation. These inconclusive findings demand for further research to 
explore if risks of contracting AD and PD can be mitigated through diet and 
translation into preventive strategies.  
1.2 Iron – a double edged sword 
1.2.1 The biological role of iron 
As the second most abundant metal and the fourth most abundant element of the 
earth’s crust, iron is a virtually indispensable micronutrient to all life-forms, from 
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mammals and lower vertebrates to unicellular organisms. It is involved in a 
plethora of metabolic processes ranging from oxygen transport and storage, 
electron transport, oxidation-reduction reactions to cell division and DNA 
synthesis (24). 
 





, depending on its chemical environment (25). Among all the oxidation states, 
ferric (Fe
3+
) and ferrous (Fe
2+
) iron are the most stable both, in the aqueous 
environment of the body and in food. The reversible interchange between these 
states is the basis of many biological redox reactions (26). Consequently, the ease 
of donating and accepting electrons renders iron the required capability to carry 
out redox reactions that are essential for cellular metabolic processes occurring 
within the biological systems.  
 
Being the most abundant trace element present in the human body, iron 
constitutes ~38 mg/kg of body weight in an average adult female and ~50 mg 
iron/kg in an average male. Over 65% of body iron exists primarily in hemoglobin 
in circulating erythrocytes, up to about 10% is present in the muscle as 
myoglobin, about 1% to 5% is found as part of enzymes, and the remaining 
surplus body iron is stored mostly in the liver as ferritin and hemosiderin (25). 
 
As reflected in the body iron distribution, the most essential role of iron in the 
body is to participate in O2 transport in the forms of hemoglobin and myoglobin 
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molecules. Hemoglobin consists of four globular protein subunits and each of the 
subunit contains a heme group in which iron is embedded at the center of a 
protoporphyrin IX ring (27). As only ferrous iron can bind to O2, when 
hemoglobin is not loaded, hemoglobin iron is in the form of Fe (II). In binding, Fe 
(II) is temporarily and reversely oxidized to Fe (III) by O2, resulting in subsequent 
structural change at the iron site of hemoglobin. The structure of hemoglobin 
facilitates O2 transport from lungs to tissues and carries CO2 back to the lungs. 
Myoglobin, also a heme-containing protein, is the primary O2 carrier in muscle 
tissues. In contrast to hemoglobin, myoglobin is composed of only one globin 
chain and one heme unit (28). The affinity of myoglobin to oxygen is higher than 
that of hemoglobin, allowing O2 carried by hemoglobin to diffuse into muscle 
cells.  
 
Cytochromes, as iron-containing enzymes, also carry a heme group. Cytochromes 
are capable of performing reduction and oxidation due to the redox properties of 
iron, thus can be actively involved in the production of cellular energy production 
as electron carriers (28). Iron sulfur enzymes that contain no heme group (e.g. 
nicotinamide adenine dinucleotide dehydrogenase (NADH)), are also involved in 
electron transport (29).  In other iron-dependent enzymes, iron is required as a 
cofactor or activator but is not part of the molecule. 
 
In light of the biological role of iron in the body, iron is essential for body 
development and for maintaining physiological functions. Either conditions of 
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iron depletion or overload can potentially result in iron-related disorders that 
remain one of the most common disorders worldwide. 
 
Too little iron in the body might lead to iron deficiency (ID), a condition that can 
compromise an array of normal body functions. Notwithstanding that iron is the 
most common metal on our planet and the increased food availability with 
socioeconomic development, ID is still the most widespread nutrient deficiency 
worldwide, affecting 1.6 million people globally (30). Half of the population with 
ID suffers from a more severe disorder – Iron Deficiency Anemia (IDA). IDA 
mainly affects children and women of childbearing age in developing countries, 
but its prevalence in industrialized countries are not of negligence (31). Pregnant 
women with IDA are at greater risks of poor pregnancy outcome, i.e. increased 
mortality around childbirth. In addition, IDA adversely affects immune function, 
delays physical and mental development in childhood, and impairs work capacity 
and productivity of manual workers (24, 32)  
 
Despite the crucial role of iron in metabolic processes in the body, it can be highly 
toxic at the moment that iron scavenging capacities of the body, e.g. by transferrin 
as the major iron transport protein in the body, are exceeded (33).  
 
Pathological iron overload can be classified as primary iron overload and 
secondary iron overload. The former refers to hereditary hemochromatosis (HH) 
whereas the latter represents iron overload resulting from transfusion. HH is an 
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autosomal recessive disorder characterized by disregulated intestinal iron 
absorption that leads to pathological rise in body iron (34). The excess iron is 
mainly deposited in parenchymal cells of the liver, leading to tissue damage and 
fibrosis. Mutations in the HFE gene (C282Y) leading to disease have a higher 
prevalence in populations of northern European descent (1/200). Homozygotes for 
this mutation usually develop iron overload whereas the carriers are genetically 
predisposed to HH. As 1/10 white Americans are C282Y allele carriers, HFE-
associated HH is probably the most common monoallelic genetic disease in 
Caucasians (35). Transfusional iron overload is prevalent in anemic patients 
requiring transfusion of erythrocytes, e.g. patients with thalassemia. Due to the 
high concentration of iron in red blood cell (1 ml blood contains ~0.5 mg iron), 
transfusions inevitably increases body iron stores greatly. In addition, the 
ineffectiveness in erythropoiesis in patients with thalassemia leads to the 
increased absorption of dietary iron, which also contributes to overloaded body 
iron stores (24). 
1.2.2 Iron and oxidative stress 
Free unbound iron can participate in reactions generating reactive oxygen species 
(ROS). If unshielded, iron can react with hydrogen peroxide (H2O2) resulting in 
the formation of highly ROS via Fenton chemistry and the Haber-Weiss reaction, 
which could lead to the damage of cellular integrity via oxidative stress (see Eqn. 
(1) - (3)). In the Fenton reaction, Fe
2+
 is oxidized to Fe
3+
, coupled with the 
conversion of H2O2 into a hydroxyl radical (OH
•





, in turn is reduced back to Fe
2+







(see Eqn. (1) and (2)). The Haber-Weiss reaction, is the net reaction derived from 
the combination of the two reactions from Fenton Chemistry with iron being the 
catalyst. As can be seen from Eqn. (3), hydroxyl radicals (OH
•
) are generated 




 catalyzed by Fe
2+
























 → OH• + O2 + OH




ROS serve as a source of oxidative stress that cause destruction in cellular 




and H2O2, and extremely reactive ones, like OH
•
, peroxyl radicals and singlet 
oxygen (36). It is often assumed that ROS will always result in oxidative stress. 
This assumption is erroneous to a certain extent. The term ROS was introduced by 
introduced by Sies and Cadenas in 1985 and was defined as “a disturbance in the 
prooxidant-antioxidant balance in favor of the former” (37). Normal physiological 
variation in cellular redox equilibrium can be adjusted by the body. However, 
when the cellular levels of ROS surpasses the threshold of the redox regulatory 
capacity in the body, it subsequently results in oxidative stress and leads to 
cellular damages. 
 
ROS are the by-products of normal metabolism in aerobic species. About 2% of 
the oxygen utilized in the electron chain reactions is metabolized into the 
potentially toxic ROS (see Fig. 1-1) (36, 38, 39). Oxygen is monovalently reduced 
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to water with the intermediate formation of superoxide anion, hydrogen peroxide 




 is virtually 





 and H2O2 are not very reactive but in the presence of iron, they 
can be turned into the highly reactive ROS like OH
•
, which can react with the 
adjacent cellular components and cause damages. As a result, redox-active 
ironsite-specifically determines the H2O2-mediated oxidation (40). Other metals 
like copper are more efficient catalysts than iron in the conversion to OH
•
, but 
iron is the main catalyst due to its high abundance and wide availability in living 
cells (41, 42) 
 
Fig. 1-1 Schematic representation of the reduction of oxygen to water 
 
Under normal physiological conditions, the body copes with ROS and the 
resulting oxidative stress through an array of antioxidant defense systems, 
including antioxidant enzymes (glutathione peroxidases, superoxide dismutase 
and catalase) and non-enzymatic free radical scavengers (tocopherols, vitamin C, 
glutathione, etc.), which can inactivate superoxide radicals, hydrogen peroxide 
and lipid hydroperoxides (36, 43, 44). However, when the amount of the 
generated free radicals exceeds the cellular scavenging capability, they will 
damage DNA, lipids and proteins. 
 
When free iron is exposed to H2O2, the generated ROS can possibly generate 
DNA lesions, resulting in DNA fragmentation and mutagenesis (45, 46). Among 
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lipid molecules, polyunsaturated fatty acids (PUFA) are more vulnerable to 
oxidative stress due to their electron-donating double bonds, which can react with 
OH
• 
and other radicals (47). These radicals can initiate lipid peroxidation in the 
cell membrane through reactions analogous to Fenton Chemistry in which iron 
can generate lipid radicals by splitting lipid hydroperoxides (LOOH) into alkoxyl 
(LO
•
) or peroxyl (LOO
•
) radicals.  Peptides can be attacked by free radicals at the 
backbone and side-chain via oxidative modification (48). The resulting backbone 
modification leads to protein cross-linking or peptide-bond cleavage. The side-
chain modification results in the change of chemical structure and thus properties 
via the modification of the amino acid side chains. 
 
In light of the catalytic role of iron in the generation of ROS and the possible 
accompanying deleterious oxidative damage, evolution has equipped mammals 
with elegant regulatory mechanisms to maintain iron homeostasis at both at the 
systemic level and the cellular level by modulating iron absorption, iron 
reutilization and mobilization of stored iron which will be described in the 
following. 
1.3 Body iron metabolism 
1.3.1 Dietary iron sources 
Dietary iron can be categorized by the form in which iron is bound at the 
molecular level as heme iron and non-heme iron, respectively. Heme iron can be 
found in animal foods, such as red meat, poultry and fish. It refers to all forms of 
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iron in which iron is present as hemoglobin and myoglobin in which iron is tightly 
bound within the porphyrin ring structure of the molecule. Non-heme iron, on the 
other hand, can be found in any food of plant origin. Heme iron is more 
effectively absorbed (25% to 35%) than non-heme iron (2% to 20%, on average). 
The absorption rate of heme-iron depends mainly on the proportion of iron 
enhancers and inhibitors in the diet, as well as the iron status of the individual. 
Although heme-iron constitutes about 10% to 15% of dietary iron, it may provide 
up to a third of total absorbed dietary iron (49-51). The recommended dietary 
allowances (RDA) for iron are 8 mg for adult males and18 mg for adult females 
(25). 
1.3.2 Intestinal iron absorption 
The absorption of iron occurs predominantly in the apical membrane of duodenal 
and proximal jejunum enterocytes (see Fig. 1-2) (34). The absorption of both 
heme iron and non-heme iron is regulated by the iron stores in the body. The 
former, however, is not regulated as tightly as the latter (52). But the absorption 
of heme iron is more efficient than non-heme iron as it remains soluble at 
intestinal pH as opposed to non-heme iron and its solubility does not seem to be 
affected by the oxidation state of heme iron. Moreover, in comparison to non-
heme iron absorption, the absorption of heme iron is less sensitive to extrinsic 
factors (e.g. dietary iron absorption inhibitors or enhancers). Heme iron thus has a 




Heme iron is released into the lumen of the stomach and duodenum by 
proteolysis, before it can be taken up by enterocytes (53, 54). The uptake of heme 
iron by enterocytes is not as well understood. The heme carrier protein 1 (HCP1) 
on the apical surface of enterocytes is proposed be involved in this process due to 
its high expression in enterocytes (52). The principal role of HCP1 remains to be 
elucidated. It appears that in addition to the function of heme transport, it is also 
responsible for the uptake of folate (55). Heme iron binds to HCP1 and is 
absorbed intact into the cytoplasm through endocytosis (56). In the cytoplasm, the 
heme molecule is present in the membrane bound vesicles. Heme is then degraded 
to iron, carbon monoxide and bilirubin by the enzyme heme oxygenase-1 (HO-1). 
The degraded iron will then be released in ferrous form into the intracellular iron 
pool and follows the same metabolic pathways as non-heme iron as discussed 
below. 
 
Fig. 1-2 Intestinal iron absorption 
Fe3+ can be reduced to Fe2+ either by ascorbic acid and apical membrane ferrireductase cytochrome B 
(Dcytb). At the apical membrane, Fe2+ transport into the enterocytes can be driven by the H+ electrochemical 
gradient via DMT1. Heme can be taken up by HCP1 via endocytosis. Fe2+ within the endosome is then 
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liberated inside the cytosol. Cytosolic iron is either stored in ferritin or exported through basolateral transfer 
via FPN, which is coupled to the ferroxidase activity of hephaestin. Exported iron binds to transferrin in the 
blood stream for distribution. (Figure source: Zimmermann and Hurrell, 2007) (57) 
 
Non-heme iron, on the other hand, traverses into the cell via divalent metal ion 
transporter 1 (DMT1) after it has been enzymatically reduced (56). The ferric iron 
must first be reduced to the ferrous form,  a pre-requisite for DMT1 mediated 
transport, by either the ferrireductase at the brush border membrane, duodenal 
cytochrome b (Dcytb), or reducing agents present in diet such as ascorbic acid 
before it can enter the intestinal enterocytes (58). Dcytb, a homolog of heme-
containing cytochrome b, is a membrane-bound ferrireductase that can reduce 
ferric iron to ferrous iron (59). DMT1 was initially identified in rat duodenum and 
operates with a hydrogen-coupled mechanism for the transport of ferrous iron and 
other divalent metals across the cell membrane (60).  
 
While some of the absorbed iron is sequestered into ferritin (see section 1.3.4.2) 
or incorporated into iron-containing enzymes within the cell, the rest enters blood 
circulation. The stored iron in ferritin can be liberated from the ferritin molecule 
in ferrous form should iron be needed for cellular metabolism. If it is not required 
by the body, the iron remains sequestrated in ferritin and is excreted when the 
short-lived (2-3 days) mucosal cells are sloughed off into the lumen of the 
gastrointestinal tract. Intestinal ferritin synthesis is directly regulated by body iron 
stores, with increased ferritin synthesis being associated with high iron stores. 
Iron is shuttled out of enterocytes by ferroportin (FPN) which enhances the rate of 
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iron export and generates the ferric form of iron (Fe
3+
) with the aid of hephaestin 
(58, 61), a homologue of the serum ferroxidase ceruloplasmin (62).  
1.3.3 Iron transport and cellular iron uptake 
1.3.3.1 Plasma iron pool 
Iron absorbed by the intestine or released from the tissues enters the plasma prior 
to further utilization. This intermediate state of iron in the plasma forms a plasma 
iron pool. The iron sources contributing mainly to the plasma iron pool mainly 
include 1) gastrointestinal absorbed dietary iron, 2) iron from reticulo-endothelial 
macrophages which catabolize and store red cell iron, and 3) iron from 
hepatocytes are storing iron. Iron released from myoglobin and iron-containing 
enzymes contributes only a small fraction of iron to the plasma iron pool for iron 
turnover (29).  
 
Plasma iron turnover is estimated to be 20-30 mg of iron per day (63, 64). While 
only 10% of this turnover iron originates from duodenal absorption, the majority 
of turnover iron comes from macrophages pointing to the essential role of these 
cells in iron recycling from senescent erythrocytes and thus for the maintenance 
of body iron homeostasis (65). Iron turnover is therefore primarily determined by 
the degradation of senescent erythrocytes by the reticulo-endothelial system (66) 
but the role of dietary iron in iron turnover is also of great significance as the sole 
external source. In the human body, about 80% of functional iron is found in 
erythrocytes with an average lifetime of 120 days. Senescent erythrocytes are 
degraded by phagocytosis in macrophages, liberating iron from heme. About 85% 
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of the liberated iron re-enters circulation. Approximately 0.66% of total body is 
recycled in this manner each day (67). The regulation of iron release from 
macrophages is largely dependent on hepcidin (see section 1.3.7.2) (68), the 
dysregulation of which can result in the disruption of iron homeostasis as seen in 
hereditary hemochromatosis. 
 
About 70–80% of plasma iron is incorporated subsequently by bone marrow into 
developing erythroid cells for hemoglobin synthesis which requires by far the 
greatest iron amount on a daily basis (58, 69). As the plasma pool of iron is 
commonly maintained at a level of less than 4 mg of iron and the iron demand for 
body metabolism is rather high, the half-life of plasma iron are therefore quite 
short.  
1.3.3.2 Transferrin 
As free iron is highly toxic, the exported Fe
3+ 
from enterocytes to the blood 
stream is sequentially accepted by circulating plasma transferrin (Tf) (34, 56), a 
transporter used for iron delivery to organs where iron is required for metabolic 
processes. Tf is not only responsible for the delivery of iron from the basolateral 
surface of enterocytes to peripheral tissues, but also for the redistribution of iron 
to various body compartments. In addition, Tf also protects iron from body 
excretion during glomerular filtration by the formation of a large molecule, Tf-
bound iron (Tf-Fe
3+




Tf (Mr ca. 80 kDa), a single chain of 680 amino acid residues, is a member of a 
closely related family of iron-binding glycoproteins that also includes lactoferrin, 
melanotransferrin, and ovotransferrin (70). It has two binding sites for Fe
3+
in a 
ternary complex of protein ligands, bicarbonate and water with a very high 
affinity of 10
-22
 M for iron at pH 7.4 (50). The two binding sites, although 60% 
identical in amino acid sequence, are functionally distinct in sequestering iron and 
involve a conformational change during iron binding. In the plasma and other 
extracellular fluids, Tf exists as a mixture of apo-Tf (Tf that binds zero iron ions), 
monoferric Tf (Tf that binds to one Fe
3+
) and diferric Tf (Tf that binds to two 
Fe
3+
). Their relative abundance is dependent on the relative concentrations of iron 
and Tf (26). 
 
Tf is able to bind two Fe
3+
 ions tightly, but reversibly with concomitant binding of 
two carbonate anions. The carbonate anions serve as bridging ligands to shield 
water from binding iron in the coordination sphere, to lock the iron ions firmly to 
the protein and to avoid hydrolysis (24). In the reversible binding mechanism, the 
release of iron from Tf is the result of the protonation of the carbonate anion. 
Several other metals may also bind to the iron-binding sites of Tf, e.g. aluminum, 
cadmium, and manganese. Iron, however, has the highest binding affinity and will 
displace the other metals (26). 
 
Abundant amounts of circulating Tf are present in the blood plasma where the 
majority of non-heme iron binds to Tf. It is estimated that approximately 0.1% of 
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total body iron is found in Tf (51, 71). In normal adult plasma, the concentration 
of Tf is about 30μM whereas that of iron is approximately 20μM (69). Each Tf 
can bind up to two Fe
3+ 
(72). Under normal conditions, plasma Tf is thus 
approximately saturated to only 1/3 with iron (73). The unoccupied iron binding 
sites on Tf offer a large buffering capacity in the case of an elevated level of 
plasma iron (72). Plasma Tf is thus always in excess of iron to prevent the body 
from the potential toxicity of free iron. Fasting Tf saturation can serve as one of 
the criteria for the assessment of iron status. Tf saturation for normal people is 
within the range of 16% - 45%. In establishing iron deficiency, Tf saturation 
should be <15% (35, 58), below the level of which, insufficient amount of iron is 
delivered to bone marrow and fails to maintain normal rates of erythropoiesis. If 
Tf saturation is above 45%, iron level in the body is considered elevated and 
further tests are required to be carried out to confirm the condition of iron 
overload. 
 
In addition to the primary function of plasma Tf as a iron carrier in the plasma and 
interstitial fluid of the body, two secondary functions of Tf have been 
demonstrated, namely as a bacteriostatic agent and a growth factor, which is 
probably associated with the capacity of the protein to act as an iron donor (26). 
1.3.3.3 Transferrin-dependent iron uptake mechanisms 
Tf-Fe
3+
 in the plasma is nonreactive, but is also difficult to extract for utilization 
by organs. Several mechanisms for Tf-dependent iron uptake have thus been 
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Two transferrin receptors (TfR) have been identified in mammals to mediate the 
internalization of Tf into the cell, transferrin receptor 1 (TfR1) and transferrin 
receptor 2 (TfR2), both of which are type II transmembrane homodimer 
glycoproteins that share 45% of their chemical identity. They consist of two 90-
kDa subunits linked by disulfide bonds (74). 
 
The uptake of Tf-Fe
3+ 
via the TfR1 mediated endocytic pathway has been most 
extensively investigated (75). Due to the ubiquitous expression of TfR1, most cell 
types might take up iron via TfR-mediated pathway. This appears to be the most 
important pathway for iron uptake in developing erythroid precursors, which 
require enormous iron for hemoglobin synthesis. 
 
The Tf-TfR1 interaction depends on the iron saturated status of Tf and the pH of 
the milieu (64). At the extracellular pH of 7.4, TfR1 has high affinity to diferric 




 M) whereas apo-Tf does not compete 
significantly. When the pH drops below 6.5, however, the affinity of TfR1 for 
diferric Tf decreases whereas that for apo-Tf increases. For instance, when 
between pH 5 to 6, the affinity of TfR1 for apo-Tf increases to the level that is 




Following the binding of Tf-Fe
3+
 to TfR1 at the cell surface at the extracellular 
pH 7.4, Tf-Fe
3+
/TfR1 complexes localize to clathrin-coated pits and enter the cell 
by endocytosis with the aid by the adaptor protein complex-2 (70) (see Fig. 1-3). 
Upon internalization, a smooth vesicle, is formed by shedding its clathrin coat 
into a sorting endosome. Early Tf-containing endosomes are acidified by a proton 
pump (H
+
-ATPase) which lowers the pH in the endosome to pH 5-6, effecting 
conformational changes in both Tf and TfR1 to release iron. The released iron is 




 by an unidentified ferrireductase, possibly 
six-transmembrane epithelial antigen of the prostate 3 (STEAP3), allowing DMT1 
to transfer Fe
2+ 
across the endosomal membrane into the cytoplasm (78). This 
released  iron is then channeled into one of three pathways: iron-utilizing proteins, 
iron-regulatory proteins, or storage iron (50). TfR1 and Apo-Tf are returned to the 
plasma membrane, where each can be recycled for iron uptake and binding. About 
1% of the apo-Tf/TfR1 complex, however, enters the late endosomes and is 






Fig. 1-3 Transferrin receptor mediated endocytosis for cellular iron uptake 
Tf-Fe3+ binds to TfR1 on the membrane. The Tf-Fe3+/TfR1 complex is internalized and forms a endosome 
which is later acidified by a proton pump, resulting in the release of iron from Tf. The released iron is 
subsequently transported out of the endosomes via DMT1 into cytosol to participate in cellular metabolism or 
for storage. The apo-Tf/TfR1 complex are returned to the plasma membrane, where they dissociate at neural 
pH and can be recycled for iron uptake and binding.(Figure source: Qian et al., 2002 ) (70) 
 
In contrast to the ubiquitous expression of TfR1, TfR2 is mainly restricted to 
hepatocytes, suggesting a more specialized role (64, 80). TfR2 appears to have 
dual roles in iron metabolism: iron transport and iron regulation (81). TfR2 binds 
diferric Tf with an affinity approximately 25-fold lower than TfR1, possibly 
serving as an alternative pathway for the uptake of Tf-Fe
3+
 by hepatocytes (81). 
Paradoxically, mutations in the human TfR2 gene result in a genetic disorder of 
iron overload - hemochromatosis (82), pointing to its role in iron regulation other 
than iron uptake. 
 
Besides TfR1 and TfR2, cubilin, a 460-kDa protein that is located within the 
epithelium of intestine and kidneys, was demonstrated to be the third 
physiologically and quantitatively important TfR involved in iron uptake. 
Polarized epithelial cells of the kidney utilize this third uptake mechanism for Tf-
Fe
3+
, via megalin (coreceptor colocalizing with cubilin) dependent, cubilin-
mediated endocytosis (83). Renal proximal tubules may acquire iron mainly via 
this pathway. 
 
The cellular uptake of iron based on the TfR-mediated endocytosis is largely 
determined by the number of TfR present on the cell surface which is regulated by 
body iron status and the rate of cellular proliferation. Production of the receptor is 
 20 
 
thus stimulated by iron deficiency and inhibited by increased iron supply. The 
regulation of the synthesis of receptors is achieved by a posttranscriptional 
mechanism known as the IRP/IRE system (see section 1.3.7.1) (26) 
1.3.4 Body iron storage 
1.3.4.1 Body iron distribution 
While most of body iron (ca. 60%) is bound in erythrocytes for functional use 
(62), the liver and the reticulo-endothelial macrophages serve as the main sites of 
iron deposition and storage (84, 85). Distribution of storage iron, mainly in the 
form of ferritin, is heterogeneous among tissues. Approximately 60% of body 
ferritin is found in the liver whereas muscle tissues and reticulo-endothelial 
system contains the remaining 40% (73).  
 
Under normal physiological conditions, ferritin constitutes 95% of liver iron and 
is stored in hepatocytes whereas the remaining 5% is found predominately as 
hemosiderin in Kupffer cell lysosomal remnants. Hepatocytes constitute 80% of 
the liver mass and play the most prominent role in hepatic iron metabolism (84). 
As a main site of iron storage, it has a high capacity for iron storage protein 
synthesis. 
 
Macrophages of the reticulo-endothelial system are responsible for iron recycling 
from senescent erythrocytes. The structure of the erythrocyte membrane changes 
towards the end of the life cycle of the red blood cell. Once these changes are 
recognized, erythrocytes will be phagocytosed at extravascular sites by liver 
 21 
 
Kupffer cells (resident macrophages in liver) and spleen macrophages. Iron 
released from heme by HO-1 either enters the cellular iron pool and is stored 
mainly as ferritin or returns to circulation. 
1.3.4.2 Ferritin 
Ferritin is ubiquitously distributed in the human body and is used, in general, for 
intracellular sequestration of iron and its detoxification and storage (26). It is a 
hollow spherical protein complex (molecular weight: ca. 450 kDa) composed of 
24 subunits that are arranged in cubic symmetry surrounding a hollow cavity with 
an internal 8-nm diameter (86, 87). Ferritin can store up to 4,500 iron atoms 
inside the protein shell as an iron(III) mineral, traditionally described as 
ferrihydrite [Fe
III
10O14(OH)2] (88). Individual ions, such as water, metal cations 
and hydrophilic molecules of the appropriate size, can migrate into and out of the 
cavity through eight hydrophilic channels locating at the C3 symmetry axis of 
ferritin (86, 88). Other biological molecules, on the other hand, are prevented 
from reacting with the iron mineral stored in the ferritin cavity (89). Ferritin is 
resistant to the change of temperature and pH. It is demonstrated to be stable at up 
to 70
◦
C and over an extreme pH range of 3-10. At pH <3 the ferritin subunits 
dissociates but reversibly reassembles at pH > 3 (88). 
 
The 24 subunits of the apoferritin shell can be classified into two types of 
polypeptide chains: the H (or heavy) subunits of 178 amino acids (21 kDa), and 
the L (or light) subunits with 171 amino acids (19 kDa). Despite their different 
physiological roles, H subunits and L subunits are structurally closely related 
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(∼53% protein sequence identical in primary structure) (90, 91). H subunits 
possess the catalytic ferroxidase center for rapid iron (II) oxidation to detoxify 
iron. L subunits, however, possess the iron nucleation sites providing Fe
3+
-
binding ligands that initiate crystal growth within ferritin (92). L subunits are 
therefore responsible for mineralization and long term iron storage in the ferritin 
cavity (93). During the storage process, two Fe
2+ 
are recognized by the ferritin 





(94). The oxidized Fe
3+ 
thereafter diffuse into the interior of the 
ferritin cavity where Fe
3+
 binds to the nucleation sites of the L subunits for 
mineralization (92). 
 
In agreement with the different roles of H and L subunits in iron storage, the H/L 
ratio in a ferritin shell varies widely in different tissues. H-rich ferritins 
predominate in organs that require mainly iron detoxification capacities, cellular 
protection and rapid iron turnover such as the macrophages, heart and brain while 
iron storage organs such as the liver and spleen contain mostly L-rich ferritins 
(95). For instance, the H/L ratio is 1:10 to 1:20 in human liver ferritin and 1:4 in 
rat liver ferritin (96, 97). 
 
In contrast to the high expression of ferritin in tissues, ferritin is also present in 
plasma but with in very limited amounts. Plasma ferritin accounts for < 1% of the 
amount of iron bound to Tf. It is cleared from plasma by the liver via receptor-
mediated endocytosis. The concentration of plasma ferritin correlates positively 
 23 
 
with body iron stores and widely used as a indicator of body iron status in clinical 
practice (26). 
1.3.4.3 Hemosiderin 
Hemosiderin (molecular weight: 12.9 to 17.8 kDa), as the second iron storage 
molecule, is a water insoluble protein of ill-defined nature and considered a 
partial lysosomal degradation product of ferritin with a much higher iron to 
protein ratio found in hemosiderin than ferritin (24, 98-100). Hemosiderin is 
mainly found in pathological iron overload, e.g. hemochromatosis and siderosis 
(101). The mass accumulating rate of liver hemosiderin is 10 times that of ferritin 
during iron overload (102). 
 
The protein shell of ferritin is usually partially degraded to form hemosiderin by 
lysosomal proteases when the average tissue ferritin capacity reaches 
approximately 4000 iron atoms per ferritin molecule (103). It is found that up to 
40% of the mass of hemosiderin consists of iron. Depending on the sources and 
conditions under which the iron was obtained, the form of hemosiderin iron 
varies, including ferrhydrite, amorphous ferric oxide, and goethite (104). In 
general, the chemical reactivity of these forms of iron is lower than ferritin iron 
and their availability for mobilization is less. 
1.3.5 Cellular iron metabolism 
Cellular iron homeostasis includes iron uptake, utilization, storage and export. 
Iron taken up by the cell is mainly via a TfR-mediated endocytosis pathway (see 
section 1.3.3.3). The iron liberated into the cell will enter the cellular iron pool. A 
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labile intermediate iron pool within the cell has been hypothesized from which 
iron is accessible and ready for heme synthesis, for ferritin storage, and for the 
synthesis of iron-dependent enzymes within the cell, or for extracellular Tf after 
export from the cell (105-107). 
 
The concept of the labile iron pool (LIP) was first proposed by Greenberg and 
Wintrobe in 1946 who defined it as “an intermediate stage which receives iron 
from hemoglobin breakdown or from oral absorption or iron that is injected 
parenterally” (106). It was later reintroduced by Jacobs (1976) and defined as a 
pool of redox-active iron complexes associated with proteins, serving as 
crossroads of metabolic pathways of iron-containing compounds (105, 107). 
 
Although the actual functioning mechanism for LIP remains unexplained, its 
sources have been well defined. The LIP is replenished iron release from heme, 
from ferritin, iron export from endosome or from mitochondria etc. (108). To 
maintain cellular iron metabolism, a constant iron flux from an extracellular 
milieu to the cytoplasm is required. The daily dietary iron uptake (1–2 mg) is one 
of the major sources of LIP and theoretically should enter LIP prior to the 
distribution to the targeted proteins. 
 
Iron in LIP can be complexed by a variety of low-molecular weight ligands with 
low affinity to iron ions, e.g. phosphate, carboxylates, citrate, nucleotides and 
nucleosides, polypeptides and phospholipids (107, 109, 110). The weakly 
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) can potentially cause free radical 
generation, catalyze extensive oxidative modifications of cellular components and 
thus, cellular dysfunction (36). The loosely bound iron, however, can be 
scavenged by iron chelators. 
 
LIP represents only a minor fraction (3–5%) of the total cellular iron (250 – 
550μM) (111), however, it has been proposed to have two crucial functions: 1) 
provide a rapidly adjustable source of iron for immediate metabolic utilization, 
and 2) participate in iron regulation via sensing by iron regulatory proteins (108). 
The fraction of iron in the LIP covers a wide range, allowing a high tolerance for 
change in iron flux. However, in extreme cases when the change of iron influx 
exceeds the homeostatic capability of the LIP, the redox active forms of cellular 
iron may lead to a variety of physiological and pathological conditions via ROS 
induced oxidative stress (108, 109). 
 
Due to the critical role that LIP plays in cellular homeostasis, the body stringently 
regulates the iron level in LIP to maintain normal cellular iron metabolism but 
also restricts iron to be involved in free radical generating chemistry (112). It is 
speculated that down regulation of labile iron may have a favorable impact on 
health in general and aging in particular (36). Iron chelators targeting LIP are 





The mechanism of cellular iron export has been far less extensively studied than 
that of iron uptake, but the molecular understanding has advanced recently. The 
main protein responsible for cellular iron export is FPN (see section 1.3.2). Iron is 
exported out of the cell via FPN with the aid of a ferroxidase. As the only current 
known cellular iron exporter in vertebrates (113, 114), FPN is distributed in cells 
such as hepatocytes, duodenal enterocytes and macrophages, where major iron 
flows are regulated. Studies on zebrafish (114) and mice (115) indicated that FPN 
is also the sole significant iron exporter in tissues involved in the process of iron 
absorption, storage and recycling. 
1.3.6 Iron excretion 
Evolutionally, the human body has not been equipped with a mechanism for 
active iron excretion (24). Prior to the presence of molecular oxygen, with the 
essentially reducing atmosphere on Earth, both the natural abundance of iron and 
its redox properties predisposed it to play a crucial role in the first stages of life on 
Earth. Since the advent of oxygen into the earth atmosphere, iron’s bioavailability 
has been seriously compromised by the formation of iron hydroxide. Due to the 
crucial role of iron in life, the mammalian body has therefore developed a 
stringent regulatory system to conserve iron for reproduction and other biological 
functions. 
 
As there is no mechanism for active iron excretion, it is of great importance to 
regulate dietary iron absorption to maintain body iron homeostasis (51). It is well 
established that under normal physiological conditions an adult person can absorb 
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only 1-2 mg of ingested dietary iron per day (116) which is shown to be adequate 
for the compensation of the ~1-2 mg of unregulated iron loss (see Fig. 1-4). 
 
 
Fig. 1-4 Iron distribution in the body and exchange pools. 
Figure source: Beard et al. (1996) (50). 
 
The biggest contributor to the unregulatory iron losses is basal iron excretion. 
Basal iron excretion, predominantly arising from cellular exfoliation of the 
gastrointestinal tract, is limited, and is the primary determinant for nutritional 
requirements for absorbed iron in humans (117). Iron losses from this route 
amount to 0.6 mg/day in adult males via fecal excretion (67), derived from 
desquamated mucosal cells, minute blood loss, and biliary heme breakdown 
products. The skin losses of ~0.2 to 0.3 mg iron are due to desquamation of 
surface cells from the skin in adult males (66). Iron losses through the urogenital 
system are minimal and are estimated to be 0.08 mg iron (25). Increased losses of 
iron, however, may occur in people with gastrointestinal ulcers or intestinal 




Other sources of unregulatory iron losses include menstruation, pregnancy, or 
other bleeding. The variation in iron losses with the gender of the individual is 
considerable. Daily iron losses by male have been determined to be ~0.9 to 1 
mg/day while basal iron losses are slightly lower for postmenopausal women, 
~0.7 to 0.9 mg/day, owing to their smaller surface area (25). 
1.3.7 Regulation of body iron 
Evolution left the body a closed system for iron metabolism with minimal iron 
excretion. The regulation of body iron content is therefore solely dependent on 
iron absorption efficiency. Iron absorption by the human body is regulated by the 
total amount and forms of consumed iron and the iron status of the individual. 
The iron absorptive efficiency has a wide range (118). The amount of iron 
absorbed by iron-loaded individuals is proportionally less (up to 15 times) than 
that by iron-deficient individuals (58). Regulation of intestinal iron absorption is 
the fundamental principle of body iron homeostasis (73). 
 
Iron homeostasis must be maintained both at the cellular and the systemic level. 
Expression of proteins involved in iron absorption (DMT1), storage (ferritin), 
utilization (Tf and TfR), iron export pathway (FPN, HFE, the bone morphogenic 
proteins and hepcidin) and iron signaling (IRP/IRE system) must be regulated in a 




1.3.7.1 Cellular iron regulation – IRP/IRE system 
At the cellular level, iron concentrations are sensed by two homologous 
cytoplasmic iron regulatory proteins (IRP)-IRP1 and IRP2 (64) and 
posttranscriptionally modulated by IRP/iron regulatory element (IRE) system. 
IRE-containing mRNAs encode key proteins of iron metabolism, such as H- and 
L-ferritin, TfR1, DMT1, FPN and others (120). When cytosolic iron levels are 
low, IRPs bind to IREs that possess hairpin structures in the untranslated regions 
(UTRs) of mRNAs of iron-associated proteins, and control their translation or 
stability. The synthesis of the iron-associated proteins is affected by the binding 
site on the IREs of mRNA: binding of IRPs to IREs in the 3’UTR results in the 
stabilization of mRNA, leading to elevated protein synthesis, whilst binding of 
IRPs to IREs in the 5’UTR inhibits the translation of mRNA, as a result protein 
synthesis decreases (see Fig. 1-5) (113) 
 
The detailed operation of the IRP/IRE system can be exemplified by the 
translation of ferritin and TfR1. When cytoplasmic iron is high, the IRPs bind to 
iron instead of the IREs of ferritin and TfR1 mRNA. Due to the lack of IRP 
binding, the translation of the ferritin mRNA may precede forward whereas the 
TfR1 mRNA degrades, resulting in an elevated level of ferritin and reduced level 
of TfR1 synthesis. When cytoplasmic iron is low, IRP1 binds to the IRE in the 
5’UTR of ferritin mRNA and 3’UTR of TfR1 mRNA, leading to the decreased 
translation of ferritin protein and increased TfR1 synthesis via the stabilization 
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and protection of the TfR mRNA from degradation. The expression of TfR2, on 
the contrary, is not regulated by the IRP/IRE system (51) 
 
Fig. 1-5 The effect of cytoplasmic iron levels on IRE/IRP system. 
When cytoplasmic iron concentrations are low, the binding affinity of IRP1/2  to mRNA is high. IRP1/2 
binds to the IREs in the 5’UTR of ferritin mRNA and 3’UTR of TfR1 mRNA, leading to the decreased 
translation of ferritin protein and increased TfR1 synthesis. Under conditions of high cytoplasmic iron 
concentrations, IRP1 binds to the assembly of a [4Fe–4S] cluster whereas IRP2is targeted for proteasomal 
degradation (121, 122).  
 
1.3.7.2 Systemic iron regulation - Hepcidin 
Systemically, iron fluxes in the body are strictly controlled by a liver-derived 
regulatory hormone known as hepcidin (123). Hepcidin, with its ability to inhibit 
the functioning of the protein FPN that is responsible for cellular iron release, is 
demonstrated to affect iron homeostasis by the regulation of gastrointestinal iron 
absorption, hepatic iron storage and iron recycling from macrophages since 
enterocytes, hepatocytes and macrophages rely all on FPN for cellular iron export 
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(120). The secretion of hepcidin from the liver is largely in response to iron 
overload or inflammation. In the event that systemic iron increases (high iron 
stores), hepcidin can be secreted by the liver to target FPN on the basolateral 
membrane of duodenal enterocytes and tags it for internalization and lysosomal 
degradation, thereby effectively down-regulating dietary iron absorption (85). 
Within a day or two, the unabsorbed iron is removed concomitantly with the 
shedding of the short-lived enterocytes into the intestine. Conversely, synthesis of 
hepcidin is suppressed when iron stores are low. As a result FPN molecules are 
displayed on basolateral membranes to aid in iron transport to plasma Tf. 
Similarly, iron recycled from senescent erythrocytes is trapped in macrophages 
when hepcidin induces the degradation of FPN (113). 
 
Iron fluxes in FPN-expressing organs is controlled by hepcidin (124) while the 
plasma level of hepcidin is in turn regulated by iron. Hepcidin regulatory system 
is likely to be extremely complex and remains to be further explored. It is 
reported that the HAMP gene encoding hepcidin is transcriptionally induced by 
high iron intake (125), resulting in the inhibition of iron efflux from the 
cytoplasm. Conversely, iron deficiency, anemia or hypoxia suppress hepcidin 
mRNA transcription (125, 126), allowing elevated iron absorption and iron 
release from macrophages. 
 
Under physiological conditions, the level of HAMP is regulated via a complex 
cell signaling pathway that includes several cell membrane proteins such as bone 
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morphogenetic protein (BMP), hemojuvelin (HJV), TfR2 and HFE etc. (127). 
Mutations in these genes lead to iron loading syndrome, implicating their role in 
hepcidin synthesis in the liver (123). In cell cultures and murine models, hepcidin 
expression was shown to be associated with the BMP/SMAD pathway (128). The 
treatment with BMP results in increased hepcidin expression whereas the 
inactivation of the cofactor HJV of the pathway decreases hepcidin expression 
(129). In addition, the mRNA expression of hepcidin was reported to be 
influenced by inflammatory conditions and the transcription was induced by 
interleukin-6 (IL6) (130). Furthermore, hemochromatosis protein (HFE) might be 
involved in hepcidin regulation as previous human and animal studies 
demonstrated that this disorder was linked with lower level of hepcidin 
production (131) 
 
By blocking cellular iron export, hepcidin may indirectly affect the cellular 
IRE/IRP system due to increased intracellular iron levels. Though the extent of 
interaction between hepcidin-FPN and the IRE/IRP system remains to be 
elucidated in detail, the effect of which on the expression of the IRE-containing 
proteins DMT1, TfR1, and FPN has been demonstrated (113). 
 
The hepcidin regulatory system is compromised under pathological condition. 
Over expression of hepcidin is associated with severe iron deficiency anemia in 
transgenic mice (132) whereas considerably reduced hepcidin expression is found 
in patients with hereditary hemochromatosis (131, 133).  
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1.4 Brain iron homeostasis 
Iron is not only the most abundant trace element in the body, but also in the brain 
(134). Like other organs in the body, the brain also requires iron for metabolic 
processes, which include electron transfer and oxygen transport, myelin 
production, neurotransmitter synthesis and neurogenesis (135).  
1.4.1 Brain barriers 
Brain is encompassed by the blood-brain barrier (BBB) and blood-cerebrospinal 
fluid barrier (BCB), across which iron traverses into the brain. 
1.4.1.1 The blood-brain barrier 
The BBB is a separation of circulating blood from the brain extracellular fluid and 
exists at the capillary endothelium, the cells of which are joined together by 
multiple bands of tight junctions that are not present in normal circulation. These 
junctions seal adjacent endothelial membranes, thereby closing off the 
paracellular diffusion space (136), allowing the cerebral microvasculature to 
selectively protect the brain from the rapid changing milieu of systemic 
circulation (137). Unlike small gas molecules (e.g. O2 and CO2) that can diffuse 
freely across lipid membranes into the brain (138), the lipophic nature of the BBB 
precludes circulating hydrophilic molecules from entering the brain. Mechanisms 
thus exist to ensure selective brain uptake of hydrophilic nutrients, amino acids, 
glucose, vitamins, and essential metals including iron (26).  
1.4.1.2 The blood-cerebrospinal fluid barrier 
The other barrier, BCB, is formed by the choroid plexus epithelial cells and the 
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arachnoid membrane (139). The choroid plexus, composed of many capillaries, is 
a vascular tissue present in cerebral ventricles. Unlike the capillaries that form the 
BBB, the endothelium of the capillaries in the choroid plexus has no tight 
junctions and allows the free movement of molecules. The epithelial cells, instead, 
are linked together by tight junctions. The BCB is therefore formed at the choroid 
plexus epithelial cells. The arachnoid membrane envelops the brain and its cells 
are also joined by tight junctions.  
 
The choroid plexus produces the majority of cerebrospinal-fluid (CSF) in the 
brain (100-150 mL in normal adults), which circulates substances from 
ventricular cavities into the subarachnoid space. The CSF is then absorbed into 
venous sinus blood via the arachnoid villi, where the CSF may be filtered by the 
arachnoid membrane. While CSF is known as the major source of the transport of 
a variety of molecules into the brain, it also has a “sink action” by which it 
selectively removes molecules produced during metabolic activity in the nervous 
tissue. The turnover rate of CSF is very high, approximately 3-4 times a day.  
1.4.2 Brain iron distribution 
1.4.2.1 Brain regional iron distribution 
An average adult brain contains approximately 60 mg non-heme iron, distributed 
heterogeneously in accordance to brain structures, with some regions, e.g. 
substantia nigra, caudate nucleus, globus palladus and putamen, containing iron 
well above average levels (140-142). The rank order for regional iron distribution 
in normal brain was found to be globus pallidus> putamen > substantia nigra > 
 35 
 
caudate nucleus > cerebral cortex = cerebellum (143). It is noteworthy that the 
iron levels in substantia nigra and globus pallidus exceed hepatic iron levels, 
retaining iron at concentration of 3.3-3.8 mM in the normal adult brains. These 
two areas belong to the basal ganglia, which is situated at the base of the forebrain 
and which is associated with motor functions. The high brain iron levels can be 
attributed mainly to the high iron requirement in these areas to maintain ionic 
membrane gradients, synaptic transmission and axonal transport (144). Besides 
basal ganglia, iron concentration in hippocampus are also high at ca. 50 ng/mg 
(88). While it is widely accepted that the progressive degeneration of neurons in 
iron rich substantia nigra is involved in the development of PD, the loss of 
neurons cells in iron rich hippocampus is associated with AD. 
1.4.2.2 Cellular iron distribution 
The majority of brain iron is stored in the form of ferritin in brain cells. Neurons 
in many brain regions, however, do not contain ferritin. The abundant presence of 
TfR and the lack of ferritin indicate that the iron uptake by neurons is mainly for 
the immediate use for neuronal metabolic activities and non-utilized iron is 
exported out of the cell after use, possibly via FPN, instead of being stored as 
ferritin (145). In contrast to neurons, glial cells, except astrocytes which are 
largely responsible for iron transport into the brain, express the iron storage 
protein ferritin, indicating that these cells have the capacity to store iron (146). 
The ratio of H- to L- subunit in ferritin, however, varies in different cell types. H-
subunits are mostly expressed in neurons, L-subunits are more abundant in 
microglia and both subunits are expressed in similar amounts in oligodendrocytes 
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(88, 147). When the brain ages, ferritin that contains stable and soluble forms of 
iron is selectively changed into hemosiderin and other oxyhydroxide derivatives 
that sequester relatively highly reactive iron (148), making the brain more 
vulnerable to oxidative stress. 
 
In the brain, the ferritin level in oligodendrocytes is much higher than in neurons 
(145, 149). Due to higher levels of iron, the oligodendrocyte is the principle cell 
type used for iron staining (150). This has led to the hypothesis that the main 
function of oligodendrocytes is myelin production (151), the process of which 
requires the participation of iron. Aberrations in the iron metabolism of 
oligodendrocytes are associated with hypomyelination. Previous studies 
demonstrated that hypomyelination in brain can result from dietary iron restriction, 
suggesting the importance of iron in myelin production (151, 152). During aging, 
the iron content in oligodendrocyte remains relatively constant (153). 
 
Brain iron can also be stored in neuromelanin, one of the primary pigments in the 
human brain. Neuromelanin is a dark-colored, highly insoluble intracellular 
granular pigment that can bind to metals (147, 154). Neuromelanin has a much 
higher affinity for iron than other metals. On binding to iron, it forms stable 
octahedral complexes that contain oxy-hydroxide iron clusters. Neuronal iron is 
predominately bound to neuromelanin (155). In the human brain, neuromelanins 
are commonly found in dopaminergic neurons in the substantia nigra and the 
noradrenergic neurons in the locus coeruleus. Several studies have demonstrated 
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that neuromelanin accumulates during normal aging (154, 156, 157) and might be 
implicated in the development of PD (157, 158) (see section 1.5.2.2.2). The 
melanized dopaminergic neurons are more vulnerable than other neurons (157). 
The preferential loss of the melanized dopaminergic neurons is one of the 
characteristics of PD.  
1.4.3 Brain iron uptake and export 
1.4.3.1 Brain iron uptake 
All tissues in the mammalian body share a common liver-dependent macro-
regulatory system of iron delivery and homeostasis which is based on systemic 
iron circulation and involves regulation of intestinal iron uptake and circulating 
Tf. The three exceptions to this macro regulatory system are CNS, testes and 
retina (159, 160). The CNS is encompassed by the BBB and BCB across which 
iron traverses into the brain. The mechanism of brain iron uptake via these 
barriers has not yet been completely elucidated. 
1.4.3.1.1 The blood-brain barrier pathway 
It was believed for many years that iron uptake by the brain occur predominately 
during infancy before the BBB matured (159). In the last decade, with the 
discovery of the expression of TfR1 by endothelial cells on the luminal side of the 
capillaries (24), accumulating evidence reveals that TfR-mediated endocytosis is 
highly likely to be largely responsible for Tf bound iron uptake across BBB in 
adult mammals (138). Moreover, the expression of TfR on the luminal endothelial 
surface is modulated by iron status within the brain (159). In this pathway, Tf 
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binds to the extracellular portion of the TfR and the Tf-TfR complex gets 
incorporated into endosomes of the cerebral endothelial cells. The slightly acidic 
inner environment of endosomes facilitates iron release from Tf (see section 
1.3.3.3). Besides the TfR-mediated pathway, iron might also transverse the BBB 
via a ferritin receptor mediated pathway as H-ferritin receptors were detected on 
the brain micro-vasculature (24, 161). 
 
Additionally, previous studies report the possibility of non-transferrin-bound-iron 
(NTBI) transport across the BBB cells which serves as an alternative uptake 
pathway for iron in brain (162-164). The NTBI pathway is, however, responsible 
for only a small proportion of iron transport across the BBB especially at low 
serum Tf levels (165). 
 
Iron taken up by the cerebral endothelial cells can be exported into the brain 
interstitial fluid by FPN (166). The existence of FPN in the membrane has been 
demonstrated by immunohistochemistry (167). Alternatively, iron can be released 
into the brain interior via the astrocytes, the end-feet of which encircle the 





 to become apo-Tf, which has a high affinity to 
TfR. Apo-Tf thereafter reenters circulation (168). Astrocytes maintain high 
concentration of protons at the end-feet and release ATP and citrate, creating a 
favorable microenvironment for the release of iron from Tf (24, 166).   
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1.4.3.1.2 The blood cerebrospinal fluid barrier pathway 
It has been reported that the expression of iron-related proteins, e.g. DMT1, FPN, 
ceruloplasmin and hephaestin, in the choroid plexus was higher than in virtually 
all other regions of the brain (85), suggesting that this could be another pathway 
for iron transport into the brain. Few previous radioactive isotope studies have 
demonstrated that the contribution of iron transported through the BCB is minute 
compared to the amount of iron transported through the BBB into the brain (165, 
169). 
1.4.3.2 Brain iron efflux 
It was reported that the human brain conserves iron as the levels of iron-storage 
proteins like ferritin and neuromelanin in the human brains were revealed to 
increase with age (147, 170) (see section 1.5.1). The question remains whether 
iron uptake is uni-directional or bi-directional with a higher influx rate than efflux 
rate for iron. 
 
Results obtained from some previous radio-isotope studies (171, 172) have 
demonstrated that iron uptake by the brain is a uni-directional process with no 
iron export occurring from brain. Other studies, however, suggest that the process 
is bidirectional (168, 173-176). Structurally, the tight junctions of the BCB are 
quantitatively leakier than those of the BBB. Very little is known about potential 
brain iron efflux mechanisms. It is speculated that BCB might be responsible not 
only for brain iron uptake (162) but also for iron efflux in the brain owing to its 
structure and functions (174, 175). Bradbury (1997) proposed a probable route to 
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export brain iron via the bulk drainage of CSF based on the estimation of the 
difference between iron influx rate in rats, iron concentration in CSF of rabbits, 
and the CSF drainage rate in rats (174). It was further demonstrated in rats that 
iron may efflux from the CSF to the blood via the re-absorption of Tf-Fe
3+
 into 
the blood, by the injection of radio-labeled iron into the lateral cerebral ventricle 
(168, 175, 177). However, the estimation by Bradbury (1997) was tentative and 
the method in the rat studies was too invasive to allow iron equilibrium for 
drawing valid conclusions. Despite the presence of fully iron-saturated Tf in CSF 
(174, 178), the low level of Tf in CSF lack of the capacity for iron export via this 
route. The CSF also contains other iron-bound proteins and molecules, such as 
ferritin, lactoferrin and non-protein-bound iron (178, 179), which can serve as 
additional means for brain iron export. Moreover, researchers speculated that the 
iron accumulation rate with age was slower than the rate of iron uptake from the 
blood at the different ages (24, 168), suggesting the presence of a route for brain 
iron efflux. Nevertheless, despite all the speculations and studies on iron efflux 
mechanisms, it is not clear whether iron is persistently conserved in the brain 
without exchange or just enters the brain with an influx rate higher than efflux 
rate that results ultimately in iron accumulation. The understanding of this 
question would shed light onto the pathological mechanisms responsible for 
excessive iron accumulation in the brain of AD and PD patients. 
1.4.3.3 Cellular iron uptake and export in brain 
Iron that crosses the BBB or BCB is most likely to be transported to different 
cells within the brain in interstitial fluid (IF) and CSF bound to brain-specific Tf 
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or in the form of NTBI (e.g. low-molecular-weight proteins such as citrate or 
ascorbate) (152, 162). The brain-specific Tf is synthesized in oligodendrocytes 
and choroid plexus epithelial cells and specifically for brain iron transport (162, 
174, 178). The affinity of Tf to iron is 10
10
 times higher than affinity of citrate to 
iron. Tf is therefore the first molecule to bind free iron among all other iron 
transporters. When Tf in the CSF and IF is fully saturated with iron, the excess 
free iron will thus bind to other transporters (162). 
 
As iron is indispensable for the development and survival of neurons, the 
mechanism for iron uptake by neurons has been investigated intensively (74, 145, 
180). Due to the ubiquitous presence of Tf in the brain extracellular fluids and the 
detection of TfR in the neurons, it is widely accepted that neurons acquire iron 
mainly via a TfR-mediated pathway with the aid of DMT1 to release iron from 
the endosome into the cytosol. However, the role of TfR in iron uptake by glial 
cells is still unclear (181, 182). Though Tf is essential for oligodendrocyte media 
in culture and TfR was found in oligodendrocyte progenitors in cell culture, TfR 
has not yet been detected in oligodendrocytes in vivo. The immunoactivity of TfR 
has not been detected in oligodendrocytes, microglia and astrocytes in adult mice 
(180). Moreover, it has been shown that oligodendrocyte cultures continue to 
acquire iron under the conditions of Tf deprivation. These evidences suggest that 
oligodendrocytes might take up iron through a non-TfR dependent pathway. 
Supporting the notion, H-ferritin receptors were found to be present in 
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oligodendrocyte progenitors. It was proposed that glial cells may acquire iron via 
ferritin-receptor mediated endocytosis. 
 
Owing to the existence of NTBI in the brain extracellular fluids, it was suggested 
that both neurons and glial cells might take up Tf-free iron as an alternative to the 
TfR-dependent pathway (145). The uptake of NTBI by the brain cells might be 
facilitated by the protein SFT (stimulator of Fe transport) across cell membranes 
(183, 184). 
1.4.4 Brain iron regulation 
Despite the tight regulation of iron uptake by BBB and BCB, systemic iron 
fluctuation may occur which could lead to neuronal dysfunction (185). A delicate 
intrinsic regulatory system that is partially independent of peripheral iron status 
was therefore, proposed to be in place to control brain iron metabolism (186). 
Scientists debate if there are similarities between systemic and CNS iron 
regulation (159). Studies indicate that, in response to iron-depletion, animals 
increase iron uptake in the CNS by increasing TfR expression in brain endothelial 
cells (174), while in HFE-related iron-overload hemochromatosis patients, iron 
was found to accumulate in specific regions in the brain. These studies have led to 
the suggestion of the involvement of the cellular IRP/IRE regulatory system and 
systemic hepcidin-mediated pathway in the maintenance of brain iron 




Key proteins of iron metabolism that are encoded by IRE-containing mRNAs 
(120), are also found to be expressed in various cell types in the brain for different 
functions, including iron uptake (TfR1 and DMT1), iron storage (ferritin) and iron 
export (FPN). The possible role of IRP/IRE regulatory system on brain iron 
regulation has been further demonstrated by genetically modified animals with the 
deletion of IRP-related genes, which were shown to be involved in the process of 
neurodegeneration (24, 159, 187). In addition, an increased stability of the IRP-
IRE complex in AD patients was revealed by Pinero et al. (2000) (188), resulting 
in an elevated level of TfR1 and a lower level of ferritin in the brain, possibly 
contributing to iron accumulation (189). 
 
With regard to the hepcidin-mediated regulatory pathway (see section 1.3.7.2), it 
is unclear whether the CNS relies entirely on the peripheral hepcidin or utilizes 
intrinsic hepcidin (186). The gene expression for hepcidin was revealed to be 
widespread in both human and mouse brain although the expression of hepcidin 
protein was found to be low in mouse brain (186, 190). The expression of the 
hepcidin targeted protein, FPN, has been reported in neurons in mice and rats 
though controversies remain about the FPN expression in cell types, like 
endothelial cells and astrocytes (167, 191). 
 
The hypothesis that the brain shares the similar hepcidin-mediated regulatory 
system with the liver is still in debate (186). The expression of hepcidin in liver is 
regulated by multiple proteins, e.g. HJV, TfR2 and HFE etc. Though the mutation 
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in these genes will induce iron-overload in the body system, the effect of their 
mutation on the brain iron status is known to be limited (159). This might be 
partly due to the low expressions of these proteins in the brain (192, 193). 
 
In contrast to the liver, the brain might adopt other regulatory systems to control 
brain iron homeostasis (186, 194). One of the possible regulatory pathways might 
be blocking the brain iron uptake via HFE protein in response to high iron status. 
The expression of HFE protein is co-localized with that of TfR1, suggesting the 
role of HFE in brain iron uptake via the interaction with TfR1 (195). Bennett et al. 
(2000) and Feder et al. (1996) reported that the competition for TfR between HFE 
and Tf resulted in cellular iron change by the blocking of endocytosis of iron 
uptake (196, 197). 
1.5 Iron and neurodegeneration 
1.5.1 Age-related iron accumulation in brain 
Age-related iron deposition in the brain has been observed in all species 
examined, including mice, rats, monkeys and humans (198-203). To date, both 
post-mortem (203-205) and in vivo MRI studies (142, 206, 207) have 
demonstrated that compared to younger controls iron deposits in the brain of older 
individuals are increased. The pioneering work of Hallgren and Sourander (1958) 
showed that the rate of accumulation of whole brain iron increases sharply during 
growth, slows down after the first three decades of life and reaches a “plateau” or 





Fig. 1-6 Relation between the non-haemin iron and the age in different cortical fields 
Relation between the non-haemin iron and the age in different cortical fields. (1) motor cortex; (2) occipital 
cortex; (3) sensory cortex; (4) parietal cortex; (5) temporal cortex; (6) prefrontal cortex. This figure is 
obtained from Hallgren and Sourander  (1958) (203). 
 
 
Moreover, iron accumulation is regionally clustered in the brain (206, 208). Motor 
function-related brain regions, e.g. basal ganglia and hippocampus, were 
demonstrated to have higher iron levels in adult individuals compared to other 
non-motor associated regions (163, 209-211). Studies have proven that these 
motor related regions have little iron at birth and accumulate significant amounts 
of iron with age (147, 209).  
 
This age-related iron accumulation in the brain is consistent with “the free radical 
theory of aging” discussed below. 
1.5.2 Iron and neurodegeneration 
1.5.2.1 The free radical theory of aging 
During the aging process, living organisms undergo gradual alterations that lead 
to both structural changes and functional decline, compromising the ability to 
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cope with internal and external challenges, which ultimately increase the 
probability of contracting diseases and causing death (36, 200, 212). Among the 
more than 300 theories on aging, the “free radical theory of aging” proposed by 
Harman 1956 has attracted a lot of interest (213) and reported to be the most 
prone to intervention (36, 214). The basic concept of the theory is that during 
aging, the balance between free radical induced damage in cell components and 
antioxidant defense system progressively shifts in favor of the former (36, 200). 
However, the exact molecular mechanisms underlying this theory remain an 
enigma. As excess free iron can possibly lead to the generation of ROS, iron may 
accumulate in the brain with age not only in general but also regional specifically, 
promoting the oxidative damage in the brain via free radicals. 
 
Though iron also accumulates in other body organs with age, due to its special 
properties, the brain is considered more susceptible to oxidative damages 
accompanying aging than other tissues (39, 47). First of all, it has a high demand 
for oxygen, the main source of ROS, to maintain its normal function, consuming 
up to 20% of the total oxygen usage for its relatively small weight (2%). It also 
possesses more easily peroxidizable unsaturated fatty acids (20:4 and 22:6) which 
are vulnerable to the attack of free radicals (215). In addition, the CNS is not 
equipped with strong antioxidant defenses despite the needs. For instance, the 
catalase activity in brain is 10% lower than that in liver. The abovementioned 
properties collectively lead to a supposedly high age-related oxidative stress in the 
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brain, potentially resulting in a higher risk of developing dementia and 
neurodegenerative diseases in the aged populations. 
 
Supporting the notion, recent studies have shown that iron accumulation in the 
brain with age may contribute to the functional cognitive decline (216-220). 
Penke et al. (2012) demonstrated that higher iron deposits were correlated with 
lower cognitive ability in human subjects with various ages using MRI (217). 
Similarly, another study identified that higher iron level in the basal ganglia was 
associated with lower scores on the Dementia Rating Scales and longer reaction 
times with the semi-quantifying method for iron deposits with MRI (220). Iron 
levels elevating in other brain regions, e.g. hippocampus and frontal cortex, was 
revealed to correlate with DNA strand breaks, potentially jeopardizing the 
functional ability of the brain (219). On the other hand, one study conducted on 
monkeys discovered that lower level of brain iron in basal ganglia and temporal 
cortex might lead to a reduction in age-related inflammation and oxidative stress 
(218).  
1.5.2.2 The roles of iron in Alzheimer’s and Parkinson’s diseases 
Neurodegenerative disorders (NDD), are on the rise with AD and PD, the two 
most common NDD, expected to reach epidemic levels in the coming decades (1, 
2). This situation will pose tremendous economic and social burden on the 
society, necessitating a better understanding of the etiology of the two diseases for 




Although the etiologies of AD and PD are still not completely understood, many 
lines of evidences support that iron accumulation in the brain with age is 
implicated in the pathogenesis of age-related AD and PD with the iron induced 
oxidative stress as the underlying mechanism. A good deal of studies have shown 
that, as compared to the age-matched control subjects, elevated levels of iron were 
observed in hippocampus of AD patients and substantia nigra of PD patients, 
although it remains unclear whether this represents a cause or a result of neuronal 
destruction. In addition, the abnormal iron deposits in the brain of AD/PD patients 
could be a consequence of malfunction in iron homeostasis, which might serve as 
one of the primary causes of the diseases (33, 147, 221, 222). Advancing the 
understanding of the relationship between iron and AD/PD can help us identify 
the cause of the diseases and the development of relevant therapeutic and 
preventive measures.    
1.5.2.2.1 The role of iron in Alzheimer’s diseases 
An imbalance of brain iron homeostasis is suggested to be implicated in the 
pathogenesis of AD (4). As mentioned, increased levels of iron demonstrated by 
brain MRI scans were observed in hippocampus in AD patients as compared to 
healthy age-matched controls (223). In addition, a growing body of evidence 
supports the role of iron-associated oxidative stress in AD, which is manifested by 
elevated levels of lipid peroxidation, free radical formation, oxidation products of 





More specifically, brain iron is inextricably linked with the two pathological 
hallmarks of AD: senile plaques and neurofibrillary tangles (NFT). The former is 
created by extracellular insoluble amyloid-β peptide (Aβ) whereas the latter is 
formed by the aggregation of protein tau and collapsing of microtubule that 
results from it (228).  
 
Goodman in 1953 first described the presence of large amount of iron in AD-
associated senile plaques (229), where the accumulation of iron is up to 3 times 
that of normal neutrophil levels (940 µM compared to 340 µM) (230). In line with 
the abovementioned findings, Aβ deposition was observed in the same regions in 
AD brains where iron also accumulated, such as hippocampus (231, 232). Iron 
might be implicated in the process of Aβ aggregation since the binding of metal 
ions is supposed to be an integral part of this process (233, 234). In presence of 
iron, Aβ can efficiently reduce Fe3+ to generate hydrogen peroxide. The generated 
H2O2 may degrade to form unstable ROS via Haber-Weiss reaction and Fenton 
Chemistry, resulting in cellular oxidative damage and subsequent cell loss and 
neuronal dysfunction (235). This may explain the observed increased oxidative 
stress in concurrence with increases iron deposits and Aβ aggregation. 
Furthermore, iron is also involved in Aβ formation, 
 
Aβ is produced by the proteolysis of amyloid-β protein precursor (APP). The 
production of Aβ however, can be terminated by the cleavage of APP via α-
secretase to form a neuroprotective sAβPPα fragment. This process is promoted 
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by furin protein, which is capable of converting precursor proteins into their 
biologically active form (236). The expression of furin protein is modulated by 
the brain iron level. When brain iron concentration increases, the furin protein is 
down-regulated, leading to the reduced level of neuroprotective sAβPPα fragment 
and promoting production of Aβ (237). It was therefore proposed that the 
regulatory role of iron in the expression of furin protein may also play a role in 
AD development which would explain elevated levels of iron and Aβ found in 
brains of AD patients.  
 
Moreover, it is also reported that APP might potentially play a role in iron 
regulation. The two most notable features of APP implicated in the process are, 1) 
an IRE is located on the 50 untranslated region of APP and the subsequent APP 
translation event is influenced by iron levels (228, 238, 239), 2) APP contains a 
REXXE ferroxidase consensus motif (184), implying a ferroxidase activity in 
neurons (235). As iron is present in cytosol in ferrous form, the cellular Fe
2+
 




, which is subsequently 
transported out via FPN on the cell surface (34). Numerous studies indicated that 
APP possesses ferroxidase activity and is able to facilitate the export of Fe
2+
 from 
cultured neurons, in an attempt likely to minimize the potential ROS generation 
by the presence of reactive iron (240, 241). However, the ferroxidase activity of 




Furthermore, iron deposition was also observed in neurons with NFT (243). Ferric 
iron was reported to have the ability to bind to the tau protein, promoting of the 
aggregation of hyperphosphorylated tau and the subsequent formation of NFT. It 
was also recently revealed that the amount of tau protein is inversely correlated 
with the number of APP on neuronal surface. The increase of tau protein in 
specific regions of AD patients can potentially lead to neuronal iron retention by 
decreasing the number of APP on the cell surface (242). 
1.5.2.2.2 The role of iron in Parkinson’s diseases 
PD is clinically manifested by the degeneration of the dopaminergic neurons in 
the substantia nigra pars compacta (SNpc) (228), to which chemical properties of 
iron have been linked (5). Under normal physiological condition, iron distribution 
within the brain is cell-type dependent and iron is found most abundant in regions 
rich in dopaminergic neurons in globus pallidus and SN of the basal ganglia (143, 
244-246). However, an augmented iron level was demonstrated in SN in PD by 
studies employing different techniques as compared to age-matched controls (247, 





 ratio from 2 : 1 in normal subjects to 1 : 2 in PD (249, 250). This 
abnormal deposition of iron in the brains of PD patients reflects a dysfunction of 
brain iron homeostasis (245, 248, 251). To date, the mechanism behind the altered 
iron level in PD, however, remains an enigma. 
 
A growing body of evidence has suggested that the ability to sequester the excess 
redox active metals in the brain has been compromised in PD patients. In healthy 
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individuals, excess iron in the brain can be sequestered in ferritin and 
neuromelanin. Approximately half of the total neuromelanin is saturated with 
iron, suggesting a neuroprotective role. As brain iron content is found to be 
increased in PD as compared to normal subjects, the normal physiological 
response would be an up-regulation of ferritin and neuromelanin expression in 
PD. However, a marked reduction of both ferritin (248, 251) and neuromelanin 
(252) coupled with the alteration of neuromelanin structure was demonstrated in 
PD patients (33) and may compromise their abilities to sequester the redox active 
metal, leading to the accumulation of free iron that is able to produce free 
radicals, ultimately resulting in cell death. 
 
Iron is also shown to be associated with the hallmark of PD, Lewy bodies, which 
are formed by the aggregation of intracellular, eosinophilic protein. They mainly 
consist of α-synuclein and are observed in dopaminergic neurons, axons, and 
synapses of SN (253). The aggregation of α-synuclein was shown to be promoted 
by iron (254, 255). Previous studies reveal that the removal of free iron with the 
iron chelators desferrioxamine can block the aggregation of α-synuclein (256, 
257). In addition, α-synuclein can exacerbate oxidative damage via the generation 
of OH
•
, triggering the PUFA peroxidation, promoting the formation of HNE, a 
reliable oxidative stress marker, which was identified immunohistochemically to 




PD is characterized by the loss of dopamine-secreting neurons in SN. Although 
iron is a pivotal cofactor of tyrosine hydroxylase and monoamine oxidase, both of 
which are important for dopamine metabolism (228), iron can also promote the 
oxidation of dopamine that may lead to oxidative stress via the generation of 
hydrogen peroxide catalyzed by iron. Furthermore, iron is able to catalyze the 
conversion of excess dopamine to neuromelanin, a redox active iron sequester 
with a high affinity for Fe
3+
. Neuromelanin tends to become a pro-oxidant when 




 back to Fe
2+
, which is then released due to 
its weak affinity. The released Fe
2+
 thus increases the fraction of iron participating 
in the ROS-generating reactions.  
1.5.3 Dietary iron and neurodegeneration 
Neurodegeneration, accounting for the major impediment of healthy aging, can be 
influenced by numerous factors namely genetic factors, environmental factors, 
and life style factors. In the absence of effective curative treatments for NDD like 
AD and PD at present, preventive measures are of significance to lessen the 
disease burden. The potential effect of nutrition has become a topic of increasing 
scientific and public interest (12, 258, 259). In light of the effect of dietary iron on 
brain iron and that iron is implicated in the pathogenesis of AD/PD, the role of 
dietary iron in the development of AD/PD starts to gain research interest. Even 
after age correction, the prevalence of the age-related AD and PD still increases 




This increasing trend could be attributable to the worldwide rising affluence, 
which shifted the diet paradigms to a high-iron based pattern – an increased 
dietary intake of highly bioavailable form of iron (red meat, iron-fortified food 
and iron supplements) (8). Evolutionary, the human body is virtually a closed 
system for iron with minimal habitual losses (117) to store iron for reproduction 
as iron is vital for life (260). With increased dietary iron intake, high iron stores 
might result from body iron accumulation if ingested dietary iron overcorrects for 
habitual losses. 
 
High iron stores, however, is associated with increased oxidative stress in the 
body, which can accelerate the aging process (214, 261, 262). Data showed that 
abnormally high body iron stores were observed in approximately 10% westerners 
for various reasons, e.g. genetics, diet and others (263). Whether high body iron 
stores are associated with higher risk of NDD, however, remains unclear (264). 
But studies demonstrated that individuals with iron metabolism protein encoding 
gene variants (hemochromatosis H63D; HFE H63D) have higher iron stores, 
higher brain iron levels (265) and shorter life expectancy (266).High body iron 
store, therefore, might be related to increased iron accumulation in the brain, 
which is implicated in age-related neurodegeneration (267). The understanding of 
the effect of dietary iron on adult brain iron and its implication in the development 
of AD/PD are therefore, of utmost importance. 
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1.5.3.1 The effect of high dietary iron intake on brain iron homeostasis 
Some researchers demonstrated that, unlike the liver (268), moderate dietary iron 
supplementation had minimal effect on brain iron content of both young animals 
(269, 270) and adult animals (271, 272). However, extremely high dietary iron 
can induce a detectable increase in total brain iron content (270) as well as 
regional brain iron of young rats (cortex, hippocampus, striatum and substantia 
nigra) (273). The abovementioned observations suggest that brain iron is highly 
regulated even if dietary iron supply is moderately high (<5 g per kg body weight 
per day); however, the brain iron regulative system is compromised when dietary 
iron intake is extreme (>10 g iron per kg body weight per day). This was further 
supported by the observation that increased glutathione levels (antioxidant 
defense) were associated with moderately high iron intake whereas reduced 
glutathione levels were linked with extremely high-iron diet (274). 
 
The high tolerance of brain iron in response to high dietary iron intakes can be 
basically attributed to the tight regulation of iron transport through the BBB. It 
was suggested that the expressions of TfR as well as TfR mRNA in endothelial 
cells were decreased in response to dietary iron overload (273, 275). 
Alternatively, similar to the response observed in low-iron diet (166), in the event 
of high peripheral iron supply, the brain might regulate the brain iron uptake via a 
slower TfR turnover in the brain capillary endothelial cells as compared to normal 




Besides the changes in brain iron uptake, high dietary iron may result in subtle 
changes in other iron-relevant gene and protein expressions in the brain, e.g. an 
elevated level of ferritin and a decreased level of Tf (188). In addition, microarray 
analysis of mouse brain gene expression showed that transcripts for IRP1 
decreased and transcripts for L-ferritin increased in response to high dietary iron 
(263). On the contrary, another study demonstrated that ferritin expressions were 
not altered by dietary iron overload (26).  
1.5.3.2 The effect of systemic iron deficiency on brain iron homeostasis 
As iron deficiency and iron-deficiency anemia remain severe nutritional problems 
worldwide among infants and adolescents, the effect of iron-depleted diet on brain 
iron has been extensively studied during the developmental stage of humans (32, 
152) and animals (176, 276-279), but much less during adulthood.  
 
In light of the role of iron in neuronal function and metabolism, the lack of iron in 
the infant diet was reported to lead to the delay of neuronal development as a 
result of alterations in neurotransmitter synthesis, myelin formation and other iron 
iron-involved neuronal processes (152). 
 
Animal studies demonstrated that dietary restriction on young animals resulted in 
a decrease in brain iron content as well as ferritin level (277, 278, 280). The brain 
iron, however, is less responsive to dietary iron alteration than liver iron, the level 
of which was largely reduced (174). But brain iron repletion is much slower than 
that of liver, probably due to the slower iron turnover rate of brain (174, 176, 
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276). Besides the decrease in brain ferritin levels to maintain brain iron 
homeostasis in the event of low body iron status, the brain also increases the Tf 
levels to accelerate brain iron transport (277), especially in hippocampus (281). 
 
The uptake of brain iron is highly regulated upon entering the BBB via the TfR-
dependent endocytosis pathway. Although expression of TfR in endothelial cells 
in response to low dietary iron is still not completely understood, it was shown 
that brain iron uptake was greater in iron-deficient animals than that in controls 
(169, 282). It was revealed that an increased number of TfR in brain capillary 
endothelial cells was observed in iron-deficient animals (74, 275). In addition, 
TfR turnover rate was found to be elevated by the brain iron regulation system to 
cope with low body iron status (26, 166).  
 
Different from the early stage of life when iron is in high demand for neuronal 
development in the brain, brain requirements are much lower later in life.  
However, as the brain is designed to conserve its iron, the iron obtained in the 
early stage might be largely retained within the brain. This concept is supported 
by the observation of age-related iron accumulation in different brain regions 
(203). In adults, the body might be less sensitive to the alteration of dietary 
restriction as previous studies reported that total body iron store increased with 
age (283) and potentially had higher tolerance for low-iron diet. This was 
reflected by relatively constant brain iron content in adult rats treated with iron-
deficient diet as compared to the control (280). 
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1.5.3.3 Dietary iron and risks of Alzheimer’s and Parkinson’s diseases 
In light of the above-discussed effect of dietary iron on brain iron, the relationship 
between dietary iron and the development of AD/PD is worth investigating. 
 
Albeit relationships between the diet and cognitive decline or AD/PD have been 
extensively investigated in previous epidemiological studies, research focus lied 
largely on the combined effect of dietary factors (284-286). Very few studies 
investigated the effect of a specific dietary component such as iron on the 
development of AD/PD. 
 
Most epidemiological studies revealed that dietary iron intake correlates with 
cognitive decline or risks of contracting AD/PD while a few studies could not find 
such a correlation or found an opposite effect. A study conducted in Japan has 
shown that higher iron intakes have a protective effect against PD (12) while 
other studies suggest that high dietary iron intake may contribute to the risk of 
developing PD (9-11). Interestingly, data obtained by Logroscino et al. (2008) 
failed to support an association between total iron consumption and risk of PD but 
suggested that a diet containing high non-heme iron increases the risk of PD (13). 
With regard to AD, it was proposed that excessive iron intake should be avoided 
in order to prevent AD (14, 287) whereas findings reported by Ortega et al. (1997) 
suggest that increasing iron intake may be advisable not only to improve cognitive 
function but also to improve the general health of the elderly (15). However, 
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epidemiological studies are chronically sensitive to unidentified confounding 
factors which may explain contradictory findings.  
 
In contrast to epidemiological studies, animal studies point to a clearer correlation 
between dietary iron intake and risks of age-related NDD. Arruda et al. (2013) 
proposed that iron supplementation accelerates the aging process whereas iron 
restriction retards it (268). In line with this finding, Shoham et al. (2004) reported 
that nutritional iron deprivation attenuates the neurotoxicity induced in rats (288). 
As progressive neurodegenerative diseases do not afflict rats or mice (289), 
researchers commonly induce the disease-like symptoms in a rodent model by the 
injection of neurotoxins (e.g. 6-hydroxydopamine (6-OHDA) or 1-methyl-4-
phenyl-1,2,3,6-tetrapyridine (MPTP) for PD) or use transgenic mouse models 
(e.g. Tg2546 mice generated for AD based on double mutation in APP gene) to 
test new neuroprotective agents or strategies (21, 290, 291). 
 
The results obtained from dietary iron manipulation studies in animal models of 
AD/PD suggest that iron-loaded diet shall be avoided for the prevention of 
AD/PD. In MPTP-treated mice, researchers found that an iron-loaded diet 
contributed to the etiology of PD (292, 293). In addition, dietary iron restriction 
protected the mice against PD-inducing insults but the essential role of iron in 
neuron production and dopamine synthesis should also be taken into consideration 
(290, 294). In a transgenic mouse model of AD, spatial memory impairment was 
observed in the iron supplemented group as compared to the control group (295). 
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1.5.3.4 Strategies for reducing brain iron content 
In consideration of the protective effect of iron deprivation on PD/AD, clinical 
iron chelators (e.g. clioquinol, VK-28, M30 and desferrioxamine etc.) have been 
tested for their efficacy to alleviate disease symptoms of AD/PD both in animal 
models and in clinical trials (16-21, 296-299). The results obtained from these 
studies are promising. However, problems accompanying iron-chelator treatment 
are emerging: 1) the side effects of the long-term treatment, e.g. iron chelators 
interact with other metabolic pathways in the body and thus affect the 
homeostasis of the interacting substances; 2) the toxicity of the inactive iron 
chelators deposited in the body - chelators are supposed to be designed to 
scavenge free iron and be excreted them safely through urine; 3) the sizes of the 
iron chelators are required to be small enough to cross the BBB to target the labile 
iron in the brain. 
 
In light of the current obstacles in the application of clinical iron chelators, dietary 
iron chelators/free radical scavengers/antioxidants/iron absorptive inhibitors 
(phytic acid in legumes/cereals/seeds and polyphenols in tea) can serve as 
alternatives in the prevention of AD/PD or to alleviate the symptoms (22, 23, 300-
305). 
 
In line with previous findings that tea consumption is able to lower the risk of 
AD/PD (302, 306), it has been extensively reported that polyphenolic compounds 
(22, 301, 305, 307, 308) present in tea have the ability to penetrate the BBB (244, 
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304) and are proven to be effective in neuroprotection. However, as compared to 
green tea, black tea which accounts for 80% tea consumption worldwide (309), 
received much less research attention. The differences between these two types of 
tea are the distinct multimeric polyphenols (thearubigins and theaflavins) present 
in black tea as a result of the oxidation and fermentation of catechins, the 
processes of which are absent in green tea production (23). As theaflavins are the 
strongest antioxidants among catechins (310) and black tea is a more potent 
inhibitor in iron absorption than green tea (311), black tea consumption, not green 
tea, is inversely correlated with risks of PD.  
 
Phytic acid, enriched in legumes and seeds, is an effective iron-chelating agent, 




 but suppressing the hydroxyl radical 
formation catalyzed by iron (312). Studies both in vivo and in vitro demonstrated 
that phytic acid protects the neurons against dopaminergic cellular apoptosis (300) 
and has beneficial effect on amyloid-β pathology (313). 
 
On the whole, a majority of evidences indicate that dietary iron can serve as a 
possible intervention approach to prevent AD/PD or delay their onset while some 
other studies raised doubts on the effect of dietary iron. The conflicting statements 





2 Chapter 2 Methodology 
Due to limited information on the effect of dietary iron intake on brain iron 
balance in adulthood, a novel technique was developed in this project for long-
term tracing of dietary iron into brain in adult rats. 
 
There are several reasons why rats were chosen as a model organism, one of them 
is the large library of neurological information of rats (314). Furthermore, iron 
metabolism and the sequence of events in iron transport to the rat brain share 
many common features with those of humans and connections can easily be made 
(28, 315). Having a life-span of 2-3 years, the rat is also among the shortest-lived 
mammals (316). This makes rats ideal for long-term feeding experiments in 
relation to ageing processes. In fact, the observational period of 4 months in rats 
in our experiments is equivalent to approximately 7-10 human years (317). Mice 
can also be used as a model organism to study long-term dietary iron effect on 
brain. However, due to the small size of the animal, the amount of iron inside the 
mouse brain is limited and thus requires extremely demanding technique for 
quantification. It is therefore less suitable for iron tracing studies. Despite all the 
listed advantages of rat models, data obtained from rat studies still requires 
extremely careful interpretation as humans and rats are still different organisms. 
 
In the conducted experiments, we were interested to understand how dietary iron 
intake affects brain iron accumulation during young adulthood as iron 
accumulation at this stage of life might be related to the development of AD/PD at 
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advanced age. The rate of whole brain iron accumulation in humans was reported 
to increase steeply during the first two decades of life, slow down during the third 
and fourth decades and reach a “plateau” thereafter or the increment is minimal 
(203). A similar trend was also observed in rats and the increment slows down at 
about the fourth month of life (172, 275, 318-320). Adult rats that are 6-8-month 
old were therefore chosen, corresponding to an age of twenty-odd human years. In 
this project, stable isotope techniques were used to trace the fate of dietary iron 
and to investigate the effect of dietary iron intake on brain iron at the systemic 
level. 
2.1 The application of isotope tracing techniques in nutritional 
studies 
2.1.1 Stable isotopes versus radioactive isotopes 
Isotopes have been widely used as tracers. The use of isotopes as tracers in 
metabolic research can be traced back to 1923 (321). Hevesy published the first 
study on the application of radioactive isotopes in studying metabolic processes of 
plant in 1923. He used the naturally radioactive 
212
Pb as radioactive tracer to 
follow the absorption and translocation of lead in the plant. Later in 1942, the first 
tracer study to investigate mineral metabolism in animals was conducted using a 
radioactive iron isotope – 59Fe (322). The application of radioisotopes was soon 
extended to human studies (323). With the increasing availability of enriched 
stable isotopes of minerals after the Manhattan Project during World War II, the 
use of stable-isotope tracer started to gain popularity in mineral metabolic 
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research (324). The use of stable-isotope tracer was further expanded in the last 
few decades with the advances in mass spectrometric instrumentation for 
providing highly accurate and precise isotope ratio measurement. 
 
With regard to the study of iron metabolism in the body, both radioisotopes and 
stable isotopes are commonly used as tracers; however, both types of tracers have 
their own merits and limitations, which are summarized in Table 2-1 (325). 
 
Table 2-1 Merits and limitations of the use of radioisotopes and stable 
isotopes as metabolic tracers 
(This table is modified from Patterson et al. (2001) (324)) 
 
Radioisotopes Enriched stable isotopes 
Safety Potential risks for the subjects and the 
researchers 
No risks 
Dose True tracers, relatively lower dose Sufficient amounts must be given to be 
detectable 
Study time Dependent on the half-life of the 
radioisotope 
No time restrictions 
Sample 
storage time 
Dependent on the half-life of the 
radioisotope 
No time restrictions 
Study design One radioisotope is generally given Multiple isotopes of an element and/or 
isotopes of different elements can be given 
simultaneously 
Cost Relatively inexpensive Generally expensive 
Analysis and 
Detection 
Direct quantification via the detection 
of emitting particles and/or gamma 
rays; 
Whole-body counting allows in vivo 
measurement;  
Less demanding for instruments and 
researchers due to good measurement 
sensitivity. 
Indirect quantification via the induced 
changes in isotopic abundances; 
Whole-body counting not available; 
Extensive sample preparation;  
Sophisticated instruments and technicians 
are required for good measurements. 
 
In most nutritional studies, dietary iron is the tracee and iron isotopes can serve as 









Fe with their natural abundances as 5.85%, 91.75%, 2.12% and 0.28% 
respectively (326). The enriched forms of the isotopes with lower natural 
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Fe. In addition, 
iron has a number of radioactive isotopes, out of which 
55
Fe (67, 327, 328) and 
59
Fe (176, 329, 330) are widely used as tracers due to their relatively long half-
lives. The former has a half-life of 2.73 years and emits X-rays in the electron 
capture decay process, whereas the latter has a half-life of 44.5 days and emits γ-
radiation in the β-decay process (331). The strong penetrating power of γ-
radiation has enabled a wider use of 
59
Fe as tracers in this field as compared to 
55
Fe. 
2.1.2 The application of radioisotopes to assess brain iron metabolism 
Brain iron uptake mechanisms and underlying kinetics have been extensively 
investigated using radioisotopes. These studies were, however, largely based on 
the single administration of a radiotracer (
59
Fe) to groups of young animals, 
usually through intravenous or peritoneal injection, and sacrifice of animals some 
time after dose administration (Table 2-2). While this technique permit to study 
short-term iron turnover in the brain, it is less suitable to assess the effect of diet 
on brain iron content as well as brain iron balance due to the short half-lives of the 
radiotracers. For a single dose, the time span between injection and sampling must 
be long enough to take brain iron turnover into account. Moreover, tracer 
administration by injection circumvents the intestine as the main regulatory 
barrier for maintaining body iron homeostasis. In consequence, this approach does 





Unlike radioisotopes, stable isotope techniques can be applied in long term 
nutritional studies and pose no risks to the involved personnel (324). However, to 
the best of our knowledge, long-term studies involving continuous feeding of 
stable isotopes have not been conducted so far. Such an approach allows not only 
to study brain iron uptake as in earlier experiments but also, for the first time ever, 
to study efflux of iron from brain that has been taken up earlier by the brain 





Table 2-2 Summary of studies on brain iron uptake using radioactive isotope techniques on animal models*. 














2-59 days 59FeCl3 
I.P. 
24 hrs Perfusion 
Iron uptake by rat brain increased from Day 3 to 
15, and dropped sharply from Day 15 to 35; Brain 
iron content thereafter remained relatively 
constant. 
15 days 59FeCl3 6 -135 days Perfusion Slow brain iron turnover: virtually no loss of 





Normal 17-25g 59Fe3+ I.V. 90 mins Decapitation 
Iron and Tf have transport systems across the 
BBB that are bidirectional and slow 
Dwork et.al., 
1990 (332) 





Iron acquired by the rat brain at 15-days was 
sequestered but translocated from different areas 
with development.  
28 days 14 -28 days 







7-70 days 59FeCl3 I.V. 2 hrs Perfusion 
Iron uptake in to the rat brain climbed rapidly 
during the first 15 days of life, reaching the peakat 
the 15th day and declined thereafter. 
15 days [59Fe-125I] Tf I.V. 0-312 hrs Perfusion 






ID/IL/normal 15-63 days [59Fe-125I] Tf I.V. 2 hrs Perfusion 
1. Iron uptake is greater in ID rats and lower in IO 
rats 
2. The expression of TfR on the brain capillary 








15 - 63 
days 




1. Iron uptake by the rat brain is unidirectional 
2. Iron uptake into the brain and CSF decreased 
with age 
3. Iron uptake by the brain was greater in the ID 
rats than in controls at the age of 21 days. 
63 days 56 days Non-perfusion 
ID 
18 days 56 days Non-perfusion 





Normal 650-700g 59FeCl3 I.V. 5 min-8 days Decapitation  
1. The BBB permeability to iron is ~15 times 
higher than to Tf; 
2. Regional iron distribution by autography and 
histochemistry 
3. The route of brain iron uptake 
*Abbreviations: SD: Sprague Dawley; WT: Wild-type; HP: hypertransferrinemic; IL: iron loaded; ID: iron deficient; IV: intravenous; IP: intraperitoneal. 
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Table 2-2 (continued) Summary of studies on brain iron uptake using radioactive isotope techniques on animal models*.





















Iron influx into the brain is dependent on TfR 




















Iron uptake by the mouse brain occurred in the 
following order: cerebellum > brainstem > frontal 
cerebral cortex > parietal cortex > occipital cortex 









Although iron transport across the BBB is largely 









[59Fe-125I] Tf I.V. 2/24 hrs Perfusion 
1. Once 59Fe had entered the brain no chelator used 
was able to mediate its release 
2.Similar iron uptake mechanisms for femur and 
brain 










ID diet (Age 
28 - 56 days) 
14 days 
59FeCl3 




Sequestration of cerebral iron acquired at age 2 
wks and its distribution were not affected by ID 
diet 
Normal 28 days 
I.P. on Day 
28 
14 days Regional iron distribution 
ID diet (Age 
21 - 49 days) 
21 days 
I.P. on Day 
50 
13 days 
The choroid plexus might buffer the brain against 








15 - 63 days [59Fe-125I] Tf I.V. 2 hrs Perfusion 
1. ID rats had lower liver iron levels and elevated 
brain iron uptake as compared to the controls. 
2. The level of lead intoxication produced in this 
investigation had no impact on iron uptake by the 
brain 




Table 2-2 (continued) Summary of studies on brain iron uptake using radioactive isotope techniques on animal models*.














Normal 15-56 days 
[59Fe-125I] 
Tf 
I.V. 2 hrs Perfusion 
NTBI is present extracellularly in CSF and 

















4-72 hrs Perfusion 
1. Injected Tf disappeared after 24 hrs, whereas 
18% 59Fe retained in brain parenchyma in 50-day 
rats. 
2 .59Fe was remained to a higher degree in young 





Normal/IL 12 wks 59FeCl3 I.V. 1 hr/1 wk Perfusion 






Normal/IL 7 days 59FeCl3 
Subcutaneous 
injection 
24 hrs Decapitation 
1.Brain iron distribution is changed by Tf 
deficiency; 






Normal/IL 10 wk 59FeCl3 I.V. 24 hrs Decapitation 
The concentrations of 59Fe  in all brain regions 
tested of iron-loaded mice were approximately 
40–50% of those of control mice except the 






Normal 9-12 wks 
59Fe; 
[59Fe]Tf 
Infusion 5-30 mins Perfusion 
For iron delivery to the CNS, the transport of 
circulating Tf-bound and free iron could be 














I.V. 120 mins Perfusion 
Brain iron transport and distributional pattern of 
DMT1 




Table 2-2 (continued) Summary of studies on brain iron uptake using radioactive isotope techniques on animal models*













diet/ID diet  
(8 wks 
feeding) 
~11-12 wks 59FeCl3 I.V. 24 hrs Perfusion 
1. Iron uptake by the brain may be constitutive 
and independent of plasma Tf, Tf saturation, or 
regional brain iron concentration; 
2. The data is supportive of a NTBI pathway. 











I.V. 5-60 mins Perfusion 
Brain capillary endothelial cells probably mediate 
iron delivery into the brain by separating iron from 














I.V. 12 hrs-28 days Non-perfusion 
A kinematic model of the dynamic system of iron 
pools and fluxes, including the brain 




2.2 The use of stable isotopes as tracers 
To trace iron from diet in and out of brain or other tissues in an animal model, the 
iron in the test diet (tracee) has to be labeled isotopically. When using enriched 
stable isotopes as labels (tracers), they are not distinguishable from the stable 
isotopes in the sample due to their identical physical and chemical characteristics 
(340). The amount of iron tracer retained in the brain/other tissues, therefore, can 
only be quantified indirectly via the induced changes in the iron isotopic 
abundances in the sample by the tracer addition. As isotopic abundances in nature 
are highly constant, the greater amount of the tracer present in the sample, the 
more the isotopic abundances are altered (341). The underlying mathematical 
concept is known as the ‘isotope dilution’ principle (see section 2.2.1). With the 
calculated amount of iron tracer detected in the brain and the ratio of the tracer to 
tracee in the diet, the amount of iron in the brain originating from the diet can be 
obtained.  
 
The number of stable isotopic labels in isotope dilution that can be used in parallel 
is determined by the number of stable isotopes that exists for a given element 
(341). For an element having n stable isotopes, (n-1) isotopic labels are available. 








Fe, three isotopic labels 
can be used in parallel. Since 
56
Fe is the most abundant iron isotope, it is more 






Fe are therefore commonly used as isotopic labels. 
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2.2.1 Study Design 
In this project, enriched iron isotopes were administered continuously via the 
drinking water (see Section 3.3.1), which was fed together with feed to the rats for 
a period of 4 to 6 months (see Chapter 3, 4 and 5). The amount of consumed 
tracer in the drinking water was determined by weighing the drinking bottle 
before and after water consumption. All drinking bottles were checked for water 
dripping or leaking before use. Monthly blood samples were taken for isotopic 
analysis to assess the change of iron absorption rate with time. At the end of each 
study, rats were hyper-perfused to remove the blood from the brain as well as 
other organs to minimize interferences between blood iron and tissue iron. 
Relevant tissues were harvested and stored for iron quantification and isotopic 
analysis. 
2.2.2 Isotope Dilution Mass Spectrometry (IDMS) 
Quantification of stable isotope tracers in the tissues or body fluids can be 
performed with high precision and accuracy using Isotope Dilution Mass 
Spectrometry (IDMS) which is derived from the isotope dilution principle and 
originally developed to quantify elements (342, 343) 
2.2.2.1 Quantification of iron content in tissues using IDMS 
To assess changes in tissue iron induced by dietary iron in tracing studies, an 
accurate assessment of total tissue iron content is as important as the 
quantification of the tracer uptake by the brain so that the relative brain iron 
uptake (the amount of iron uptake by the tissue from diet relative to total brain 
iron) can be reliably determined. Tissue iron contents in our studies were 
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therefore analyzed using IDMS via isotope ratio analysis (see Chapter 4). IDMS 
is widely considered as a reference technique for elemental analysis as all sources 
of analytical uncertainty can be identified and quantitatively assessed (342, 344, 
345). Although more tedious steps are required, this approach permits a more 
accurate assessment of iron contents than what can be achieved by conventional 
elemental analysis using colorimetry (346), inductively coupled plasma atomic 
emission spectroscopy (ICP-AES), atomic absorption spectrometry (AAS), or 
inductively coupled plasma mass spectrometry (ICP-MS).  
 
The basic principle of IDMS is illustrated in Fig. 2-1. In IDMS, the unknown 
amount of the element in the sample can be determined by the addition of a 
known amount of a stable isotope tracer (enriched isotope [mass number X] of the 
element) to alter the abundances of the natural isotopes in the sample (340, 342). 
The isotopic composition change in the sample is in proportion to the mixing ratio 
of the natural element (nnat) in the sample and the tracer (niso). This mixing ratio 
can be obtained from the abundances (a) of the isotope with mass number X and a 









anat) together with the measured isotope ratio of the 
mixture 
X/W
Rsample (Eqn. (4)). Since the amount of the stable isotope tracer added 
(niso) is known, the amount of natural iron in the sample (nnat) can easily be 
obtained. For example, a known amount of enriched 
57
Fe can be added to native 
rat brain (rats that are not fed with enriched iron isotopes) prior to sample analysis 
to determine the exact amount of natural iron in the native rat brain, provided that 
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the mixture is homogenized (Eqn. (5). With regard to the brain samples obtained 
from the rats fed with enriched iron isotopes, the method for determination still 
follows the basic IDMS principle though the calculation is more complicated, 
which will be illustrated in detail in Chapter 4. 
 
Fig. 2-1 The illustration of the principle of IDMS 
In IDMS, to determine the element of interest in the sample (S), a known amount of an enriched stable 
isotope of that particular element (spike or Sp) is required to mix with the sample. Fig. 2-1 illustrates the 
schematic mass spectrum of an element with two isotopes (mass 1 and mass 2) of the mixture of the sample 
and the spike. In Fig. 2-1, n represents the number of atoms whereas a refers to the isotopic abundance. The 
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2.2.3 Instrumentations for iron isotope ratio measurement 
Since the first mass spectrometer was constructed by J.J. Thomson in 1912 to 
study the isotopic nature of neon (347), mass spectrometry has evolved as the 
primary, although not only, tool to measure the ratio of stable isotope abundances 
of an element. Thermal Ionization Mass Spectrometry (TIMS) and Multi-
Collector Inductively Coupled Plasma Mass Spectrometry (MC-ICP-MS) are 
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currently the two most widely used methods for the determination of metal 
isotope ratios, both of which have their own merits and limitations.  
2.2.3.1 Thermal Ionization Mass Spectrometry (TIMS) 
TIMS has long been the reference technique for isotope ratio determinations at 
highest precision and accuracy (324, 348-350) and has been applied to many 
stable isotope studies for the determination of iron isotope ratios (351-354). 
 
A TIMS is composed of three main components: an ion source where ions are 
produced, accelerated, and focused; a magnetic analyzer where ions are separated 
based on their mass-to-charge ratio; and one or more detectors for measuring 
beam intensities.   
2.2.3.1.1 Filament arrangement 
In an isotope ratio measurement by TIMS, the pre-treated sample is loaded on a 
filament made of a refectory metal, rhenium or tantalum, of high melting point. 
Two different filament configurations can be used for the thermal ionization 
process, single- or double-filament. A single-filament arrangement is preferred if 
evaporation and ionization of the element of interest take place at the same 
temperature. For elements that evaporate and ionize at different temperatures, use 
of a double-filament arrangement can be advantageous (see  
Fig. 2-2) (348, 355). In the case of iron, a double-filament ion source made of 
rhenium is the configuration of choice due differences in the optimal evaporation 





Fig. 2-2 Ion source configuration used in thermal ionization mass spectrometry 
(Figure source: Triton Manual) 
2.2.3.1.2 Principles of TIMS 
In the ion source, the sample is evaporated and ionized by passing a current 
through a filament under vacuum (see Fig. 2-3). The ionization process is 
theoretically described by the Langmuir–Saha equation, which states that 
elements with a high ionization potential are ionized at higher temperatures than 
elements with low ionization potential (348). The generated ions move randomly 
and slowly, forming an ion cloud which are later focused into an ion beam by 
acceleration across an electrical potential gradient via a set of slits and plates at 
high voltage (up to 10,000V) (356). Ions are extracted out of the source by the 
first slit plate which has a potential just a few volts below 10,000 V. After passing 
the last slit which is at ground potential, ions that share the same charge will have 
the same velocity. Based on Lorentz force law and Newton’s second law, the 
focused ion beam will be forced into different circular paths in the magnetic 
field,, the radius of which are dependent on the mass to charge ratio of the ions. 
The lighter the ions are, the smaller the radius and vice versa. Ions are commonly 
collected by Faraday cups inside which the ions flow to ground potential via a 
Double-filament arrangement  Single-filament arrangement  
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large resistor (e.g. 10
11Ω for the model used in the study). Several Faraday cup 
detectors can be set up such that the isotope beams are measured simultaneously 
to perform isotope ratio measurements at high precision (multi-collector TIMS). 
The ratio of the ions of different mass to charge ratio can be obtained via the 
measured ratio of ion currents in the respective detectors. For detection of low 
abundant isotope and for isotopic analysis of very small quantities of analyte, 
mass spectrometers with Faraday cup detectors can also be equipped with 
Secondary Electron Multipliers (SEM) to further extend the sensitivity of the 
instruments by several orders of magnitude (up to 10
4
), either in current 
amplification or ion-counting modes (357). SEM is the most sensitive detectors 
for measuring extremely small ion current or particle count rates. 
 
 
Fig. 2-3 Analyzer system of the TRITON 
 (Courtesy of Thermo Finnigan) 
2.2.3.2 Multi-Collector Inductively Coupled Plasma Mass Spectrometry 
(MC-ICP-MS) 
ICP-MS has been introduced as a new tool for elemental and isotopic analysis in 
the 1980s (358). During the past three decades, tremendous improvements have 
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been made on both the instrumentation and the methodology of iron isotope 
analysis of biological samples using ICP-MS (359, 360). This refers in particular 
to the advent of MC-ICP-MS (Fig. 2-4), which opened up the possibility for high-
throughput isotope ratio measurements at high precision and sensitivity. 
 
Fig. 2-4 Schematic of a Neptune MC-ICP-MS 
(Courtesy of Thermo Finnigan) 
The main difference between ICP-MS and TIMS is the ion source. Usually liquid 
samples are introduced into the high energy plasma by pneumatic or ultrasonic 
nebulization for ionization. The ions are later accelerated and focused into an ion 
beam for separation of ions by their mass to charge ratio (355). The ability to 
reach close to 100% ionization efficiency for nearly all the elements of the 
periodic table has contributed to the popularity of ICP-MS in isotope ratio mass 
spectrometry (349). 
 
With regard to iron isotope ratio measurements, the accuracy and precision of the 
data obtained using ICP-MS is limited by isobaric and polyatomic interferences 
(Table 2-3) generated during the measurement either in the samples or through 
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chemical interactions in the plasma of the ICP (361, 362). For instance, the 
presence of calcium in incompletely purified biological samples can lead to the 













showing the same nominal mass-to-charge ratio as the iron isotopes. Similarly, 
the use of the noble gas Ar in the plasma source system can produce Ar-based 












). Besides interferences from molecular 













(362, 363)  
Table 2-3 Interferences encountered in iron analysis by ICP-MS* 
Isotope Abundance  (atom %)** Interfering species 
54Fe+ 5.85 54Cr+, 40Ar14N+ 
56Fe+ 91.75 40Ar16N+, 40Ca16O+ 
57Fe+ 2.12 40Ar16N1H+, 40Ca16O1H+ 
58Fe+ 0.28 58Ni+, 40Ar18O+, 40Ca18O+, 42Ca16O+ 
*Table source: Ingle et al. (2002) (350). 
** Rosman et al. 1999 (326) 
 
The double-focusing magnetic-sector technology applied to MC-ICP-MS offers 
the possibility to remove isobaric interferences to the biggest extent via the 
increased mass resolution (364, 365). The mass analyzer of double sector 
instrument consists of two analyzers, an electrostatic analyzer and a magnetic 
sector field. When combined together, the former filters out ions of the same 
energy while the latter separates them by their mass-to-charge ratio. By varying 
the slit width, mass resolution can be modified. In addition, interfering species 
can be removed by interacting with a cell gas in collision or reaction cells. ‘Cool 
plasma’ also facilitates the suppression of interfering effects. To further minimize 
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the effect of interfering ions, sample purification prior to analysis and 
mathematical corrections of the measured the isotope ratios can also be applied.  
2.2.3.3 TIMS versus MC-ICP-MS 
Modern high resolution MC-ICP-MS is now widely considered as the tool of 
choice for iron isotope ratio measurements of high accuracy and precision due to 
its flexible sample introduction system (either in solution or aerosol form) as well 
as the high ionization efficiency (366, 367). In contrast, TIMS requires the sample 
to be in the solid form and isolated from the matrix by a series of steps prior to the 
measurement.  
Advantages of MC-ICP-MS, however, are balanced by unrecognized isobaric 
interferences and the larger mass fractionation of isotope in the ion source as 
compared to TIMS (368, 369, 370). Ideally, the measured isotope ratio should 
reflect the true isotope ratio of the sample. However, due to inevitable isotope 
fractionation occurring in the mass spectrometer during sample ionization, the 
measured isotope ratio inevitably deviates from the true ratio. Isotope 
fractionation thus becomes the limiting factor for isotope ratio measurement with 
high precision and accuracy by mass spectrometers (369). While matrix effects on 
isotope fractionation are minimal for TIMS, they can be significant for MC-ICP-
MS. As a consequence, the element of interest must be separated from the sample 
matric for MC-ICP-MS analysis as in TIMS which reduces advantages in terms of 
analytical efforts. In addition, MC-ICP-MS is more susceptible to artifacts which 
requires more robust quality control measures and repeated analysis of samples in 




Samples were analyzed in thesis by TIMS as the more robust technique delivering 
isotope ratio measurements on par with MC-ICP-MS in terms of precision. Both 
Positive TIMS (P-TIMS) and Negative TIMS (N-TIMS) have been used for iron 




) represent the forms of the ionized isotopes to be detected. However, one 
drawback of this technique is that molecular ions with same nominal mass-to-










. To achieve a better precision of iron isotope ratio 
measurement, Walczyk (1997) developed a technique using N-TIMS, in which 
iron isotopes were in the form of FeF4
- 
(375). This technique offers a variety of 
advantages as compared to the conventional iron isotope ratio measurement by P-
TIMS: a better control of mass-fractionation effect (375-376), the improved 
sensitivity as opposed to P-TIMS (377), as well as the capability to circumvent 
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3 Chapter 3  
Stable iron isotope tracing reveals significant brain iron 
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Iron deposits in brain are a common hallmark of Alzheimer’s disease and 
Parkinson's disease. This has spurred the hypothesis that iron may play a 
functional role in the pathogenesis of neurodegenerative disorders through free 
radical damage. Previous short-term studies using radiotracers suggested that 
brain iron uptake is small as compared to other tissues in adult rodents. This has 
led to the assumption that brain iron uptake must also be marginal in humans after 
brain development is complete. In this study we applied a novel approach to 
determine directly the fraction of iron that was transferred over time from diet to 
brain and other organs in adult rats. A known amount of a stable iron isotope 
(
57
Fe) was fed with drinking water to adult rats over 4 months. Uptake of tracer 
iron and final iron content in tissues were assessed by Negative Thermal 
Ionization Mass Spectrometry (NTI-MS). We found that only a very small 
amount of dietary iron has entered the brain (0.000537 ± 0.000076%). This 
amount, however, is considerable relative to total brain iron content (9.19 ± 
0.71%), which was lower but comparable to percentage uptake in other tissues. 
Whereas it remains unclear if excessive dietary iron intake is a risk factor in 
neurodegenerative diseases or if high systemic iron correlates to iron deposits in 
brain, our study suggests that uptake of dietary iron is much higher than 
previously thought. This finding challenges current beliefs and points to a 




Neurodegenerative disorders are on the rise with Alzheimer’s disease (AD) and 
Parkinson's disease (PD) expected to reach epidemic levels in the coming 
decades. In 2006, 26.6 million people worldwide were living with AD. It has been 
predicted that more than 100 million people will suffer from AD in 2050 (1), 
while prevalence of PD may double from about 4.3 to 9 million people worldwide 
over the next 25 years (2). The projected rise in these neurodegenerative disorders 
necessitates a better understanding of the etiology of the disease.  
 
AD and PD are age-related disorders without a known isolated cause (3). Their 
prevalence is increasing, even when adjusted for aging demographics (4, 5). This 
points to a possible role of environmental and lifestyle factors in the development 
of AD and PD in addition to ageing. Economic welfare has increased significantly 
over the past decades in industrialized countries and has affected lives in many 
ways, including diet. One significant change is the sharp increase in consumption 
of red meat over the past 50 years in industrialized countries and more recently in 
the developing world, with its consequent increase in dietary iron supply (6). Over 
the same time span, iron fortification of foods has become common practice due 
to its undisputed benefits for children and women of fertile age. In parallel, 
dietary supplements became widely available and easily accessible to the 
consumer beyond the control of health professionals.  
 
Iron is vital for brain development, neurogenesis as well as normal brain function 
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(7). Free unbound iron, however, can induce oxidative stress through catalysis of 
Fenton and Haber-Weiss chemistry which results ultimately in the formation of 
highly reactive free radicals (8, 9). Iron deposits in brain in AD and PD patients 
have led to the suggestion that iron is possibly involved in the pathogenesis of 
neurodegenerative disorders (10) with many lines of evidence pointing to free 
radical damage as the underlying mechanism (11-13).  A recent report also 
suggests an iron-dependent cell-death pathway to be critical in neuronal injury 
(14). Potential links between dietary iron and incidence of AD and PD have been 
studied in rats (15, 16) as well as humans (17-21) but, as yet, no firm conclusions 
can be drawn. 
 
Although abnormal iron deposits are a common observation in the brain of AD 
and PD patients, the actual cause of this accumulation remains unknown. Iron 
deposits in the brain of AD and PD patients can result, theoretically, from iron 
translocation within the body due to a pathological impairment of brain iron 
uptake and/or release. Alternatively, deposits can be reflective of dietary iron 
exposure and an overall accumulation of iron in the body. Evolution has left the 
human body with no pathway to actively excrete iron. Systemic losses are 
uncontrolled and accidental with menstrual blood loss, occult bleedings in the 
intestine or secretion of digestive juices being major routes of iron loss from the 
body. This lack of control over iron excretion requires iron homeostasis to be 
exclusively maintained by tight regulation of iron absorption in the intestine (22, 
23). If absorbed iron overcorrects for habitual losses, iron inevitably accumulates 
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in the body. This occurs, for example, in hereditary hemochromatosis as the most 
common genetic disorder in western populations. Some studies have shown that 
homozygotes for this disease show not only an excessive iron uptake in the 
intestine but are also at higher risk to contract neurodegenerative disorders (24, 
25). For healthy individuals, however, it remains to be seen if excessive iron 
intake is a risk factor and if high body iron correlates with iron deposits in brain. 
 
Our current understanding of brain iron dynamics has primarily come from 
radioisotope studies. To date, about a dozen short-term studies have been 
published in which brain iron uptake was studied in mice or rats using radioactive 
isotope tracers followed by tracer quantification in brain (26-34). These have been 
based on a single administration of a radiotracer to groups of animals at a given 
age, usually through intravenous or peritoneal injection, and sacrifice of animals 
relatively shortly after dose administration. While such an approach permits to 
study the effect of growth on brain iron uptake and underlying mechanisms and 
kinetics, it is less suitable to assess the effect of diet on brain iron content, 
particularly considering the importance of the intestine for systemic iron 
homeostasis.  Furthermore, studies to date have not quantified brain iron uptake 
relative to total brain iron content, which is critical to assess proportional uptake 
and risks of iron accumulation. 
 
In this study we have used for the first time ever a stable iron isotope (
57
Fe) in 
brain research which has a low enough natural abundance to be employed as a 
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tracer. The tracer was added at fixed concentration to the drinking water and was 
fed continuously with the diet over 4 months to better mimic dietary intake. Stable 
isotope tracers do not decay and as such they do not emit radiation and are safe to 
use in animals and man. Because of their stability, they can be fed over extended 
periods and samples stored without any time limit, if deemed necessary (35). In 
addition, stable isotope spiking has permitted determination of tissue iron to 
determine relative iron uptake. Relative iron uptake of a tissue or organ is more 
relevant for identifying possible risks of iron accumulation than absolute iron 
uptake which can be misleading if tissue iron content is low. 
3.3 Methods and materials 
3.3.1 Animals 
Seven male Wistar rats (6 to 8-month-old ex-breeders, body weight 664 ± 33 g) 
were obtained from a local supplier for laboratory animals. Rats were housed 
individually under laboratory conditions (12 hrs day and night lighting cycle, 21 ± 
1 °C, 55 ± 5% humidity). All experimental protocols were reviewed and approved 
by Institutional Animal Care and Use Committee (IACUC) of the National 
University of Singapore.  At the end of the study, rats were anesthetized by 
intraperitioneal injection of a cocktail of ketamine (Parnell Laboratories PTY. 





In order to answer how dietary iron is distributed between brain and other organs 
in adult mammals, we provided 6-8 month old ex-breeder male Wistar rats with 
isotopically-enriched 
57
FeCl3. Male rats were used because they do not experience 
diestrus blood loss, which may confound iron concentrations (36). The isotope 
was delivered via the drinking water at an iron concentration of 4 µg/g, which 
translates into an intake of labeled iron of approximately 100 µg per day and rat. 
The pH of the drinking water was adjusted to 2.5 to prevent precipitation of iron 
as per established protocols. Water of low pH is well tolerated by rats as they 
have no taste receptors for water (37). All rats had ad libitum access to the 
57
Fe-
enriched drinking water and conventional rat chow (Teklad 2018S Rodent Diet, 
Harlan, Indianapolis, USA; iron concentration 200 mg/kg). Drinking water was 
changed every 3-4 days and bottles were weighed before and after each change to 
accurately assess stable isotope intake by each rat. Mean amount of enriched 
57
Fe 
and natural iron consumed over the course of the study (16 weeks) was 8.90 ± 
0.66 mg and 529 ± 16 mg per rat, respectively.   
3.3.2 Stable isotope labels 
Both isotopic labels were prepared from iron metal (Chemgas, Boulogne, France), 
isotopically enriched in 
57




Fe (99.879 ± 0.027 % 
58
Fe). The isotopically enriched iron spikes were dissolved in 37% HCl and 
diluted with water to yield 5 M HCl solutions. The iron isotopic composition of 
the spike solutions was determined by negative thermal ionization mass 
spectrometry (NTI-MS) following published procedures (38). The iron 
concentration of the spike solutions was determined against a commercially 
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available iron standard solution (Titrisol, Merck, Darmstadt, Germany) by 
reversed mass spectrometric isotope dilution analysis (38, 39). 
 
For all work involving isotopically enriched labels and blood/tissue samples, 
principles of inorganic trace analysis were followed so as to minimize the 
alteration of their iron isotopic composition through contamination with natural 
iron. All solutions were prepared and handled in polyethylene or Teflon 
containers pre-cleaned with 10% (v/v) HNO3. Only analytical grade chemicals 
were used while nitric acid and hydrochloric acid were further purified by sub-
boiling distillation. Samples and solutions were handled in metal free class 10 
laminar flow hoods to minimize contamination of samples with natural iron. 
3.3.3 Tissue sampling 
Animals were sacrificed by hyper-perfusion, i.e. effective removal of blood from 
tissues by washing of vessels and organs in situ with excessive volumes of saline. 
This was done by opening the abdomen and chest of the anesthetized animals, 
incision the right atrium and perfusion through the left ventricle at room 
temperature with heparinized Ringer’s solution (5 I.U. heparin/mL, NaCl 0.85%, 
KCl 0.025%, CaCl2 0.03%, NaHCO3 0.02%) using an infusion set and a 19 gauge 
¾ inches winged-needle. Perfusion was continued until the effluent became 
colorless and the liver ochre brown. Used volumes of saline solution (2.5 L to 3 L 
per rat, 50-60 times the blood volume) were similar or higher than in earlier 
studies. After hyper-perfusion, whole brain, liver, heart and kidneys were 
removed and a muscle sample was taken from the upper calf of the hind leg. 
 109 
 
Samples were then rinsed with physiologically buffered saline and stored at -20°C 
until analysis.  
3.3.4 Preparation of blood/tissue samples for iron isotopic analysis 
For isotopic and elemental analysis, samples were freeze dried and grinded 
carefully into a fine powder with a ceramic pestle after encasing the samples in 
two layers of polyethylene zip lock bags to protect them from contamination. A 
weighed aliquot of the homogenized tissue was transferred into a Teflon vessel 
together with a known amount of enriched 
58
Fe label to determine the amount of 
natural iron in the sample following isotope dilution principles (see below). 
Samples were mineralized in a microwave digestion system (Ethos 1, Milestone, 
Sorisole, Italy) using 8 mL conc. HNO3 (Merck, Darmstadt, Germany) and 2 mL 
30% H2O2 (Merck, Darmstadt, Germany). Samples were dried down under 
laminar flow conditions and digested a second time using the same procedures to 
effectively destroy the organic sample matrix. Isotopic analysis of tissue samples 
was performed in triplicate.  
 
After mineralization, the solution was dried down and redissolved in 6 M HCl for 
iron separation by ion-exchange chromatography using the strongly basic ion-
exchange resin Dowex AG 1-X8 (200 - 400 mesh, Sigma, St. Louis, USA). For 
separation, the solution was transferred to the top of a column (8 mm inner 
diameter) filled with the ion-exchange resin to a height of 40 mm. The column 
was rinsed with 20 mL 6 M HCl after loading and sample iron was eluted with 10 
mL 1 M HNO3 from the column. After evaporating the iron solution to dryness, 
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sample iron was redissolved in 6 M HCl and rerun through a second column using 
the same procedure. The eluate was evaporated to dryness, reconstituted in 0.2 
mL 1 M HNO3 and alkalized by an addition of 1 mL 25% ammonium hydroxide 
(Merck, Darmstadt, Germany) for iron precipitation. Iron was separated by 
centrifugation for 45 minutes at 13,000 rpm. The obtained precipitate was washed 
twice with water and centrifuged each time for 20 minutes at 13,000 rpm. The 
precipitate was dried in a 70°C water bath and stored for mass spectrometric 
analysis in a capped polyethylene vial. With each batch of samples, a known 
amount of pure 
58
Fe spike was passed through the entire sample preparation 
procedure to monitor procedural blanks. Each blood/tissue sample was prepared 
and isotopically analyzed in triplicate. 
3.3.5 Iron analysis of blood 
To verify that rats did not become anemic, blood samples were collected at the 
beginning of the study from the tail artery and the end of the study by cardiac 
puncture. Concentration of hemoglobin in the rat blood was indirectly determined 
by measuring the iron concentration of blood using Graphite Furnace Atomic 
Absorption Spectrometry (GF-AAS). The concentration of hemoglobin in the 
blood was then calculated based on the concentration of iron, the density of blood 
(1.06 g/mL) and the iron content of hemoglobin (3.47 mg iron/g). Blood iron 
concentration was determined in triplicate. 
3.3.6 Mass spectrometry 
The iron isotopic composition of the isotopic labels and the prepared samples 





 molecular ions and a rhenium double-filament ion source (40). The 
evaporation filament as well as the ionization filament were coated with BaF2 to 
promote the formation of negatively charged ions. Sample iron was loaded as 
FeF3 in HF (40%) on top of the BaF2 layer on the evaporation filament which was 
then coated with a AgF layer. All mass spectrometric measurements were carried 
out with a multi-collector thermal ionization mass spectrometer (Triton, Bremen, 
Germany) equipped with set of Faraday cups for simultaneous ion beam detection. 
For each individual measurement, 5 data blocks per run and 10 scans per data 
block were collected. Baseline measurement was performed before each block 
and the integration time for each scan was 16.777 sec. Precisions for replicate 





ratio for samples and 0.01% for standards after internal normalization to correct 
for instrumental fractionation in the ion source. Data for samples containing tracer 













Fe tracer relative to natural iron using algorithms described elsewhere 










Fe in the tracers and natural iron. Measured isotope 
ratios were then normalized to this isotope ratio using an exponential law (41), the 




Fe isotope ratio 
in the sample re-estimated for normalization of measured isotope ratios. Iterative 
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Fe isotope ratio of the sample 
differed by less than 10
-14 
between cycles.   
3.3.7 Data analysis 
Amount of tracer and natural iron in samples was determined after internal 
normalization of measured data sets following isotope dilution principles as 
described earlier. The amount of natural iron n(
nat
Fe)  in the sample aliquot was 




Fe) amount ratio and the known 
amount of added 
58
Fe spike (in moles) before digestion. The total amount of 
57
Fe 




Fe) ratio and 
the n(
nat
Fe) in the analyzed sample. Total amount of tracer in the organ was 
calculated by taking the mass of tissue analyzed and the total mass of the 
organ/sample into account. Mass of blood was estimated from blood volume BV 
(BV (mL) = 0.06 (mL/g) × body weight (g)+ 0.77(mL)) (42) and blood density 
(1.06 g/ml). Element amounts (in units of moles) were converted into masses (in 
units of grams) and vice versa using the atomic weights of natural iron and that of 
the isotopic tracers, respectively.  
 
Isotopic enrichment (E) of a tissue sample was calculated as the percentage 




Fe isotope ratio in the sample compared to natural iron. 
Transfer rates from diet to tissues (T) were calculated as total moles of tracer 
recovered in the sample/organ relative to total moles of tracer consumed with the 
drinking water. From the amount of dietary iron consumed and the transfer rate, 
the amount of non-tracer iron taken up from the diet and transferred into the 
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different body tissues was calculated. To better assess the magnitude of iron 
transfer, the amount of iron transferred into each tissue is expressed relative to the 
amount of total iron in the analyzed tissue. 
3.4 Results 
No premature deaths were observed among the treated rats. The rats showed a 
moderate increase in body weight from 664 ± 33 g to 728 ± 51 g over the course 
of the study, consistent with adult aging. Hemoglobin concentration was 141 ± 10 
g Hb/L at the beginning and 140 ± 10 g Hb/L at the end of the study, i.e. within 
the normal range of 130-170 g/L (43) and with no detectable change over time, 
indicating that 
57
Fe provision in drinking water had little effect on gross 
physiology.   
 
Tracer dosage of approximately 1.75 μmole57Fe per rat per day was found to be 
sufficient to reliably detect changes in isotopic iron composition of the target 
tissues (Table 3-1). Tracer doses could be kept low by high precision iron isotope 
analysis using multi-collector NTI-MS. Limit of quantification (LOQ) for isotopic 





ratio over its natural value of at least 10 times the standard deviation of replicate 
measurements. LOQ in this study was found to be limited primarily by available 
sample iron and ion signal intensities. Variations between individual rats were 
relatively small as indicated by the low standard deviations obtained for each type 
of tissue. To compare tracer iron uptake in our study with earlier studies involving 
tracer injection, we have to estimate the efficiency by which tracer iron was 
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absorbed in our study. Calculations were based on tracer recovery in blood (Table 
3-1) and an incorporation efficiency of about 80% of absorbed tracer iron in red 
blood cells (44). Our estimated tracer absorption efficiency of 1.9% compares 
well with data in the literature. 
Table 3-1 Iron concentration and iron isotopic enrichment of analyzed tissue 
samples. 
Tissue 
c(Fe) [μg/g] E [%]
a n(57Fe)/n(natFe)[mol/mol] b n(57Fe) [nmol] c 
Wet weight Dry weight 
Blood 459 ± 32 - 27.0±3.0 0.00600±0.00066 2314±  264 
Liver 112 ± 11 439 ± 42 20.1±1.6 0.00445±0.00036 207 ± 38 
Kidney 36.1 ± 6.3 349 ± 40 18.2±2.9 0.00404±0.00063 14.3 ± 2.5 
Heart 40.7 ± 3.8 224 ± 13 8.50±0.81 0.00188±0.00018 2.80 ± 0.37 
Brain 13.50 ± 0.65 59.8 ± 3.9 6.94±0.57 0.00154±0.00013 0.85 ± 0.12 
Muscle - - 5.32±0.84 0.00118±0.00019 - 
aIsotopic enrichment E is expressed as the relative deviation of the measured from the natural 57Fe/56Fe 
isotopic ratio of 0.023096 ± 0.000072 (45). 
bMolar ratio of 57Fe tracer to natural iron. 
cAmount of tracer recovered  in blood/organs. 
 
 
Fig. 3-1 Iron transfer efficiency from diet to organs 
Absolute iron uptake is presented as the percentage of tracer recovered in the organ relative to the total 
amount of tracer iron given in feed (156 ± 12 µmol over 4 months). Values are given as arithmetic means ± 






































Liver:  0.132 ± 0.019 % 
Kidney:  0.0092 ± 0.011 % 
Heart:      0.00180 ± 0.00029 % 






Fig. 3-2 Fraction of iron in the organ coming from feed. 
Relative iron uptake was calculated as the amount of iron in the organ that could be traced back to feed 
relative to total iron content of the organ. Values are given as arithmetic means ± SD (n=7 rats; each sample 
was analyzed in triplicate). 
 
Isotopic enrichments (E), as the percentage change in an isotope ratio relative to 
its natural value, ranged from 27.0 % for blood down to 5.32 % for muscle in 
good agreement with expected differences in iron turnover rates (Table 3-1). 
Blood has the highest turnover rate of all body iron pools due to constant renewal 
of red blood cells and hemoglobin synthesis. In contrast to blood, iron turnover of 
muscle tissue is low. Iron in muscle is mainly present as myoglobin for oxygen 
storage and is only released/replaced when muscle cells are catabolized. 
Consistent with previous studies (26), efficiency of iron transfer from the feed to 
the liver (0.132 ± 0.019 %, Fig. 3-1), was about ten times lower than for blood 
(1.48 ± 0.11%). Iron uptake of heart and kidney was lower by 3 orders of 
magnitude as compared to blood and even lower for brain (see Fig. 3-1). 
However, differences between tissues are much smaller when the fraction of iron 
taken up from the diet is expressed relative to total tissue iron content (see Fig. 


















































Liver:  27.1 ± 2.5 % 
Kidney:  24.4 ± 3.4 % 
Heart:  11.5 ± 1.3 % 





this amount constitutes approximately 9% of total brain iron taking the low iron 
content of the organ into account. Thus, our study suggests that iron uptake of 
mammalian brain even in the mature organ is of similar order of magnitude as for 
the other tissues under investigation (11.5-27.1 %). This makes brain, in principle, 
as vulnerable to systemic iron overload and iron accumulation as the other studied 
organs. An increase in iron content of these tissues is well documented for high 
iron status or pathologically excessive iron absorption as observed in patients with 
hereditary hemochromatosis. 
3.5 Discussion 
In this study we used successfully a stable iron isotope to assess distribution of 
absorbed iron between organs and the magnitude of iron uptake relative to total 
iron content of body tissues. Isotopic iron fed to adult rats was broadly distributed 
among the analyzed tissues at surprisingly similar fractional quantities. This 
finding challenges the current belief that iron is largely excluded from entering 
brain by tight regulation of iron entry at the blood-brain barrier (46, 47). 
 
Our current knowledge of the efficiency by which iron is taken up by the brain 
comes exclusively from merely a dozen animal experiments employing 
radiotracers. In these experiments, tracer iron uptake of brain was measured in 
sacrificed animals after administration of a single tracer dose, usually through 
intravenous or peritoneal injection. Studies were largely conducted in young rats 
looking at iron as a limiting nutrient for brain development. While such an 
approach permits to study the effect of growth on brain iron uptake, it is less 
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suitable to assess the effect of diet on brain iron content during adulthood. Firstly, 
findings for young animals cannot be extrapolated to adult life. Brain iron uptake 
drops sharply at an age of 15 to 30 days in rats and declines thereafter at a slower 
rate up to 5 months (26, 27, 32, 48, 49) and 11 weeks in mice (34). Secondly, the 
time span between injection and sampling must be long enough to consider that 
tracer entering brain may not be permanently deposited and possibly subject to 
export. Accordingly, we yet know little about brain iron turnover as the fraction 
of iron taken up and leaving brain per unit time. Finally, tracer injection bypasses 
the intestinal tract as the key regulator of systemic iron uptake. The normal 
physiological response to a change in dietary iron intake is up-regulation or down-
regulation of intestinal iron absorption over time. To take an adaptive response of 
the body into account, continuous feeding of the tracer over longer periods of time 
is necessary. In contrast to stable isotopes, such studies are difficult to conduct 
using radiotracers because of their instability and radiation safety.  
 
Earlier radiotracer studies have shown that only a very small fraction of dietary 
iron is used by the brain even in the growing organism. In these studies, tracer 
iron was injected bypassing the intestinal tract. To put our study into perspective, 
we had to estimate fractional iron absorption from diet in our study for assessing 
the amount of tracer iron that has entered circulation. Intestinal iron absorption in 
the rat is age dependent and declines rapidly with age. Ezekiel (1967) reported 
that intestinal absorption in the rat dropped from 80%-100% at 15 days to 60% at 
20 days and 8.7% at 2-3 months (50). Similar observations were made by Forbes 
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and Reina (1972) (51). Our estimated average absorption rate of about 1.9% at an 
age of 10-12 months of our rats at sacrifice follows this declining trend.  
Generally, isotopic enrichment for the organs in our study followed the same 
trend as reported in earlier studies (26, 28, 34). At an estimated absorption rate of 
1.9% and an efficiency of tracer transfer from diet to brain of 0.00054% it can be 
calculated that about 0.028% of the tracer would have been recovered in brain had 
it been given via intravenous injection. This recovery is in good agreement with 
previous data taking the age of our rats (10-12 mo) into account. Prior studies 
reported a decline of tracer uptake with age in adult animals (26, 27, 32, 48, 52). 
Recovery of injected tracer iron was 0.055% for 10-wk mice (34) and 
approximately 0.05% for 63-day old rats (28, 32). 
 
One of the unique advantages of the stable isotope approach described here is the 
possibility to assess brain iron uptake over extended periods of time relative to 
total brain iron. Brain iron uptake must always be evaluated relative to total brain 
iron to assess risks of iron accumulation. This makes an accurate assessment of 
total brain iron content as important as a reliable estimate of intake. For this 
reason we have analyzed tissue iron contents by isotope ratio analysis and IDMS. 
IDMS is widely considered as a reference technique for elemental analysis as all 
sources of analytical uncertainty can be identified and quantitatively assessed (53-
55). Although more tedious, this approach permits a more accurate assessment of 
iron contents than what can be achieved by conventional elemental analysis using 
inductively coupled plasma mass spectrometry, optical emission spectroscopy, or 
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atomic absorption spectrometry as the more widely employed techniques for 
measuring iron concentration and content. Using these more sophisticated 
analytical techniques, the determined iron levels  in the brain of middle-age rats in 
the present study (Table 3-1) were in good agreement with concentration ranges 
reported in earlier studies (26, 27, 32, 56).  
 
The most surprising finding in our study is the observation that iron uptake by 
brain is significant in normal adult rats. About 9% of brain iron could be traced 
back to the diet over a period of four months, a time span that compares to 7-10 
human years. Most published studies on brain iron uptake have focused on the 
developing brain and the consequences of iron deficiency due to its critical role in 
brain development (26, 27, 29, 30, 32, 34, 52, 57). In our study we have chosen 
rats that were 6-8 months old at study onset, an age at which growth can be 
considered complete and no significant gain in brain mass and whole body iron 
should occur. Brain uptake of injected radio-iron was also found to decrease near 
exponentially with age in earlier studies (26, 27, 29, 32, 48, 52) dropping sharply 
at approximately 20 days after birth (26, 52). These observations show a variable 
iron permeability of the blood brain barrier to iron and have let to the suggestion 
that brain iron uptake is only marginal during adulthood. Information on brain 
iron turnover is yet very limited due to methodological restrictions arising from 
the use of radioisotopes and the misconception that a low iron uptake of brain 
makes iron accumulation unlikely. Earlier studies point to a very slow turnover or 
even an unidirectional import into brain, i.e. iron taken up by the brain may 
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remain in brain over the life-time once it has entered brain (26, 52). Linear 
extrapolation of our data would point to a gain in brain iron during adulthood as 
high as 50-70% of the amount of iron present in early adulthood due to the 
naturally low iron content of brain as compared to other tissues. This would be in 
good agreement with the fundamental study of Hallgren et al. (1958) in humans 
who analyzed brain iron content of 81 individuals of different age (58). After a 
sharp rise in brain iron content in the first years of life, iron accumulation appears 
to slow down but with a steady increase over the remaining lifetime.This could be 
confirmed in more recent post mortem studies which showed an increase in iron, 
ferritin and neuromelanin with age in the substantia nigra (SN) of normal human 
subjects (46, 59). Although not possible yet for reasons of analytical sensitivity, it 
is possible in principle to trace brain iron uptake down to the different element 
species and brain regions by continuous feeding of iron stable isotopes. The 
methods presented here are the first step in this direction.  Molecular mechanisms 
of iron uptake and release of iron from the brain and shuttling within brain are 
still poorly understood. 
3.6 Conclusion 
By studying for the first time ever long-term iron uptake by the adult brain in a 
mammalian model we found that absolute brain iron uptake is small as compared 
to other tissues but considerable when measured relative to brain iron content. 
This became possible by using a stable iron isotope for tracing instead of short-
living radiotracers and by measuring directly the fraction of iron in brain that 
originates from diet. Iron accumulation in brain is a still unexplained phenomenon 
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in the development of AD and PD. Using the developed methods and protocols, it 
is now possible to explore factors leading to iron accumulation by the brain in 
adulthood or strategies how to lower brain iron content during ageing, a 
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4 Chapter 4  
Imbalance of iron influx and efflux results in brain iron 
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Iron accumulation in the brain with age is supposed to be involved in the 
development of neurodegenerative disorders including Alzheimer's and Parkinson 
Disease. The question remains, however, whether this accumulation process in the 
brain is uni-directional without efflux of deposited iron or a bi-directional process 
in which brain iron exchanges with body iron. The answer to this question may 
open up new possibilities to slow down brain iron accumulation and, thus, iron 
induced oxidative stress in the brain as a suspected mechanism of 
neurodegeneration.  
 
In two separate studies we have fed up to three stable isotope tracers in parallel 
over 5 months to adult male 6-8 months old wild-type Wistar rats (n=7 per study). 
Tracers were fed continuously with the drinking water in a staggered design 
together with diet to assess if iron taken up earlier by the brain is subject to export 
(Study 1) and to determine iron influx and efflux into brain as well as its half-life 
in brain, liver, heart, kidneys and blood (Study 2).  
 
In our study we could confirm the hypothesis that iron deposition in brain is bi-
directional but unbalanced, i.e. iron influx from diet into brain was higher than 
iron efflux. The half-life of dietary iron in the adult rat brain was estimated to be 
about 9 months, which may serve as an indicator for the rather slow turnover rate 
of dietary iron in the brain. Based on the long half-life of dietary iron in the 
healthy rat brain, brain iron of the rats in our study can be estimated to increase by 
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27% from early adulthood (6-8 months of age) to the end of their average life 
span. It remains to be seen if brain iron accumulation as a possible risk factor for 
the development of neurodegenerative disorders can be moderated by dietary iron 
intake.  
4.2 Introduction 
Iron is the most abundant trace element within the brain. The ease in donating and 
accepting electrons renders iron an indispensable cofactor for a plethora of 
enzymatic reactions involved in neurogenesis, brain development and cognition 
sustenance (1). However, iron is potentially toxic to cells if systemic 
concentrations of free unbound iron exceed the body’s scavenging capabilities. 
Uncomplexed iron can induce oxidative stress through catalysis of the Fenton and 
Haber-Weiss reactions which result ultimately in the formation of highly reactive 
free radicals (2, 3). 
 
Age-related iron deposition within the brain has been observed in all species 
examined, including mice, rats, monkeys and humans (4-9). Progressively 
elevated brain iron with age may pose a threat to the brain’s oxygen-rich 
environment by inducing oxidative stress via reactive oxygen species (ROS), 
ultimately leading to cell death (10-12). Many lines of evidence support now the 
hypothesis that iron accumulation in the brain with age might be implicated in the 
pathogenesis of age-related AD/PD with iron induced oxidative stress as the 
underlying mechanism (13, 14). It has been speculated that iron deposition in the 
brain could be reflective of dietary iron exposure and an overall accumulation of 
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iron in the body. Iron accumulation in the body is thus inevitable if iron absorbed 
from diet overcorrects for habitual losses.   
 
In an earlier study we could demonstrate that stable iron isotopes can be used for 
tracing iron transfer directly from feed to brain in adult rats (15). In agreement 
with earlier radiotracers studies we found that less than 0.001% of iron in the diet 
was transferred to brain. However, due to the low iron content of brain this small 
amount constituted about 9% of total brain iron. Measurement of relative brain 
iron uptake became only possible by using stable isotope tracers as they do not 
decay. Furthermore, stable isotope tracing permits continuous tracer feeding to 
study brain iron dynamics at the systemic level as opposed to radiotracer 
protocols in which the tracer is commonly given only once by injection. The key 
question that remains now is whether brain iron import equals export or if more 
iron is imported than exported from brain and at which rate. The first scenario 
would not affect brain iron content in the long-term and tracer influx would 
reflect brain iron turnover. The second scenario would point to gradual 
accumulation of iron over time. The answer to this question may open up new 
possibilities to slow down brain iron accumulation. 
 
In our first study we pioneered long-term feeding of a single tracer to mimic 
dietary iron influx into brain. In the present study, we have fed up to three stable 
isotope tracers in parallel to the same rat in a staggered design to assess iron 
influx/efflux and the half-life of dietary iron in the brain. As in our first study, we 
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conducted experiments in adult rats. It is reported that the rate of whole brain iron 
accumulation slows down after the first three decades of life (4) and it is possibly 
the amount of iron accumulated after that which contributes mainly to the 
development of the disease.  
4.3 Methodology 
4.3.1 Study design 
The fate of dietary iron was investigated through dual- and triple-isotope feeding 
schemes. While the dual-isotope feeding scheme provides a qualitative 
assessment of brain iron balance, the triple-isotope feeding scheme permits to 
study iron dynamics quantitatively by comparing rates of iron influx and iron 
efflux and by estimation of the half-life of iron taken up by the brain, respectively. 
 
The dual isotope feeding scheme involves the staggered administration of two 
different stable iron isotopes, Tracer 1 (T1; 
57
Fe) and Tracer 2 (T2; 
54
Fe) which are 
fed continuously over an equal duration of time. Two possible scenarios are 
illustrated in Fig. 4-1. If there is no export of iron after its deposition into brain, 
tracer amount ratios in brain must equal that of the feed at the time of sacrifice 
(see Fig. 4-1A). The more of imported iron is exported from brain, the larger is 
the difference in the amount ratio of both tracers in brain and feed at the end of 




Fig. 4-1 Dual-isotope tracing for studying brain iron import and export 
Tracer 1 (T1) is administered from month 1 to 3 and Tracer 2 (T2) from month 2 to 4 together with the feed. 
Vertical lines X and Y indicate the time points when tracer administration was terminated. Dashed lines 
represent the fate of the tracer thereafter. In Fig. 4-1A, iron is deposited in the brain in an uni-directional 
manner, resulting in the accumulation of both tracer in the brain. Without iron export from brain, the amount 
ratio of both tracers in brain should be equal to the amount ratio in the consumed feed In Fig. 4-1B, iron 
enters the brain in a bi-directional manner. If iron is exported from brain, the amount of the first tracer in 
brain will decrease when tracer administration is terminated. The amount ratio of both tracers in the brain is 
lower than the ratio in the consumed diet.  
 
 
Fig. 4-2 Triple-isotope tracing for modeling kinetics of iron release from brain 
The first tracer (T1) is administered from month 1 to 3, the second tracer (T2) from month 2 to 4 and the third 
tracer (T3) from month 3 to 5. Vertical lines X and Y indicate the time points when tracer administration was 
terminated. Dashed lines represent the fate of the tracer thereafter. At the time of sacrifice (Z), amount ratios 
of tracers in brain differ from that of the feed when tracer has been exported from brain. Differences in 
amount ratios T1/T3 and T2/T3 in brain will be proportional to the rate by which deposited iron tracer is 
released from brain.  
 
The triple-isotope feeding scheme involves the staggered administration of three 
different iron isotopes, Tracer 1 (T1; 
57
Fe), Tracer 2 (T2; 
54
Fe) and Tracer 3 (T3; 
58
Fe), respectively, see Fig. 4-2. If iron taken up from diet is exported from brain, 
tracer amount ratios in brain should be lower than that of the feed. For iron 
export, the amount ratio of T1 to T3 in the brain relative to that in the diet should 
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be lower than that of T2 to T3, since T1 is administered first, followed by T2 and 
lastly T3. Differences in amount ratios between tracers, i.e. n(T1)/n(T3) and 
n(T2)/n(T3) can be used to model kinetics of iron release from brain.  
 
4.3.2 Animals 
Eight male Wistar rats  (6 to 8-month old, body weight 625 ± 48 g) were obtained 
from a local supplier (Laboratory Animals Centre, LAC) and housed individually 
at a temperature of 21 ± 1 C, with a humidity of 55 ± 5 % and a 12 hour 
light/dark cycle. Rats were randomly assigned to the two different feeding groups, 
DI (dual-isotope feeding scheme) group (n=3) and TI (triple-isotope feeding 
scheme) group (n=5). The body weight of the rats and the amount of water 
consumed by the rats were monitored weekly. All experimental protocols were 
reviewed and approved by Institutional Animal Care and Use Committee 
(IACUC) of National University of Singapore (NUS).  
 
All rats had ad libitum access to a standard rat chow diet (Teklad 2018S Rodent 
Diet, Harlan, Indianapolis, USA; iron concentration 200 mg/kg) and isotopically 
enriched drinking water during the course of the study. In the DI group, the 
feeding period lasted for 4 months. The first tracer T1 (
57
Fe) was fed during month 
1-3 while the second tracer T2 (
54
Fe) was fed during month 2-4 via the drinking 




Fe in the drinking 
water for the DI group was 11.215 ± 0.021 and 5.207 ± 0.045 μg/g respectively. 
In the TI group, the feeding period was extended to 5 months to allow for feeding 
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of an additional enriched stable iron isotope. As for the TI group, all tracers were 
administered via drinking water. The first tracer T1 (
57
Fe) was fed during months 
1 to 3, the second tracer T2 (
54
Fe) during month 2-4 and the third tracer T3 (
58
Fe) 






Fe in the drinking water for TI group were, 11.201 ± 0.025, 5.216 
± 0.030 and 3.004 ± 0.016 μg/g, respectively. 
 
In order to maintain dietary iron supply in both groups constant over the course of 
the study, differences in iron intake induced by differences in tracer concentration 
in the drinking water were balanced by adding iron of natural isotopic 
composition to the water. As in our previous study, the pH of the drinking water 
was maintained at 2.5 in order to ensure no precipitation of iron. Water acidity 
should not affect water consumption as rats do not have any taste receptors for 
water (16). Isotopic enriched water was changed every 3-4 days. The masses of 
the drinking bottles before and after each change of water supply were recorded in 
order to accurately assess dietary iron tracer intake over the course of the study.  
 
4.3.3 Stable isotope labels 
All isotopic labels were prepared from iron metal (Chemgas, France), isotopically 
enriched in 
54









(99.9109 ± 0.0013 % 
58
Fe). Isotopically enriched iron spikes were dissolved in 
37% HCl and diluted with water to yield 5 M HCl solutions. Iron concentrations 
were determined against a commercially available standard (Titrisol
®
; FeCl3 in 
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15% HCl, 1000 mg Fe; Merck). Negative thermal ionization mass spectrometry 
(N-TIMS) was used to determine the isotopic composition of the spike solutions 
using the method developed by Walczyk (1997) with modifications (17). The 
concentrations of iron in the spike solutions were determined by reversed isotope 
dilution mass spectrometry against the prepared iron standard. 
 
All sample preparation work was performed in a class 10,000 clean room 
equipped with class 10 fume hoods. Only teflon labware or disposable plastic 
labware was used. Plastic lab ware was pre-cleaned by soaking in 10% (v/v) 
HNO3 (Merck, USA) for 12 hrs and teflon labware by boiling in half-concentrated 
HNO3. Acids and reagents used were of analytical-reagent grade. Acids were 
purified further by sub-boiling distillation before use. Water used throughout the 
study was ultrapure 18.2 Ω Milli-Q® water (Millipore, Billerica, Massachusetts, 
USA).  
 
4.3.4 Blood and tissue sampling 
Blood samples were collected monthly for hemoglobin concentration and to 
assess changes in iron isotopic compositions in the rat blood throughout the 
feeding period.  During the study, blood was collected from the tail artery of the 
rats using 23G needles while they were under light isoflurane anesthesia (Webster 
Veterinary Patterson Company, USA). Blood samples were obtained via cardiac 
puncture at the end of the study. Blood samples were collected in EDTA coated 




Tissue sampling followed the procedure as described in Chen et al. (2013) (15). In 
brief, animals were sacrificed by hyper-perfusion, i.e. effective removal of blood 
from tissues by washing of vessels and organs in situ with excessive volumes of 
Ringer’s solution (NaCl 0.85%, KCl 0.025%, CaCl2 0.03%, NaHCO3 0.02%). 
Heparin (5 I.U. heparin/mL) was added to the solution to prevent blood clotting 
during the perfusion process. Organs such as heart, kidneys, liver, muscle and 
brain were harvested and stored at -20C prior to isotopic analysis. 
 
4.3.5 Iron elemental and isotopic analysis 
The collected samples were freeze dried and grinded into fine powders. For DI 
group samples, a weighed aliquot of the homogenized tissue was transferred into 
a teflon vessel together with a known amount of enriched 
58
Fe label to determine 
the amount of natural iron in the sample following isotope dilution principles (see 
section 4.3.6). The mixture was mineralized in a microwave digestion system 
(Ethos 1, Milestone, Sorisole, Italy). Tissues collected from the TI group were 
digested directly without addition of an additional tracer for iron quantification. 
After mineralization, iron in the solution was separated by ion-exchange 
chromatography using a strongly basic ion-exchange resin (Dowex AG 1-X8; 200 
- 400 mesh, Sigma, St. Louis, USA). The eluate obtained was alkalized by 
addition of 25% ammonium hydroxide (Merck, Darmstadt, Germany) for 
precipitating sample iron as ferrihydrite. The iron precipitate was stored dry until 
isotope ratio analysis. The iron isotopic composition of the isotopic labels and the 
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prepared samples were determined by negative thermal ionization mass 
spectrometry (NTI-MS) using FeF4
–
 molecular ions and a rhenium double-
filament ion source with details described earlier (17). Further technical details 
are described in an earlier publication (15).  
 
Concentration of haemoglobin in the rat blood sample was indirectly determined 
in triplicate through iron concentration in the blood (15). Iron content of blood 
samples was analyzed by graphite furnace atomic absorption spectrometry (GF-
AAS) (Varian AA240 Zeeman/GTA120, Varian Inc., Palo Alto, CA, USA) by 
external calibration with an iron standard solution.  
 
4.3.6 Data analysis 
The amount ratio of tracers in the brain described were determined following 
isotope dilution principles using Eqn. (6) (17, 18) based on the abundance of the 
different isotopes in each enriched isotopic label (a) and the measured isotope 
ratios in the sample (R).  
 















n is determined by the 







Fe) and n (
58
Fe)). The iron isotopic abundance 
W
a  
(W=54, 56, 57 and 58) for both isotopically enriched tracers (iso,54; iso,57; 
iso,58) and natural iron (nat) can be obtained from the sum of all measured 
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isotope abundance ratios ∑    with 56a as the common denominator. The molar 
amount of the tracers is related to the measured isotope ratios Rsample via the total 
amount of iron in the sample n (
tot
Fe) and the abundance 
W
a of the isotope in 
natural iron and the tracers. In sum, the abovementioned relationship can be 
expressed in a matrix form which can be solved to deliver the molar ratio of a 























































































































































4.3.6.1 Efflux Rate Index 
Based on Eqn. (6), the amount ratio of two tracers in a tissue sample with the 














Fe)] relative to the total amount of iron in the sample 
[n(
tot
Fe)]. The calculated amount ratio of tracers in the brain relative to that in the 
diet was designated as the Efflux Rate Index. The higher the Efflux Rate Index, 
the less of the tracer taken up by brain was transported out of the brain after 





4.3.6.2 Tissue iron uptake (DI group) 
Based on the Eqn. (6), the amount of total iron n(
tot
Fe) in the sample aliquot in the 




Fe) ratio and the known amount of 
added 
58
Fe spike (in moles) before digestion. The total amount of 
57
Fe tracer in 




Fe) ratio and n(
tot
Fe) in 
the analyzed sample. Total amount of 
54
Fe tracer in the sample could be 
calculated in the same way as that for the 
57
Fe tracer. Total amount of tracer in the 
organ was calculated by taking the mass of tissue analyzed and the total mass of 
the organ/sample into account. Absolute tissue iron uptake (% of iron fed) was 
calculated as total moles of tracer recovered in the tissue relative to total moles of 
tracer consumed. 
 
The amount of iron transferred into each tissue is expressed relative to the amount 
of total iron in the analyzed tissue as relative tissue iron uptake (% of tissue iron 
coming from feed). For the TI group, all available enriched stable iron isotope 
tracers had already been used during the feeding and we were not available any 
more to quantify tissue iron following isotope dilution principles. Iron 
concentrations were therefore determined by graphite furnace absorption 
spectrometry (see section 4.3.5) and using standard addition techniques. 
4.3.6.3 Evaluation of kinetics of iron efflux (TI group) 
A single compartment model was used to estimate tracer efflux rates for each 
individual organ in the TI group. The amount of the last administered tracer (T3; 
58
Fe) in the organ at sacrifice was set to 100% (Efflux Rate Index of 1.0). Efflux 
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rate indices for the first administered tracer (T1; 
57
Fe) and the second administered 
tracer (T2; 
54
Fe) were expressed relative to the efflux rate index of tracer T3 and 
plotted against the time period between termination of tracer administration and 
sacrifice. The obtained data points were fitted by the Windows version of the 
SAAM/Consaam software, WinSAAM (Simulation, Analysis and Modelling) to 
determine tracer efflux rates of iron from the respective organ. 
 
4.3.7 Statistical analysis 
Comparisons of absolute/relative tissue iron uptake and iron efflux between 
different tissues were conducted by performing an independent sample t-test for 
equality of means using SPSS version 20 software (SPSS Inc., Chicago, USA). In 
all tests, a value of P≤0.05 was considered statistically significant. 
4.4 Results 
No premature deaths were observed among the treated rats. The total amount of 
consumed feed, water and iron isotopes of each feeding group is summarized in 
Table 4-1. The rats showed a moderate increase in body weight in both groups 
over the course of the study from 643 ± 43 g at the beginning to 692 ± 49 at the 
end in for the DI group and from 613 ± 49 g to 713 ± 61 g for the TI group which 
is consistent with adult aging. The blood hemoglobin concentrations of each rat 
were within the reported normal range of 130 – 170 g Hb/L (19) at the beginning 
(161 ± 13 g Hb/L)  and end of the studies (159 ± 12 g Hb/L) for the DI group and 





Table 4-1 Total amount of consumed feed, water and iron tracers for the DI 
















DI 2.93 ± 0.15 2.57 ± 0.20 10.49 ± 0.54 0.350 ± 0.030 0.800 ± 0.080 - 
TI 3.80 ± 0.20 3.56 ± 0.54 13.61 ± 0.70 0.400 ± 0.060 0.89 ± 0.13 0.220 ± 0.033 
 
4.4.1 Tracer analysis of blood samples 
The measured amount ratio of tracer to total iron in blood carries information 
about the bioavailability of tracer iron. For comparison of data obtained for 
different tracers, amount ratios of tracer to total iron were adjusted for dose to that 
of the 
57
Fe tracer for each individual rat using the tracer concentration ratios in the 
drinking water for normalization. After dose adjustment, the amount ratios of 
tracer to total iron were comparable for the different iron tracers in blood (p<0.05; 
see Fig. 4-3 and Fig. 4-4). As can be expected, amount ratios of tracer to total iron 
increased steadily over time until termination of tracer feeding on from which the 
ratios declined due to blood iron turnover. A trend towards a slower increase in 
amount ratios of tracer to total iron over time was observed. 
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Fig. 4-3 Amount ratios of tracer to total iron (mol/mol) in blood against time for the DI group (n=3 
rats). 
Feeding of the 57Fe tracer was terminated at the end of month 3. Amount ratios were adjusted to differences 




Fig. 4-4 Amount ratios of tracer to total iron (mol/mol) in blood against time for the TI group (n=5 
rats) 
Feeding of the 57Fe tracer was terminated at the end of month 3 and that of the 54Fe tracer at the end of month 
4. Amount ratios  were adjusted to differences in tracer concentration in the feed.  
4.4.2 Tissue iron uptake for the DI group 
Fig. 4-5 shows the absolute and relative iron uptake by different tissues in the DI 
group. Absolute iron uptake by different tissues was significantly different from 





























































































































study (see Fig. 4-5A). Fig. 4-5B shows the percentage of tissue iron in rat organs 
of the DI group coming from feed (relative tissue iron uptake). Relative iron 
uptake of the analyzed tissues was of the same order of magnitude (9.2% - 32.8%) 
despite the marked differences in absolute iron uptake (0.000621% - 0.102% of 
the tracer dose). Relative iron uptake of brain was comparable to that of heart 
(p=0.10) and that of liver was comparable to that of the kidneys (p=0.46) while 
relative iron uptake of both brain and heart was significantly different from those 
of liver and kidneys (p<0.05). 
  
Fig. 4-5 Tissue iron uptake 
Fig. 4-5A shows the percentage of dietary iron recovered in rat brains of the DI group (n=3 rats). Recoveries 
were calculated as the amount of 54Fe tracer recovered in the organ relative to total amount of 54Fe tracer 
given (in %). Fig. 4-5B shows the percentage of tissue iron in rat organs of the DI group coming from feed. 
Relative tissue iron uptake was calculated as the amount of 54Fe tracer recovered in the organ coming from 
feed relative to the total amount of iron in the organ  (in %). Different lower case letters indicate statistical 
significant differences between tissues (p≤.0.05). Values are given as arithmetic means ± SD (n=3) 
 
4.4.3 Iron turnover in tissue  
4.4.3.1 Qualitative assessment (DI group) 
Muscle tissues exhibited tracer amount ratios that were the closest to that of the 
diet, demonstrating the lowest iron turnover rate among all analyzed tissues. After 

































Liver:            0.102 ± 0.025 % 
Kidney:      0.0183 ± 0.0021 % 
Heart:      0.00178 ± 0.00026 % 












































) Liver:      32.8 ± 2.6 % 
Kidney:   31.1 ± 2.5 % 
Heart:     11.2 ± 1.2 % 
Brain:       9.2  ± 1.0 % 
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turnover rate among major body iron pools (see Fig. 4-6). Efflux Rate Indices 
were all lower than 1.0 which indicates that more iron was replaced in the studied 
organs over the observational period than in muscle tissue as the iron pool 
showing the slowest iron turnover. The Efflux Rate Index of brain of 0.927, was 
higher than that of the other tissues, showing that iron is exported from brain at a 
slower rate as compared to other organs. The Efflux Rate Index of brain exhibited 
no difference with that of heart (p=0.18) whereas the Efflux Rate Index of liver 
showed no significant difference to those of kidney (p=0.46) and blood (p=0.23) 
but was significantly lower than that of heart (p<0.05) and brain (p<0.05), 
respectively. 
 
Fig. 4-6 Efflux rate index of different tissues for the DI group (n=3 rats) 
The lower the index, the higher the iron efflux rate (see text). Different lower case letters indicate statistical 
significant differences between tissues (p≤.0.05). Same letter means no statistical difference. 
 
4.4.3.2 Quantitative assessment (TI group) 
For the triple-isotope feeding scheme, iron turnover of different tissues was 
quantitatively evaluated by plotting the normalized Efflux Rate Index against time 























Dietary iron was found to be released from liver, kidney, heart, brain and blood at 
different efflux rate. Efflux rates expressed as % of tracer in brain released per 
month and tracer half-lives in the studied tissues was calculated using a single 
compartment model (see Table 4-2). Consistent with findings for the DI group, 
brain iron exhibited the lowest efflux rate (8.2 ± 3.1 % tracer per month) among 
the measured tissues in the TI group (p<0.05). The half-life of dietary iron taken 
up by the brain was estimated to be 9.4 ± 3.2 months, the longest half-life among 
all analyzed tissues (p<0.05).  
Table 4-2 Efflux rates and half-lives of dietary iron in the rat tissues in TI 
group* 
  Liver Kidney Heart Brain Blood 
Efflux rate (% tracer / month) 20.5 ± 6.6
a 19.8 ± 6.8a 11.5 ± 2.1b 8.2 ± 3.1 37.6 ± 9.6a 
Half-life of dietary iron (month) 3.7 ± 1.3
a 4.2 ± 1.9a 6.2 ± 1.2b 9.4 ± 3.2 2.0 ± 0.6a 
* The values of efflux rate and half-life of dietary iron in different tissues were compared with those in brain. 

























































Fig. 4-7 Changes in Efflux Rate Indices over two months in the TI group (n=5 rats) 
Efflux Rate Indices at month 1 and 2 were normalized to its value at month 0 (see text). 
4.5 Discussion 
In the present study we could confirm the major finding of our previous study 
(15). The fraction of iron in the diet that has been transferred to brain was 
marginal after 4 months of feeding (0.00062% in this study versus 0.00054% in 
our earlier study). However, this very small iron amount constituted ca. 9% of 
brain iron in either study at sacrifice. While this does not challenge the main 
conclusion from earlier radioisotope experiments that the absolute amount of iron 
uptake by the brain is very low, it points to brain iron homeostasis and dietary 
iron intake as key factors in brain iron accumulation as observed in ageing and 
possibly in the development of AD and PD. 
 
Our studies differ in many ways from earlier radiotracer studies due to the 
different scope of our experiments. Research interests in the past lied mostly in 
the developmental stage with limited focus on the effect of dietary iron on brain 


































Blood D E 
 147 
 
is age-dependent (26, 27) and the uptake of iron from diet by the brain and its 
later release is a long term process, it was imperative for us to study brain iron 
dynamics by feeding tracer continuously to adult and not weaning or young rats. 
Our studies were conducted in 6-8 mo old rats which correspond to an age of 
twenty-odd human years at study onset. The pioneering postmortem study by 
Hallgren and Sourander (1958) demonstrated that the rate of whole brain iron 
accumulation increases steeply during the first two decades of human life, slows 
down substantially in the third decade, and reaches a “plateau” or may increase 
very slowly thereafter (4). The change in iron accumulation rate in the brain 
suggests a change in brain iron dynamics including brain iron import and export 
over the course of life. As relatively large amounts of iron are required during the 
first decade for the developing brain, it is possible that the amount of iron 
accumulating on from the third decade when brain development can be 
considered complete, contributes to the development of iron-related 
neurodegenerative diseases. Similar to humans, iron was found to increase steeply 
in rat brain early in life but slows down at about the fourth month of life (20, 28-
31).  
 
Our understanding of brain iron dynamics is largely based on short-term 
radiotracer studies. However, due to their instability and because of radiation 
safety aspects they are less useful for tracing long-term dietary iron uptake by the 
brain. Long-term feeding of non-decaying stable isotope tracers along with the 
diet, as in our study, allows not only to study brain iron uptake but also iron efflux 
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from brain over time. This is essential to assess the effect of interventions on 
brain iron balance. Furthermore, radiotracers were given only once in earlier 
studies, usually by injection, which neglects the homeostatic response of the body 
and possibly brain to changes in dietary iron supply at the systemic level. This is 
of significance when studying the role of dietary iron in brain iron accumulation.  
 
By feeding iron stable isotopes continuously with the diet we were able to assess 
brain iron balance relative to total brain iron content which was not possible in 
earlier radiotracer experiments. Because iron has four stable isotopes that can be 






Fe), it is possible to use each rats as its own 
control when studying brain iron dynamics by staggering tracer administration 
over time (see Fig. 4-1 and Fig. 4-2). This allows to reduce sample size 
significantly as compared to earlier radiotracer experiments (20, 21, 28) which 
used a single tracer for brain iron labeling only. Groups of animals in these 
studies had to be sacrificed at different time points and compared to each other 
which requires naturally larger number of animals to control for inter-individual 
variations. 
 
Iron balance of an organism or organ depends both on iron influx and efflux rate. 
Iron accumulates inevitably at the moment that influx rates exceed efflux rate 
with the rate of iron accumulation being determined by their difference. 
Considerable efforts have been made to understand mechanisms and pathways of 
brain iron uptake but our understanding here is still limited. Dietary iron was 
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proposed to be taken up by the brain either across the blood-brain barrier (BBB, 
main pathway) or the blood-cerebrospinal fluid barrier (BCB, secondary pathway) 
(32, 33). Many studies suggested that iron uptake across BBB is mainly via 
transferrin receptor (TfR) mediated endocytosis (34), while the detection of H-
ferritin receptors on the BBB led to the suggestion of an additional pathway (34, 
35). Expression of DMT1, ferroportin, ceruloplasmin and hephaestin were higher 
in the choroid plexus in BCB than virtually all other brain regions (36) which 
points to alternative mechanisms by which iron can enter brain. Our knowledge 
on iron export is even more limited as it has been studied to a much lower extent. 
It has been hypothesized that BCB might be responsible for not only brain iron 
uptake (37) but also iron efflux in the brain owing to its structure and functions 
(23, 38). Structurally, the tight junctions of the blood-cerebrospinal-fluid barrier 
are quantitatively leakier than those of the blood brain barrier. This is supported 
by other rat studies in which radio-labeled iron was injected into the lateral 
cerebral ventricle to study iron efflux from the CSF to the blood (25, 38, 39).  
 
In agreement with the described mechanisms and previous rodent studies using 
radioisotope techniques (21-23, 25, 38), our findings support the hypothesis that 
uptake of iron by the brain is a bi-directional process. Two other studies did not 
report loss of tracer iron from brain which could be either due to sample size or 
age of the studied animals (20, 40). Observations by Holmes-Hampton et al. 
(2012) point to iron incorporation being biphasic as well as age-dependent (27). 
During the early phase of life, iron influx must exceed efflux significantly to 
cover the high iron demands of the growing brain. At two years of age, human 
 150 
 
brain iron content is ca. 50% of the adult brain, approximately doubles within the 
following decade and slows down later (41).  
 
Greatly consistent with our earlier study (see Chapter 3) and in good agreement 
with findings by Bradbury (Number), the rank order of the amount of iron uptake 
by tissues were blood> liver> kidney> heart> brain (see Fig. 4-5). While we could 
demonstrate that iron entering the rat brain during adulthood is not deposited 
permanently, brain iron was found to have the lowest iron turnover among the 
studied organs. The efflux rate index of brain was 0.927 (see Fig. 4-6) which is 
statistically higher than that in other tissues, showing that iron in the brain has a 
turnover rate that is slightly higher than for muscle but the lowest of all other 
tissues under investigation. This observation is in good agreement with the 
findings by Dallman and Spirito (1977) who injected radioiron intra-peritoneally 
into young rats (2-60 days) and monitored radioactivity in the brain for a period of 
up to 135 days (21). Their results showed that the specific radioactivity of iron in 
the brain remained at its peak until the end of the observational period, indicating 
little loss or no loss of brain iron during that period. They therefore concluded that 
brain iron turnover is at an extremely slow rate based on the assumption that 
mechanism for brain iron export exist.  
 
In the present study we could estimate the efflux rate of iron from the adult rat 
brain as 8.2 ± 3.1% per month in the TI group. However, this figure must be 
considered the first gross approximation of the efflux rate of brain iron in a 
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mammalian organism as only three data points were available per rate for its 
calculation (see Fig. 4-7). The corresponding half-life of iron tracer in the brain, 
and thus that of dietary iron taken up by the brain during adulthood, was 9.4 ± 3.2 
months. This can be considered relatively long with regard to the short life time of 
the species of about 3 years (42). As iron turnover rate in rat organs cannot be 
simply extrapolated to humans based on the ratio of their life spans, the data on 
iron turnover rate in blood in these two species can be of use to extrapolate 
findings to human brain. The half life of iron tracer in blood was found to be 
approximately 83 months in adult men (43) as compared to 2.0 ± 0.6 months for 
adult rats in the present study. At an average human life time of 75 as compared 
to 3 years in rats, the half-life of iron in human brain can thus be reasonably 
estimated to be of the order of decade(s). 
 
In good agreement with our earlier study, dietary iron recovered in the rat brain 
during early adulthood amounted to ca. 9% of total brain iron after 4 months of 
tracer feeding. Half of this iron amount will leave brain within one half-life, i.e. 9 
months. After 27 months, when the rat reaches its average life span, about 10% of 
the iron that has accumulated early in adulthood will remain in brain and even 
more of any iron that has entered brain later in the life of the rat. Assuming that 
brain iron uptake and its half-life are constant over lifetime, brain iron of the rats 
in our study can be estimated to increase by 27% in from early adulthood (6-8 




The present study, for the first time ever, revealed that dietary iron enters the 
brain at an influx rate that is significantly higher than its efflux rate in adult 
animals. This will automatically lead to brain iron accumulation during adulthood 
as observed in animals and men. This permits us now to study the effect of dietary 
iron intake on brain iron accumulation in healthy organisms and in conditions 
where body iron homeostasis is impaired. Furthermore, the developed 
methodologies can be used to evaluate treatments and therapies to reduce iron 
burdens in the brain that are supposed to affect brain health later in life through 
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5 Chapter 5  
Changes of brain iron homeostasis in adult rats in 
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Iron accumulation with age in the brain has been suggested as a contributing 
factor in the pathogenesis of Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) through iron induced oxidative stress. Findings from epidemiological trials 
regarding possible links between AD/PD and iron nutrition or iron status are 
conflicting. Animal studies point to dietary iron intake as a determinant of brain 
iron uptake during growth but no such studies are available for adult mammals. 
Mechanisms of brain iron homeostasis are supposed to be age dependent due to 
much higher iron requirements of the growing brain during infancy and 
childhood.  
 
In the present study, iron was traced from diet to brain using a dual-stable isotope 
technique in adult male Wistar rats (8 months old) to monitor effects of high 
dietary iron intake (~2000 mg/kg feed) and low dietary intake (~2 mg/kg feed) 
versus a control diet (~200 mg/kg feed). Tracers were given continuously with the 
drinking water over 4 months to the rats (n=7 per group). Changing of dietary 
intake triggered a normal homeostatic response without inducing changes in blood 
hemoglobin concentration.     
 
Uptake efficiency of dietary iron by the adult rat brain was found to be 
determined by the amount of absorbed iron in the intestine and not by dietary 
intake or body iron stores alone. The low dietary iron regimen resulted in a lower 
systemic iron influx into the body which could not be compensated by 
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upregulating dietary iron absorption. Systemic iron influx was also lowered in the 
high dietary iron regimen due to excessive downregulation of iron absorption in 
the intestine. In consequence, accumulation of dietary iron in the brain was the 
highest in the control group. Brain iron uptake appears to be much less regulated 
in adulthood than during growth. Efficiency of regulatory mechanisms of 
intestinal iron absorption rather than brain iron homeostasis seems to be the 
primary determinant of brain iron accumulation during adulthood. 
5.2 Introduction 
Populations are ageing in the industrialized world and, to a lesser extent, in 
developing countries. Age-related neurodegenerative diseases, headed by 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) in particular, develop on 
an epidemic scale and are likely to have a significant social and economic impact 
in the coming decades (1). The exact underlying mechanisms involved in the 
pathogenesis of AD and PD remain an enigma. Recent studies have shown 
increased iron accumulation with advancing age at pathoanatomically relevant 
sites in AD and PD (2-4). The perturbation of brain iron homeostasis has therefore 
been proposed as a potential mechanism driving the progression of 
neurodegeneration. Iron’s innate ability to accept and donate electrons plays a 
pivotal role in normal neurogenesis and in a wide spectrum of cellular reactions 
(5). A disruption in brain iron homeostasis, however, can be potentially 
detrimental to normal brain function. When in excess, free unbound iron can 
induce oxidative stress by reducing H2O2 to the highly-cytotoxic hydroxyl (OH
•
) 
radical via Fenton chemistry and Haber-Weiss reaction (6). The resulting reactive 
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oxygen species (ROS) can damage functional biomolecules including DNA, 
proteins and lipids at the moment that cellular capacities of oxidative stress 
defense are exceeded.  
 
In the absence of curative treatments for AD/PD, strategies are needed for 
prevention or to delay the age of onset. The role of nutrition in neurodegeneration 
has become a topic of increasing scientific and public interest (7). Prevalence of 
AD and PD has increased over the past decades when corrected for age (8, 9) 
pointing to other factors than ageing in the etiology of these diseases. Dietary iron 
intake is one of them. With rising affluence over the past decades, amounts of 
bioavailable iron in our diet have increased due to a higher proportion of red meat 
and iron fortified foods and a growing intake of dietary supplements (10). As iron 
is vital for life but was difficult to acquire from diet over evolutionary time spans 
(11), the human body is virtually a closed system for iron with minimal habitual 
losses (12). If iron absorbed from diet overcorrects for habitual losses, body iron 
accumulation is inevitable and brain iron accumulation possible.  
 
Several epidemiological studies have suggested that high dietary iron intake may 
contribute to the risk of developing AD or PD (13-18) while other 
epidemiological studies showed that higher intake of iron might have a protective 
effect against AD/PD (19, 20). Animal studies provided a clearer correlation 
between dietary iron intake and risks of contracting age-related neurodegenerative 
disorders. Previous rat studies proposed that iron supplementation accelerates the 
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aging process (21) whereas iron restriction retards it (21, 22). It remains, however, 
unclear how dietary iron intake affects brain iron homeostasis and brain iron 
accumulation in the long-term as a possible risk factor for AD/PD development. 
 
Stable isotope techniques have been pioneered by our group to trace iron from the 
diet into the brain in adult rats by continuous feeding of tracer iron over several 
months (see Chapter 3 and 4). In the present study, we used the developed 
methodologies to investigate changes in brain iron homeostasis in response to 
different levels of dietary iron intake for the first time ever in adult rats and at the 
systemic level.  
5.3 Methodology 
5.3.1 Study design 
To study changes in iron import and export of brain iron, we have fed two 
different stable isotope tracers in a staggered design (see Fig. 5-1). Tracer 1 (T1; 
57
Fe) as well as Tracer 2 (T2; 
54
Fe) were fed continuously over an equal duration 
of time. Transfer of iron from diet to brain was found to be bi-directional in our 
previous study in adult rats with rates of iron import exceeding rates of iron 
export (see Chapter 4). The more of previously imported iron tracer is exported 
from brain, the bigger is the difference in the amount ratio of both tracers in brain 





Fig. 5-1 Dual-isotope tracing scheme for studying brain iron import and export in animal models 
Tracer 1 (T1) is administered from month 1 to 3 and Tracer 2 (T2) from month 2 to 4 together with the feed. 
Vertical lines X and Y indicate the time points when tracer administration was terminated. Dashed lines 
represent the fate of the tracer thereafter. The amount of first tracer n(T1)brain decreases with time when the 
administration of the tracer is terminated and previously imported tracer is exported from brain. The amount 
ratio of both tracers n(T1)brain/ n(T2)brain in the brain is thus lower than that of the consumed diet n(T1)diet / 
n(T2)diet at the time of sacrifice. 
 
5.3.2 Stable isotope labels 
Iron stable isotope tracers were prepared from isotopically enriched iron metals 
(Chemgas, Boulogne, France) which were dissolved in 37% HCl and diluted with 
water to yield 5 M HCl solutions. The isotopic enrichment was determined as 
99.8756% 
54
Fe for the 
54
Fe tracer, 97.9266% 
57
Fe for the 
57
Fe tracer and 
99.9109% 
58
Fe for the 
58
Fe tracer. Iron concentration of the tracer solutions was 
determined against a commercial iron standard solution (FeCl3 in 15% HCl, 1,000 
mg Fe, Titrisol
®
, Merck) by reverse isotope dilution mass spectrometry (23, 24).  
5.3.3 Animals 
Twenty-one adult male Wistar rats (8 months old, ex-breeders, body weight 638 ± 
26g), provided by a local supplier (Department of Comparative Medicine, 
National University of Singapore), were divided randomly into three groups of 7 
animals each and housed individually within the animal holding center at a 
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temperature of 21 ± 1 °C under a 12 h light/dark cycle. The rats had free access to 
water and food. The body weights of the rats were monitored weekly. All 
experimental protocols were reviewed and approved by the Institutional Animal 
Care and Use Committee (IACUC) of the National University of Singapore. 
5.3.3.1 Study design 
Rats were given three different type of feed which were obtained from a 
commercial supplier for experimental rodent diets (Harlan Teklad, Indiana, 
Indianapolis, USA). The low dose (LD) group received an iron-depleted rodent 
diet (TD.99397). The control (CT) group received an iron-sufficient diet 
(TD.120353) formulated by the addition of 0.02% carbonyl iron into TD.99397. 
The high dose (HD) group received an iron-enriched diet (TD.120354) formulated 
by supplementation of TD.99397 with 2% carbonyl iron. Prior to the 
commencement of the study, the concentration of natural iron in the feed was 
verified by Graphite Furnace Atomic Absorption Spectroscopy (GF-AAS). In 
accordance with the ingredient information provided by the feed supplier, the iron 
concentration was determined as 1.91 mg/g, 187 mg/g, and 1849 mg/g for LD, CT 
and HD group, respectively. 
 
Following protocols described in our earlier study (see Chapter 4) the 
57
Fe and the 
54
Fe tracer were administered in chloride form via the drinking water for 2 months 
each following the dual tracer scheme illustrated in Fig. 5-1. The first tracer (
57
Fe) 
was fed from Month 1 to 3 and the second tracer (
54
Fe) from Month 2 to 4. Tracer 
concentration in the drinking water was adjusted for the different groups 
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according to iron levels in the feed (see Table 5-1). Tracer concentration in water 
for LD group was decided to be the same as that in CT group, the dose of which 
was tested in our earlier study to be sufficient to raise isotopic changes in the rat 
body (25). The tracer dose was increased to 10 times the tracer dose of the CT 
group to adjust for the 10 times higher iron concentration in HD feed than that in 
CT feed. Because of its lower natural abundance, dose requirements for the 
57
Fe 
tracer are lower than for the 
54
Fe tracer. To ensure that iron intake was the same 
over the course of the study within a given group, resulting differences in tracer 
iron concentration of the drinking water were compensated by addition of natural 
iron (see Table 5-1). Amounts of consumed feed and water were recorded. 
Table 5-1 Iron composition of the drinking water 
The concentration of 57Fe tracer in drinking water for all groups represents the average concentration of 57Fe 
tracer present in water prepared from Month 1 to 3, while the concentration of 54Fe tracer in drinking water 
for all groups represents the average concentration of Tracer 54Fe present in water prepared from Month 2 to 
4. Natural iron was administered in the water in the first and last month to maintain the same level of dietary 






















2-3 3.0091 ± 0.074 6.0052 ± 0.0043 - 9.0143 ± 0.0063 
 
4 - 6.0036 ± 0.0017 3.0069 ± 0.0079 9.010 ± 0.014 
 
CT 
1 3.005 ± 0.010 - 6.0023 ± 0.0084 9.007 ± 0.017 
2-3 3.0035 ± 0.0040 6.003 ± 0.010  9.0063 ± 0.0094 
4 - 6.0011 ± 0.0037 3.0008 ± 0.0089 9.0019 ± 0.0094 
HD 
1 29.991 ± 0.043 - 59.998 ± 0.020 89.990 ± 0.056 
2-3 29.985 ± 0.070 59.994 ± 0.098  89.979 ± 0.089 
4 - 60.032 ± 0.050 30.012 ± 0.011 90.043 ± 0.052 
 
Blood samples were collected prior to the feeding, every four weeks during the 
course of the study and at the end of the study. For brain and organ harvesting, 
animals were sacrificed by hyper-perfusion with heparinised Ringer’s solution 
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(25). Tissues such as liver, kidneys, brain and muscle were collected and stored at 
-20C prior to isotopic analysis. Haemoglobin level in the rat blood sample was 
indirectly determined through iron concentration in the blood via GF-AAS. 
5.3.4 Iron isotopic analysis  
Sample preparation for isotopic analysis followed largely methods described in 
detail in an earlier publication (25). Tissue samples were freeze-dried prior to 
sample preparation. The amount of total iron in the sample was determined 
following isotope dilution principles by adding a known amount of a third iron 
tracer (
58
Fe) in solution to a weighed aliquot of the homogenized freeze-dried 
tissue. The spiked tissue sample was mineralized by microwave digestion and iron 
in the mineralized sample was then separated from the matrix using anion-
exchange chromatography. Separated iron was further purified by precipitation as  
iron hydroxide by addition of ammonia. The precipitate was stored dry prior to 
mass spectrometric analysis. Iron isotopic composition of tracers and iron isolated 
from tissue/blood samples was determined by Negative Thermal Ionization Mass 
Spectrometry (NTI-MS) employing FeF4
–
 molecular ions (25, 26). 
5.3.5 Data analysis 
Following Isotope Dilution Mass Spectrometry (IDMS) principles (24) (see 





Fetissue), W=54 or 57) can be calculated from the iron isotopic 
composition of the used isotopic tracers and that of iron separated from the 
tissue/blood samples as obtained by mass spectrometric analysis. The total 
amount of tissue iron n(
total













Fetissue) that was added into the sample before microwave digestion,  
 
Dietary iron absorption efficiency Feabs (%) at the intestine was estimated from 
the mole ratio of 
54







blood at sacrifice as determined by IDMS, the total amount of iron n(
total 
Feblood) in 




Fefeed) consumed through feed, see Eqn. (7). 
( ) ( )feedbloodtotalbloodabs FenFenRFe 5454 /×=                       (7) 
Incorporation efficiency of tracer iron into erythrocytes (IE) in Eqn. (7) was 
assumed to be about 70% of absorbed iron in normal adult rats; 80% in iron-
deficient rats and 60% in iron loaded rats (27). Iron amount (mol) in blood 
n(
total
Feblood) was calculated from blood volume V (mL), the concentration of iron 
in blood c(
total
Feblood) in g/g, the density of blood (1.06 g/mL) and the standard 
atomic weight of iron (55.85 g/mol), see Eqn. (8). 
                                  
( ) ( ) 06.1×85.55/×= bloodtotalbloodtotal FecVFen                           (8)  
Blood volume (mL) of the rat was estimated from body weight BW (g) using the 
equation proposed by Lee and Blaufox (1985) (28), see Eqn. (9). 
0.77 +×06.0= BWV                                       (9) 
Systemic iron influx, as the estimated amount of iron (mol) that has been 
absorbed from diet over the course of the study, was calculated from the amount 
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of iron consumed through feed n(
total 
Fefeed) and the estimated efficiency Feabs by 
which dietary iron has been absorbed. 
 
Absolute Dietary Iron Recovery was calculated as the absolute amount (mol) of 
dietary iron transferred from diet to a tissue/organ over the three months of 
54
Fe 
tracer feeding. With the abovementioned n(
total
Fetissue) obtained following IDMS 
principles, the amount of tracers in tissues n(
54





Fetissue). The absolute amount of dietary iron transferred from 
diet to tissue can be obtained from the amount ratio of tracer iron in tissue to that 
in the feed together with the amount of total iron in feed n(
total
Fefeed) in moles 
consumed over the same period in which the rat has received the 
54
Fe tracer (3 
months), see Eqn. (10). 
Absolute Dietary Iron Recovery = 
 ( ) ( ) ( )( )feedtissuefeedtotal FenFenFen 5454 /×                          (10) 
Relative Dietary Iron Recovery (%) in a tissue/organ was calculated by dividing 
Absolute Dietary Iron Recovery (mol) by the amount of total iron in feed (mol) 
consumed over the same period in which the rat has received the 
54
Fe tracer (3 
months), which is the same as tracer recovery in tissue, see Eqn. (11). 
Relative Dietary Iron Recovery (%)  
                                = ( ) ( )feedtissue FenFen 5454 /  
                               = Absolute Dietary Iron Recovery/ ( )feedtotal Fen                    (11) 
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Normalized Dietary Iron Recovery (%) in a tissue/organ was calculated as the 
ratio of Absolute Dietary Iron Recovery in a tissue (mol) to Systemic Iron Influx 
(mol), i.e. the fraction of absorbed iron (in contrast to dietary iron) that has been 
transferred to the organ/tissue. 
 
Iron efflux rates in tissues were assessed by calculation of Efflux Rate Indices. 





Fetissue) relative to that in diet based on the dual-isotope 
feeding scheme. The Efflux Rate Index is inversely correlated with the amount of 
iron transported out of the tissue per unit time. The lower the Efflux Rate Index, 
the more of the 
57
Fe tracer taken up by the tissue was released from the tissue 
after the administration was stopped. 
5.3.6 Statistical analysis 
Comparisons among the treatments in each group were conducted by performing 
an independent sample student t-test for equality of means using SPSS version 20 
software (SPSS Inc., Chicago, USA). In all tests, a value of p≤0.05 was 
considered statistically significant. 
5.4  Results 
Rats with different levels of dietary iron treatment exhibited no significant 
differences in body weight among groups at the end of the study (p>0.05). Body 
weights of the rats in all groups increased moderately from 638 ± 19 g to 729 ± 20 




No significant differences were observed between experimental groups and 
control group in terms of blood haemoglobin (Hb) levels over the course of the 
study (p>0.05), indicating that dietary iron availability has little impact on blood 
Hb levels in adult rats. The average Hb concentrations of rats at the beginning and 
end of the study were 154 ± 9 g Hb/L and 164 ± 14 g Hb/L for the CT group 
(p=0.20), 158 ± 20 g Hb/L and 167 ± 8 g Hb/L for the LD group (p=0.33) and 151 
± 8 g Hb/L and 158 ± 7 g Hb/L for the HD group (p=0.09), respectively. All the 
detected blood Hb levels fall within the reported normal range of 130 – 170 g 
Hb/L for rats (29)  
 
The total amount of consumed feed, water and iron isotopes of each feeding group 
is summarized in Table 5-2. Water and feed consumption over the feeding period 
was similar for all three groups of rats. No anomalies in eating habits were 
observed at any point of the study showing that the rats adapted well to the 
environment and the different levels of iron in the feed. 
Table 5-2 The summary of the total amount of consumed feed, water and 



















LD 2542 ± 166 2212 ± 469 0.109 ±  0.019 0.089 ± 0.018 0.179 ± 0.040 0.352 ± 0.060 
CT 2494 ± 166 1980 ± 242 8.43 ± 0.56 0.079 ± 0.010 0.163 ± 0.018 8.67 ± 0.59 
HD 2630 ± 86 1997 ± 288 87.88 ± 2.84 0.80 ± 0.12 1.66 ± 0.24 90.3 ± 2.9 
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*The amount of consumed natural iron constitutes both the amount of natural iron in feed and in drinking 
water. 
** The amount of total consumed iron constitutes the amount of consumed tracers and the amount of natural 
iron in feed and drinking water. 
 
Fig. 5-2 shows that the estimated intestinal iron absorption efficiencies of rats 
were influenced significantly by dietary iron intake. The intestinal iron absorption 
efficiency increased 5-fold in rats receiving the iron-deficient diet and decreased 
15-fold in rats receiving the iron-loaded diet as compared to the control group 
(p<0.01). Differences in the estimated amount of absorbed iron were less 
attenuated. Systemic iron influx was 5-fold lower in the LD group as compared to 
the CT group (p<0.01). Despite the much higher amount of iron in the feed, the 
very low intestinal absorption efficiency observed in the HD group (<1% of 
dietary iron) resulted in a systemic iron influx that was higher than for the LD 
group (p<0.01) but still lower than that for the CT group.  
 
Fig. 5-2 Changes of systemic iron influx in response to different dietary iron levels 
The bars represent the estimated iron absorption efficiency at the intestine of three groups (see text). The 
squares demonstrate the estimated amount of iron absorbed from the diet by the intestine (systemic iron 
influx). Values are presented as group averages (± SD, n = 7 per group). Statistical differences were 
identified relative to the CT group [* p≤ 0.05; **p≤ 0.01]. 
 
Table 5-3 demonstrates systemic changes of tissue/blood iron in response to 


































































central iron storage organ of the body, showed the highest iron content among all 
analyzed tissues and exhibited marked differences between groups (p<0.05) 
whereas no detectable differences were observed in other tissue/blood among 
groups (p>0.13).  
 
          
     
Fig. 5-3 Systemic changes of brain iron in response to dietary iron supply. 
Fig.5-3A represents total amount of iron in brain at the end of the study; Fig.5-3B represents the amount of 
iron recovered from diet in the brain; Fig.5-3C represents the percentage of the amount of iron in the brain 
recovered from diet relative to that of dietary iron intake; Fig. 5-3D represents the percentage of the amount 
of iron in the brain recovered from diet relative to that of absorbed dietary iron. Values are presented as group 














































































































As shown in Table 5-3, absolute dietary iron recovery was the highest for blood 
followed by liver as the two main iron compartments in the body. Trends for 
absolute dietary iron recovery in organs/tissues between groups followed those 
observed for systemic iron influx. Absolute recovery was lower for all organs in 
the LD group as compared to the CT group (p<0.01) with a less pronounced 
reduction in the HD group. Only changes in brain and blood reached statistical 
significance (p<0.01) for the HD group with a recovery of dietary iron that was 
lower compared to the CT group. In contrast, relative dietary iron recovery in 
tissues/organs followed trends for estimated absorption efficiency. Higher iron 
absorption efficieny in the intestine resulted in a recovery of dietary iron relative 
to intake that was higher in all organs in the LD group as compared to the CT 
group (p<0.05). Following this rationale, relative recovery was lower in all organs 
for the HD group relative to the CT group which is in line with a decrease in iron 
absorption efficiency for the high iron diet (p<0.05). However, when absolute 
dietary iron recovery by tissues/organs was normalized to systemic iron influx, 
the amount of absorbed iron available for tissue uptake, differences between LD 
group and CT goup as well as HD group and CT group became insignificant for 
all organs/tissues (p>0.25). The only exception is liver where normalized dietary 
iron recovery increased significantly for the HD group (p<0.01) and decreased in 
the LD group  (p<0.05). 
 
Fig. 5-3A shows that differences in dietary iron intake does not result in a 
detectable change in total brain iron between all three groups. However, this is 
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different for the absolute amount of iron transferred from diet to brain which was 
significantly lower for the LD group (p<0.01) as well as for the HD group 
(p<0.05) relative to the CT group, see Fig. 5-3B. Changes in absolute brain iron 
recovery between groups followed changes in systemic iron influx (Fig. 5-2) 
remarkably well. Iron recovery from diet in brain relative to dietary iron intake 
paralelled changes in intestinal iron absorption efficiency (see Fig. 5-3C). 
However, when being normalized to absorbed iron available for organ uptake 




































0.352 ± 0.060  
(↓↓)** 
45.4 ± 7.9 
(↑↑) 
0.158 ± 0.028  
(↓↓) 
0.0258 ± 0.0054 
(↓↓) 
0.0097 ± 0.0022 
(↑↑) 
0.0163 ± 0.0020 - 
(↑↑) 
0.542 ± 0.027 
Liver 
3.5 ± 1.3 
(↓↓) 
1.37 ± 0.25 
(↑↑) 




20.2 ± 6.4 
(↓) 
Kidney 
0.77 ± 0.54 
(↓↓) 
0.31 ± 0.23 
(↑) 
0.46 ± 0.25 - 
(↑↑) 
5.4 ± 2.5 
Heart 
0.056 ± 0.010 
(↓↓) 
0.0208 ± 0.0033 
(↑↑) 
0.0355 ± 0.0044 - 
(↑↑) 
1.19 ± 0.14 
Blood 
118 ±  21 
(↓↓) 








8.67 ± 0.59 8.9 ± 2.7 0.77 ± 0.20 
0.107 ± 0.019 0.00177 ± 0.00037 0.0143 ± 0.0026 - 0.524 ± 0.055 
Liver 21.3 ± 4.0 0.354 ± 0.076 2.83 ± 0.33 - 33 ± 10 
Kidney 2.9 ± 1.4 0.047 ± 0.019 0.38 ± 0.14 - 4.9 ± 1.8 
Heart 0.253 ± 0.048 0.00418 ± 0.00084 0.0344 ± 0.0099 - 1.255 ± 0.080 
Blood 376 ± 97 6.2 ± 1.9 - - - 
HD Brain 
90.3 ± 2.9 
(↑↑) 
0.60 ± 0.16 
(↓↓) 
0.54 ± 0.15 
(↓) 
0.0743 ± 0.0074  
(↓↓) 
0.000114 ± 0.000010 
(↓↓) 
0.0144 ± 0.0027 - 0.552 ± 0.054 
Liver 
24.6 ± 2.6 0.0379± 0.0045 
(↓↓) 




67 ± 15 
(↑↑) 
Kidney 
2.8 ± 1.5 0.0042 ± 0.0022 
(↓↓) 
0.56 ± 0.43 - 7.1 ± 3.1 
Heart 
0.210 ± 0.049 0.000323 ± 0.000069 
(↓↓) 
0.0396 ± 0.0055 - 
(↑↑) 
1.38 ± 0.12 
Blood 
232 ± 66 
(↓↓) 
0.36 ± 0.10 
(↓↓) 
- - - 
*Efflux rates were derived from Efflux Rate Indices. 
** Statistical differences were identified relative to the CT group [↓ or ↑ p≤ 0.05; ↓↓ or ↑↑ p≤ 0.01] 
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Lowering dietary intake decreased systematically efflux rates (p<0.01, see Fig. 
5-4) and, thus, led to an increased iron efflux (see Table 5-3) from all 
organs/tissues in the LD group over time. Observations were less consistent for 
the HD group. Here, an increased dietary intake decreased systemic iron influx as 
for the LD group (see Fig. 5-2) which supposedly gave rise to an increased iron 
efflux from the heart (p<0.01) and decreased iron efflux from the liver (p<0.05).  
 
Findings for brain show clearly that lowering dietary iron intake over the long-
term results in a lower uptake of dietary iron (lower absolute dietary iron 
recovery) and a lower retention of iron taken up by the brain (higher efflux rate) 
during adulthood. Both should lower accumulation of iron originating from diet 
when the rat is ageing. Similar conclusions can be drawn for the HD group in 
which iron intake was higher but systemic iron influx lower as compared to the 
CT group. Because absolute uptake of dietary iron by the brain could be lowered 
without a detectable effect on iron efflux from brain (see Fig. 5-4), we can 
conclude that brain iron accumulation over time could also be slowed down in the 





Fig. 5-4 Efflux rate indices of different tissues of the three feeding groups 
The lower the index, the higher the iron efflux rate (see text). Values are presented as group averages (± SD, 
n = 7 per group). Statistical differences were identified relative to the CT group [* p ≤ 0.05; ** p ≤ 0.01] 
 
5.5 Discussion 
Iron homeostasis at the systemic, organ and cellular level involves a machinery of 
genes for iron transport, storage, export and regulation, each of which presents a 
possible avenue for systemic malfunction (30). Dietary iron manipulation perturbs 
iron regulatory systems in the body and may change iron balance if over- or 
under-corrected. Several epidemiological studies revealed links between dietary 
iron intake and the risks of developing AD/PD but it is unclear whether 
association are  positive (19, 20) or negative (13-17). The present study 
demonstrated, for the first time ever, that both low and high dietary iron intake 
can potentially lower iron transfer from diet to the adult rodent brain.  
 
Methodological concepts we have used in the present study are in many ways 
unique. Previous rat studies on the effect of dietary iron on brain iron centered 
mainly on the developmental stage with a research focus on the molecular level, 



























response to change of dietary iron supply in young rats (31, 32). Brain iron 
homeostasis, however, differs between adult and young rats (33). Rate of brain 
iron uptake is age-dependent (33). Most brain iron is acquired during the first 
years of life and slows down until early adulthood on from which brain iron 
content raises slowly but steadily and possibly reaches a plateau late in life (34). 
Findings in young animals therefore cannot be extrapolated to adult or old rats. 
We have therefore decided to do our experiments on fully adult rats at an age of 
6-8 month, which correspond to age of 20-30 years in humans (35). Furthermore, 
we tried to assess brain iron homeostasis at the systemic level, firstly, by feeding 
and not injecting tracer iron as in earlier experiments and, secondly, by 
administering isotopes not as a bolus but continuously with the feed. Long-term 
feeding of tracer iron considers a possible homeostatic response of the organism 
to changes in dietary iron intake and permits to study both import and export of 
tracer iron from brain. 
 
Rats in the LD and HD group were given either about ten times less or ten times 
more iron through diet as compared to the CT group. While still extreme in range 
as compared to human dietary iron intake, dietary iron levels in our HD group 
were still much lower than those in some earlier studies where iron intake was 
increased 100 times or more to toxic levels (36-38) which may result in 
pathological changes. By feeding different iron levels, we triggered a normal 
homeostatic response in the rats as intended and expected. In none of the groups 
we have observed a detectable change in blood hemoglobin concentration over 
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the four months of the study. This indicates that functional levels of body iron 
could be maintained in all three groups within statistical limits despite marked 
differences in dietary iron supply. Instead, liver iron stores were either emptied to 
provide sufficient iron for erythropoiesis or filled up to store excessively absorbed 
iron (see Table 5-3). In line with our finding, previous studies demonstrated that 
adult rats did not develop anemia when provided with 50 times less iron than 
controls for 2 months (39). In humans, less than 0.03% of body iron is lost and 
need to be replaced per day (40). With liver iron serving as a buffer, it can take 
years until changes in functional iron become significant, even for extreme 
changes in iron influx, similar to the rats in our study. 
 
For most organisms, including rats, iron has been a limiting nutrient over 
evolutionary time spans. This has made the development of excretionary 
pathways for iron redundant. Body iron homeostasis in mammals is solely 
regulated instead by controlling iron absorption in the intestine (41). In the LD 
group, iron absorption efficiency in the intestine was up-regulated from 9% to 
45% while it was down-regulated to less than 1% in the HD group from 9% in the 
CT group. However, the drop in iron supply exceeded apparently regulatory 
capacities in the intestine in the LD group. Systemic iron influx into the rat's body 
dropped (see Fig. 5-2) and liver iron stores had to be emptied for maintaining 
erythropoiesis (see Table 5-3). Remarkably, changes in iron influx were over-
compensated in the HD group. Despite a much higher iron supply through diet, 
lowering of intestinal iron absorption efficiency in the HD group also lowered 
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levels of systemic iron influx relative to the CT group. Absorbed iron in the HD 
group was used primarily for erythropoiesis as recovery of dietary iron in liver 
was much lower than the change in total liver iron. Liver iron stores were 
therefore built up mainly from iron released from phagocytosis of senescent red 
blood cells and not from freshly absorbed iron (42). 
 
Surprisingly, changes in systemic iron influx were paralleled in our study with 
absolute dietary iron recovery in brain. The lowest recovery of dietary iron in 
brain was observed for the LD group but the highest recovery was not found in 
the HD group but the CT group. At the same time total brain iron content did not 
differ between groups (see Table 5-3). But this observation must be interpreted 
with care. Changes in brain iron balance over 4 months, which is still short as 
compared to the 24-36 life span of a rat, are relatively small and to detect them 
unambiguously would have required much larger sample sizes. This illustrates 
that measuring incremental changes in iron content of brain as the outcome 
variable in animal studies inferior to tracer experiments, in particular in studies 
involving adult rats where changes in brain iron content are much smaller than 
early in life. Even for small incremental changes in total brain iron, induced 
relative changes are much larger in tracer studies as test animals are commonly 
tracer free at study onset.  
 
The observation that recovery of dietary iron in brain parallels systemic iron 
influx (Fig. 5-3D) was surprising and challenges the common assumption that 
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brain iron balance is subject to tight homeostatic control in the adult brain. When 
systemic iron influx is lowered and brain is not a closed system, i.e. brain iron is 
constantly lost and replaced, brain iron balance can only be maintained by up-
regulating brain iron import and/or down-regulating brain iron export to 
counteract systemic iron depletion. The contrary has been observed in the LD 
group. Absolute dietary iron recovery in brain dropped (see Fig. 5-3B) and iron 
efflux increased (see Fig. 5-4) instead when dietary iron and systemic iron influx 
was restricted. For high iron intake, iron efflux from brain was not measurably 
affected but absolute dietary iron recovery dropped. This result does not violate 
the assumption that brain iron homeostasis is controlled, in principle, by body iron 
status but raises questions about the efficiency by which brain iron balance is 
maintained by regulation of brain iron import and export.  
 
Our current understanding of brain iron homeostasis as well as its change in 
response to dietary iron levels is almost entirely based on studies in young rats or 
mice (31, 32, 36-38, 43-50). These studies investigated rats/mice ranged from 
ages of 7 days to 90 days with an observational period up to 84 days. In these 
studies, rats/mice ranging from 7 days to 90 days of age at the beginning were 
given either an iron-depleted diet or an iron-loaded diet or both for up to 90 days. 
Iron restriction conclusively lowered total brain iron content in growing animals 
(<3 months) as compared to controls (36, 47, 48, 50). However, the drop in brain 
iron content in response to iron-depleted diet was found undetectable when the 
rats/mice grew older (~6 month) (39). When treated with high level of dietary 
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iron, brain iron content in young rats/mice increased only when dietary iron 
reached toxic level (>10,000 ppm in the feed) (36, 46). No such information is 
available for adult rats and findings in young rodents in earlier studies can hardly 
be extrapolated and compared to older rats as in our study. In the study conducted 
by Holmes-Hampton et al. (2012), mice were given 
57
Fe tracer together with feed 
of normal iron content from weaning for 58 weeks (33). Their result suggested 
that brain iron uptake is biphasic, with a higher rate of brain iron uptake/turnover 
at young age than at old age where iron import seems to be favoured over iron 
export.  
 
Our present study indicates that brain iron balance is less well regulated in 
adulthood as compared to infancy and childhood which appears to be a reasonable 
working hypothesis from a developmental as well as evolutionary perspective. 
Due to its functional role in brain, brain iron content must parallel brain growth 
during the first years of life. It is well established that an insufficient dietary iron 
supply during childhood results in a retarded psychomotoric and intellectual 
development of the child  that can hardly be corrected by providing sufficient iron 
later in life (51). Because iron has been a limiting nutrient in the evolution of all 
forms of life, including humans, mechanisms were needed to ensure that 
sufficient iron is taken up by the brain during growth even in times when dietary 
iron supply is limited. It has been well established that iron is taken up by the 
young rodent brain through transferrin receptor (TfR) mediated endocytosis 
across the blood brain barrier (11, 38), although a few other pathways were also 
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proposed, e.g. via divalent metal transporter 1 (DMT1) (52). Results obtained 
from these studies demonstrated that the expression of TfR in the brain was dose-
dependent: expression was found to be upregulated in response to low dietary iron 
to increase brain iron uptake and vice versa (31, 38, 53). This pathway permits not 
only brain but also other tissues and organs to acquire iron from circulation even 
if systemic iron supply is low (54). Increase of soluble transferrin receptor 
concentration in serum is a common observation in iron deprived organisms when 
liver iron stores are emptied and iron deficiency develops (55, 56). Iron export 
mechanisms from brain are less well studied but are apparently through turnover 
of cerebrospinal fluid rather than regulated iron export mechanisms, at least in the 
growing brain (57). To the best of our knowledge, no studies have been conducted 
so far to look at the effect of dietary iron deprivation on TfR levels in the brain at 
different age. Correlations between brain iron uptake and systemic iron influx in 
older rats, as observed in our study, would point to a limited relevance of actively 
regulated pathways controlled by iron status making the brain susceptible to diet 
induced changes in iron balance. 
5.6 Conclusion 
Our observation that recovery of dietary iron in brain could be lowered both by 
increasing and decreasing dietary iron intake would be in good agreement with 
contradictory findings in epidemiological trials which indicated that both low and 
high dietary intake could lower risks for contracting AD and PD. Our study 
showed that systemic iron influx rather than iron intake or body iron status alone 
decides about the rate of iron accumulation in the adult rat brain. Impairments in 
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body iron homeostasis that fail to maintain systemic iron content over life-time, 
either by over-compensation or under-compensation of habitual iron losses, may 
determine brain iron balance and brain damage through iron mediated oxidative 
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